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ABSTRACT
Dipeptides and tripeptides serve as important sources of amino acids, nitrogen and
carbon for the growth of all organisms. To identify genes involved in the regulation of
small peptide utilization, I performed a systematic, functional examination of this process
in a haploid, non-essential, single-gene deletion mutant library of Saccharomyces
cerevisiae. In addition, we used high-throughput phenotyping in which we grew yeast
cells on 284 different dipeptides or 11 tripeptides as the sole nitrogen source to dissect
different mechanisms of di/tri-peptide utilization in seven genetically diverse strains. I
have identified 103 candidate genes involved in regulating peptide utilization: 57 genes
whose deletion decreased dipeptide utilization and 46 genes whose deletion enhanced
dipeptide utilization. Since in S. cerevisiae the membrane transport protein Ptr2p,
encoded by PTR2, mediates the uptake of di/tri-peptides and is a key player in the di/tripeptide utilization process, I focused our studies on the regulation of PTR2 expression,
Ptr2p-GFP localization, and dipeptide uptake assays. Forty-two genes were ascribed to
the regulation of PTR2 expression, 37 genes were involved in Ptr2p localization, and 24
genes apparently did not affect expression or localization. Together with the highthroughput phenotyping study, we have identified gene components involved in
regulation of dipeptide utilization in many cellular processes: 1) proteins involved in upor down-regulation of PTR2 transcription including the chromatin remodeling INO80
protein complex (Arp5p, Arp8p, Ies6p and Taf14p), transcription factors (Cup9p, Rpn4p,
Stp2p, and Dal81p), polymerase mediators (Ssn3p/Srb10p, Ssn8p/Srb11p, Ssn2p/Srb9p,
and Srb8p), and mRNA maturation (Kem1p and Pat1p); 2) proteins involved in the Ptr2p
vi

trafficking system including ESCRT I, II, III protein complex; 3) proteins participating in
metabolic processes including the pyruvate dehydrogenase complex (Pdx1p, Lpd1,
Pdb1p, and Lat1p), the fatty acid synthase complex (Oar1p, Mct1p, and Etr1p), and the
glycine decarboxylase multienzyme complex (Gcv2p, Gcv3p, and Lpd1p); 4) proteins
involved in other cellular processes, such as Ybt1p, a protein located at the vacuole
membrane likely related to the storage of dipeptides in the cytosol and Dal5p previously
identified as an allantoate/ureidosuccinate permease, which facilitates di/tri-peptide
transport. Specifically, Dal5p is involved in the uptake of non-N-end rule dipeptides.
Moreover, even in the absence of Dal5p and Ptr2p, an additional activity - almost
certainly the periplasmic asparaginase II Asp3p - facilitates the utilization of dipeptides
with C-terminal asparagine residues by a different strategy. Another, as yet unidentified
activity, enables the utilization of dipeptides with C-terminal arginine residues. The
identified genes regulating dipeptide utilization were distributed among most of the Gene
Ontology functional categories indicating a very wide regulatory network involved in
transport and utilization of dipeptides in yeast. It is anticipated that further
characterization of how these genes affect peptide utilization should add new insights into
the global mechanisms of regulation of transport systems in general and peptide
utilization in particular.
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PART I

GENERAL INTRODUCTION

1

A Review of the Di/tri-peptide Utilization Literature

The utilization of di/tri-peptides is an important cellular activity and has been
documented in all organisms from archaea to bacteria, plants, and animals. The
introduction of this chapter is a literature survey of what was known about peptide
utilization and transport before I undertook the research presented in this dissertation.

Proteins and peptides as a major energy source:
Organisms utilize amino acids and peptides from exogenous proteins for
nitrogen/carbon sources and protein synthesis. In the natural environment, the source of
proteins and peptides for microorganisms is mainly from decomposition of dead
organisms and secreted proteins of living organisms. While microorganisms degrade
proteins and peptides in the surrounding environment where they reside, in mammals the
digestion of proteins and peptides begins in the stomach and intestine. Both dietary and
luminally-secreted proteins and polypeptides undergo limited or complete proteolysis by
aminopeptidases, carboxypeptidases, endopeptidases and other pancreatic and intestinal
proteolytic enzymes. The brush border peptidases located at the luminal surface of the gut
further degrade oligopeptides into di/tri-peptides and amino acids.

Degradation of proteins and peptides:
The degradation of proteins is an important process not only for providing a
nutritional source for the growth of organisms, but also for the defense against
proteinaceous toxins and modulation of the host immune system (DANIEL 2004;
2

PRITCHARD and COOLBEAR 1993). Degradation of proteins and peptides, mediated by a
set of proteases, or peptidases, can take place extracellularly or intracellularly (Figure 1).
Extracellular degradation: Extracellular degradation is mediated by many hydrolytic
enzymes, and proteolytic systems can produce oligopeptides, di/tri-peptides and amino
acids useful for microbial growth. Proteolytic digestion is particularly important for some
pathogenic and parasitic organisms to acquire peptides. For example, the genome of the
fungal pathogen Candida albicans harbors ten secreted acid proteinase (SAP) genes
encoding extracellular aspartic proteinases that appear to allow adaption to variable tissue
environments such that these SAP enzymes enable C. albicans to grow on medium
containing serum albumin as a sole nitrogen source (HUBE and NAGLIK 2001) and can
function in environments from pH 2 to 7. SAPs have been shown to be involved during
the infection process and are required for pathogenicity (NAGLIK et al. 2003).

The

parasitic organism Plasmodium falciparum, the causative agent of intraerythrocytic
malaria, can secret proteolytic enzymes plasmepsins I and II (two aspartic proteases),
falcipain (a cysteine protease), and endoproteinase to generate a variety of peptides with
average length of 8.4 amino acid residues from host hemoglobin. This parasite may
solely rely on peptides for growth (KOLAKOVICH et al. 1997).
Hydrolytic enzymes can be secreted by the signal peptide-dependent general
export pathway, and this secretion process is ubiquitous from bacteria to mammals.
Signal peptidase, an endoprotease, removes the N-terminal signal sequence from
secretory proteins, and leads to the release of mature polypeptides into the surrounding
medium (DEV and RAY 1990). Hydrolytic enzymes can also be exported by ABC

3

Figure1 Protein degradation and di/tri-peptide transporters in a general model. Exogenous proteins are degraded into
oligopeptides extracellularly by secreted proteases, and further degraded into di/tri-peptides and amino acids by peptidases. Proteins
can also be degraded into oligopeptides intracellularly by the 26S proteasome via the ubiquitin pathway or by cytoplasmic proteases,
and further degraded into di/tri-peptides by endopeptidases. Proteins can be also degraded into peptides and amino acids in the vacuole
in eukaryotic organisms. Extracellular di/tri-peptides can be transported into the cell by the PTR system and by ABC transporters. The
translocation of di/tri-peptides by the PTR system is coupled with protons, and the H+ concentration is regulated by several means
including the Na+/H+ exchanger (NHE) and the H+-ATPase. Extracellular di/tri-peptides can also be translocated into the cell by an
ABC transporter in prokaryotic organisms. This process is coupled with ATP hydrolysis.

4

Proteases

Peptidases

H+
OppA

OppD

H+
ATP
Ub

OppC

OppB

PTR

ABC transporter

OppF

ADP ATP

ADP

26S Proteasome
Endopeptidases
Ub

ic
sm
pla es
o
t
s
Cy otea
pr

(3-24 residues)

Proteases

Proteins

Vacuole
ATP

H+
NHE3

H+

H+-ATPase

Na+

5

ADP

transporters in both prokaryotic and eukaryotic organisms. In Gram negative bacteria,
proteins lacking an N-terminal signal peptide can be transported by ABC proteinmediated exporters (BINET et al. 1997; WANDERSMAN 1998). In addition, a variety of
proteinases and peptidases are associated with the cell wall and are involved in
extracellular polypeptide degradation (GONZALES and ROBERT-BAUDOUY 1996).
Intracellular degradation: Peptides can also be generated intracellularly due to protein
turnover. For example, about 1-2% of intracellular proteins in log phase bacteria cells and
5-12% of proteins in stationary phase cells undergo a degradation process (GONZALES
and ROBERT-BAUDOUY 1996). Proteins are hydrolyzed into oligopeptides by the
ubiquitin/proteasome system and cytoplasmic proteases/peptidases in prokaryotic and
eukaryotic organisms (Figure 1) and by other proteolytic enzymes in vacuoles in
eukaryotes. In the ubiquitin system, target proteins are covalently tagged with multi-Ub
and processed by an ATP-dependent 26S proteasome containing a 20S core protease and
two 19S particles. The 19S particles mediate the binding and unfolding of the target
proteins and then transfer them to 20S core for degradation (XIE and VARSHAVSKY 2000).
Peptides with three to twenty-four amino acid residues are generated by 26S proteasome
with about two-thirds of the generated peptides having less than 8 amino acid residues
(SARIC et al. 2004). The oligopeptides produced in this process are further degraded into
di/tri-peptides or amino acids for nutrient recycling by aminopeptidases and other
peptidases. For example, tripeptides can be released from a free N-terminus of larger
peptides in eukaryotic cells by tripeptidyl-peptidase II (TPP II), an aminopeptidase
associated with the plasma membrane (TOMKINSON and LINDAS 2005). Furthermore,
di/tri-peptides derived from proteins or polypeptides can be further degraded into amino
6

acids by peptidases in both prokaryotic and eukaryotic organisms. For instance, at least
four aminopeptidase activities and one single dipeptidase activity were found in yeast and
were capable of di/tri-peptide degradation (ROSE et al. 1979); and at least five peptidases,
pepN, pepC, pepO, pepX, and pepT are involved in di/tri-peptides degradation in
Lactococcus lactis (KUNJI et al. 1996b). Some bacterial strains also possess beta-peptidyl
aminopeptidase, which can use unnatural beta-di/tri-peptides for carbon and nitrogen
sources (GEUEKE et al. 2005). The intracellular or extracellular degradation of proteins
provides a variety of peptides and amino acids for the growth and reproduction.

Biological significance of di/tri-peptides
A large number of different size peptides including di/tri-peptides are produced
by both microbial proteolytic systems and by gastrointestinal digestion of dietary proteins,
such as milk, animal meat, maize, wheat, soybean, or egg (KORHONEN and PIHLANTO
2003; MEISEL and BOCKELMANN 1999; PELLEGRINI 2003; YAMAMOTO et al. 2003).
These peptides contribute to many cellular functions. For example, casein-derived
peptides, produced by the activity of lactic acid bacteria in milk, contain regulatory
compounds with hormone–like activity, and other physiologically functional peptides
such as opioid peptides, immunostimulating peptides, and angiotension I converting
enzyme inhibitors (MEISEL and BOCKELMANN 1999). Some oligopeptides (peptides
containing more than three amino acids) are bioactive and are involved in Ca2+, iron, or
steroid metabolism, have antiviral/antimicrobial/antifungal or antitumor activity, are
neuroactive, inhibit proteases, regulate growth, act as hormones, or are involved in
electrolyte turnover, fertility, and coagulation (ADERMANN et al. 2004; PELLEGRINI 2003).
7

However, more and more research has documented that di/tri-peptides have a great
physiological significance as well. There are 400 possible different dipeptides and 8000
possible tripeptides composed of the 20 naturally-occurring L-α-amino acids.

Di/tri-peptides serve as a nitrogen and/or carbon source and as a source of amino
acids: Since di/tri-peptides can be further degraded by peptidases intracellularly to
release amino acids, these peptides can satisfy amino acid auxotrophic requirements in
prokaryotic and eukaryotic microorganisms (BECKER et al. 1973; MONETON et al. 1986)
(Table 1).

Di/tri-peptides possess physiological activities whose molecular mechanism has not
been elucidated: Di/tri-peptides are not only important nutrient sources, but also some of
them possess additional biological activities. A diverse group of biologically active
peptides such as antiviral agents, neuroactive peptides, enzyme regulators and inhibitors,
hormonal peptides, and immunoactive peptides have been isolated from bacteria, fungi,
plants and animals (KUMAR and BHALLA 2005).
Analysis of some naturally-occurring dipeptides reveals a variety of physiological
functions (Table 1). Kyotorphin (Tyr-Arg), an analgesic neuropeptide, has morphine-like
and naloxone-reversible effects, possibly due to depolarization of the enkephalinergic
neurons, which leads to a release of Met-enkephalin from the striatum and spinal cord
(SHIOMI et al. 1981). In addition, Tyr-Arg also inhibits the isoprenaline-induced increase
in twitch tension of rat cardiac muscle, and this inhibition can be reversed by another
dipeptide, Leu-Arg (LI et al. 2006). Lactokinin (Tyr-Leu) derived from milk proteins by
8

Table 1 The biological functions of di/tri-peptides and di/tri-peptide derived
products
Functions

Di/tri-peptides and
Components

Activity

References

Nutrient source

Some Met and Lys contained
di/tri-peptides; 284 of 400
possible dipeptides and 11
tripeptides
Kyotorphin (Tyr-Arg)

Auxotrophic requirement;
Nitrogen source

(BECKER et al.
1973; MONETON
et al. 1986)

Analgesic neuropeptide;
inhibit isoprenaline- induced
increases in twitch tension of
rat cardiac muscle
Reverses the inhibitory effect
of kyotorphin
ACE-inhibitory effect

(LI et al. 2006;
SHIOMI et al.
1981)

Naturallyoccuring
dipeptides
serve as
effective drugs

Synthetical
dipeptides
serve as
effective drugs
Naturallyoccuring
tripeptide serve
as effective
drugs

Antagonist of kyotorphin
(Leu-Arg)
Lactokinin (Tyr-Leu)
Aspartame (Asp-Phe)
Dopa derivative (Dopa-Phe)
VPP (Val-Pro-Pro) ;
IPP (Ile-Pro-Pro)
LLY (Leu-Leu-Tyr);
YGG (Tyr-Gly-Gly)
YSL or YSV(Tyrosyl-serylleucine/valinine)
Thyrotropin releasing
hormone (TRH)
(L-pyroglutamyl-L-histidylL-Prolinamide)
Cyclized dipeptides (Cyclohistidyl-proline
diketopiperazine);
pyroGlu-Glu-Pro-NH2
GPE tripeptides (Gly-ProGlu)

Di/tripeptidomimetic
products

Substrates similar to
tripeptides
(Beta-lactam; ACE inhibitors;
Bestatin)

Synthetic nonnutritive
sweetener/ Sweet taste
Increased absorption of Dopa;
effective for Parkinson’s
disease
Antihypertension
Immunopeptide; stimulates
the activities of cells of the
immune system
Inhibit tumor growth
Neuroprotective activity

TRH-like peptides;
Neuroprotective activity
Stimulates acetylcholine and
dopamine release;
Neuroprotective activity
Antibiotics; treat
hypertension and failing
circulatory output;
Antitumour

9

(LI et al. 2006)
(MEISEL and
BOCKELMANN
1999)
(ERBELDINGER et
al. 2001)
(TAMAI et al.
1998)
(YAMAMOTO
1997)
(MEISEL and
BOCKELMANN
1999)
(JIA et al. 2005);
(YAO et al. 2005)
(FADEN et al.
2005)
(FADEN et al.
2005; PROKAITATRAI et al.
2003)
(ALONSO DE
DIEGO et al.
2005)
(MEREDITH and
BOYD 2000)

the digestion has angiotensin-I-converting enzyme (ACE) inhibitory activity (Meisel and
Bockelmann 1999).
Many modified dipeptides have also been chemically synthesized for commercial
usage (Table 1). For example, aspartame (Carbobenzoxy-Asp-Phe-OMe) has been widely
used as a non-nutritive sweetener (ERBELDINGER et al. 2001). The dipeptide derivative,
L-Dopa-L-Phe is synthesized to target PepT1 and PepT2, the two major di/tri-peptide
transporters in mammals. This compound, significantly increased the absorption of Ldopa (L-3,4-dihydroxyphenylalanine), an effective drug for the treatment of Parkinson’s
disease, in a tested Caco-2 cell line (TAMAI et al. 1998).
Some naturally-occurring tripeptides also showed physiological important
activities including antihypertension, stimulation of immune system, inhibition of tumor
growth, and neuroprotective activity (Table 1). For example, Val-Pro-Pro and Ile-Pro-Pro,
generated from casein by extracellular proteinase followed by peptidase activity in sour
milk, were found to act as antihypertensive peptides (YAMAMOTO 1997). In addition,
Leu-Leu-Tyr and Tyr-Gly-Gly also derived from the degradation of milk proteins are
immunopeptides, which increase the proliferation of human peripheral blood
lymphocytes and stimulate activity of the immune system (MEISEL and BOCKELMANN
1999). The tripeptides Tyr-Ser-Leu or Tyr-Ser-Val inhibit the growth of human
hepatocarcinoma and increase the survival capability of mice carrying tumor cells (JIA et
al. 2005; YAO et al. 2005). Thyrotropin-releasing hormone (TRH) (L-pyroglutamyl-Lhistidyl-L-prolinamide) is a brain hormone and a neuro-tripeptide modulator, which has
considerable neuroprotective effects in spinal cord injuries (FADEN et al. 2005). The
related TRH metabolic product, cyclo-His-Pro (CHP) and pyroGlu-Glu-Pro-NH2 have a
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similar function as that of TRH and CHP and are more resistant to enzymatic degradation
(FADEN et al. 2005). Tripeptide GPE (Gly-Pro-Glu) binds N-methyl-D-aspartate (NMDA)
receptor and promotes the release of acetylcholine and dopamine and shows
neuroprotective properties (ALONSO DE DIEGO et al. 2005).

Di/tri-peptides regulate cellular processes by mechanisms elucidated at the
molecular level: Some di/tri-peptides can regulate gene transcription, protein translation,
and potentially modulate enzyme activity and function of regulatory proteins (Table 2)
(TROITSKAYA and KODADEK 2004). First, N-end rule dipeptides [peptides with basic (Arg,
His, or Lys) or bulky (Ile, Leu, Phe, Trp, or Tyr) residues at the N-terminus] act as
ligands to modulate PTR2 transcription in yeast. Dipeptides with N-terminal residues can
bind to the scaffold protein Ptr1p to promote Cup9p degradation via a ubiquitination
pathway and up-regulate the transcription of the PTR2 (TURNER et al. 2000). Second,
tripeptides such as PAT (Pro-Ala-Thr) and SPF (Ser-Pro-Phe) can recognize the stop
codon and serve as functional elements to decipher stop codons in the translation process.
These tripeptides can serve as translational release factors to terminate polypeptide
synthesis (ITO et al. 2000; NAKAMURA and ITO 2002). Third, some di/tri-peptides can
regulate enzyme activities. For instance, tripeptidomimetic compound Ac-AspTyr(SO3H)-Nle-NH2 inhibits the function of protein tyrosine phosphatase 1B. As a result,
this tripeptide can negatively regulate the insulin signal by dephosphorylation of tyrosine
residues on the insulin receptor and promote insulin resistance (LARSEN et al. 2002).
Furthermore, di/tri-peptides can also serve as, or promote, agonists or antagonists to

11

Table 2 The mechanisms of biological functions of di/tri-peptides and di/tri-peptide
derived products
Functions

Di/tri-peptides and
Components

Activity

References

Regulation of
transcription

N-end rule dipeptides
(dipeptides with bulky or
basic N-terminal residues)

Transcriptional
regulation on PTR2

(TURNER et al. 2000)

Regulation of
translation

PAT (Pro-Ala-Thr) and SPF
(Ser-Pro-Phe) tripeptides

Functional elements to
decipher stop codons

(NAKAMURA and
ITO 2002)

Regulation of
enzyme activity

Ac-Asp-Tyr (SO3H)-NleNH2

Inhibitor of protein
tyrosine phosphatase 1
B (PTP1B); improve
insulin resistance

(LARSEN et al. 2002)

Modulation of
receptor
function

Melanocyte-stimulating
hormone release-inhibiting
factor (PLG) and analog
PAOPA:L-prolyl-L-leucylglycinamde

Modulating agonist
binding to human
dopamine (DA)
receptor

(VERMA et al. 2005)

fMLF (N-formyl-LMethionyl-L-leucyl-Lphenylalanine)

Responsible for
neutrophil functions

(DALPIAZ et al.
2003)
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modulate the function of receptors. For example, hypothalamic tripeptide PLG and its
analog 3(R)-[(2(S)-pyrrolidinylcarbonyl)amino]-2-oxo-1-pyrrolidineacetamide (PAOPA)
enhance agonist binding to the human dopamine receptor (VERMA et al. 2005). The
formylpeptide family, derived from bacterial proteins and disrupted cells, as well as the
synthetic tripeptide N-formyl-L-methionyl-L-Leucyl-L-phenylalanine can interact with
specific receptors in neutrophil plasma membranes and activate a transduction pathway in
response to bacterial infection and tissue damage (DALPIAZ et al. 2003).

Di/tri-peptides serve as promoieties, soluble agents for covalent attachment of drugs:
Di/tri-peptides are also used as the soluble agents for covalent attachment of drugs to
increase drug delivery efficiency. The conjugation of di/tri-peptide to drugs usually alters
the physical and chemical properties of drugs and di/tri-peptides can serve as a vehicle to
deliver drugs via targeting hPepT1/2 transporters in humans (Table 3) (TEMSAMANI and
VIDAL 2004). First, di/tri-peptidomimetic prodrugs are designed to increase the solubility
and enhance the influx by increasing the affinity of the modified compound. For example,
Val-Val-ACV (valyl-valyl-acyclovir), an antiviral nucleoside used to treat herpetic
epithelial and stromal keratitis, shows high water-solubility in the physiological pH range
in vivo and an increase of absorption of drugs due to high affinity toward the hPEPT1
(ANAND et al. 2003a; ANAND et al. 2003b). The conjugation of polyoxins and
nikkomycins, antifungal agents for inhibiting chitin synthetase, with di/tri-peptides
increases the permeability of compounds via the transport system (KRAINER et al. 1991).
Second, di/tri-peptidomimetic prodrugs are designed to decrease efflux. Val-Val-SQV
and Gly-Val-SQV uptake into cells are significantly enhanced by the reduced secretion
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Table 3 The significance of di/tri-peptides serving as vehicles to deliver drugs
Significance

Di/tri-peptides and
Components

Activity

References

Increase
solubility and
influx

Val-Val- acyclovir (ACV)/
Gly-Val-ACV

Antiviral nucleoside acyclovir

Di/tri-peptidyl polyoxin and
Nikkomycin

Antifungal drugs

(ANAND et al.
2003a; ANAND et
al. 2003b)
(KRAINER et al.
1991)

Decrease
efflux

Val-Val-saquinavir (SQV)

Enhanced cellular
permeability of saquinavir
(SQV) and modulate p-gp
mediate efflux

(JAIN et al. 2005)

Increase
stability

3-(4’-geranyloxy-3’methoxyphenyl)-2-transpropenoic acid -Ala-Pro

Activated by intestinal ACE
and used in the treatment of
different forms of colon
cancer

(CURINI et al.
2005)
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of SQV, an effective HIV protease inhibitor, due to fact that the membrane bound efflux
protein P-gp can not recognize the tripeptide prodrug (JAIN et al. 2005). Third, di/tripeptidomimetic prodrugs are designed to stabilize drugs, or protect them from different
pH or from enzymatic digestion such as pancreatic and intestine peptidases. Ala-Pro
dipeptide is used to conjugate with the anticancer compound 3-(4’-geranyloxy-3’methoxyphenyl)-2-trans-propenoic acid. This dipeptidyl prodrug is highly stable but can
be activated by intestinal angiotension converting enzyme (ACE, dipeptidyl
carboxypeptidase) located on the external side of the intestinal brush border membrane of
the small and large intestines to release the anticancer compound (CURINI et al. 2005).
Dipeptides with unnatural amino acids, such as D-Asp-Ala and D-Glu-Ala have also been
used to couple with drugs for the protection of the drug from enzyme digestion by
enhancing the permeability across the intestine (FRIEDRICHSEN et al. 2001). Furthermore,
dipeptides also act as effective promoieties to deliver unnatural amino acids. (+)-2Aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid is a potent agonist for metabotrophic
glutamate receptors, and suppresses enhanced glutamatergic excitations in brain synapses
blocking anxiety. A derivative of this compound containing a N-terminal dipeptide
addition showed an 8-fold increase in drug absorption and a 300-fold increase in potency
compared with its parent chemical (BUENO et al. 2005). Other dipeptides, such as ValAsp, Phe-Gly, and Phe-Asp, were also demonstrated to be promising pro-moieties in drug
delivery (VABENO et al. 2004a; VABENO et al. 2004b). In spite of the fact that many
studies have been performed to elucidate the structural requirements for an optimal
peptide transport substrate for hPEPT1/2 (DANIEL 2004; MEREDITH and BOYD 2000;
NIELSEN and BRODIN 2003), it is not entirely clear how to design the peptide portion of
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the prodrug to facilitate drug delivery via PepT1/2 peptide transporters, although the size
of drug and modification of N-terminal amino acid side chain should be taken into
consideration (FRIEDRICHSEN et al. 2001; ERIKSSON et al. 2005).

Peptide transporter systems
Di/tri-peptide transport has been documented in a wide variety of organisms
including bacteria, fungi, plants, invertebrates, and vertebrates. Influx of di/tri-peptides is
mediated by two types of transport systems, ATP-binding cassette (ABC) peptide
transporters and proton-driven peptide transporters (Table 4) (STEINER et al. 1995).

ABC transporter systems: Three ABC peptide transporters, oligopeptide permease
(Opp), dipeptide permease (Dpp), and other single protein peptide permeases have been
reported in prokaryotic organisms. The Opp transport system consists of five essential
polypeptide proteins, OppA, OppB, OppC, OppD, and OppF (Figure 1). OppA is a
substrate binding protein located in the periplasmic space between the cytoplasmic
membrane and the outer membrane in gram-negative bacteria, and the binding of a
substrate leads to the conformational change of this protein. Similar to eukaryotic cells,
which typically have 12 transmembrane domains in their permeases, OppB and OppC are
two transmembrane proteins each containing six TMs for a total of 12 membranespanning domains. Together, these two proteins create a transmembrane pore for
substrate translocation. OppD and OppF located at the cytoplasmic membrane are related
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Table 4 ATP-binding cassette (ABC) transport systems involved in di/tri-peptide utilization in prokaryotes
Identified systems
Dpp

Opp

Transmembrane
domains
2 six-trans-membrane
domains
2 six-transmembrane
domains

Substrate

Involved proteins

Dipeptides;
Limited in tripeptides

Multiple proteins
(DppA, DppB, DppC,
DppD, DppE)

High affinity for
tripeptides; limited to
dipeptides

Multiple proteins
(oppA, oppB, oppC,
oppD, oppF)

4-35amino acids
residues
Opt

Not-reported

larger than tetrapeptides

DtpP

Not-reported

di-/tripeptides
(branched-chain
Hydrophobic peptides)

Multiple proteins
[optABCDF
two oligopeptide
binding proteins (OptS
and OptA)]
Single protein
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Regulation
Constitutively
expressed;
phosphate limitation
down regulates DppA
Induced in anaerobic
conditions and media
containing Leu Ala;
Repressed through Lrp
protein in E.coli;

Representative
organisms
E. coli
S. tryphimurium
P. Aureuginosa
S. pyogenes
E. coli
S. tryphimurium
P. aureuginosa
B. burgdorferi
B. subtilis

Repressed by codY and
branched amino acids
de-repressed.

L. lactis

unknown

L. lactis

Induced in the presence
of di- and tripeptides
containing branchedchain amino acids

L. lactis

to ATP binding and hydrolysis, where energy is needed for substrate translocation
(PAYNE and SMITH 1994). The Opp transport system has a high affinity for tripeptides
and has limited activity for transporting dipeptides in E.coli and S.typhimium. However,
Opp system can also transport 3-5 amino acid residues in B.subtilis (SOLOMON et al.
2003), and peptides of 4 to 35 amino acids in L. lactis (DETMERS et al. 1998; DOEVEN et
al. 2004). OppA is the major determinant of substrate specificity for the Opp transport
system, and has been identified in other bacterial organisms with limited differences in
OppA (LIN et al. 2001). To adapt to the changes in the environment, several versions of
OppA substrate binding proteins OppA-1,-2,-3, -4, -5 have also been identified in B.
burgdorferi. For example, OppA-5 is regulated by temperature stress; while the other
functional homolog of OppAs might be responsible for other environmental conditions.
Multiple versions of these substrate binding proteins possibly reflect the capabilities of
peptide uptake for nutrient requirements and possess an evolutionary advantage in
different environments (LIN et al. 2001).
Similar to the Opp transport system, the dipeptide permease (Dpp) system also
contains five polypeptides (DppA to DppE) and is involved in the uptake of essential
amino acids, and dipeptide chemotaxis (Table 4) (PODBIELSKI and LEONARD 1998). The
Dpp transporter system transports primarily dipeptides and to a limited extent, tripeptides
(PAYNE and SMITH 1994). DppA has structural homology to the substrate-binding OppA
protein (ABOUHAMAD et al. 1991); DppB and DppC are transmembrane proteins involved
in the translocation of substrates; DppD and DppE are membrane associated ATPases
that provide energy for translocation of the substrates.
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Other ABC transporters such as oligopeptide transporter (Opt system) have also
been identified (Table 4). Similarly, the Opt transport system contains multiple proteins
OptA, OptB. OptC, OptD, OptF. In L. lactis, OptS and OptA, two binding proteins are
identified, which might function at different environment conditions. Compared with Opp
or Dpp system, Opt has a different genetic organization and mainly transports larger than
tetrapeptides as its substrate (LAMARQUE et al. 2004). Single protein ABC dipeptide
permeases such as DtpP have also been identified in L. lactis (KUNJI et al. 1996a). DtpP
preferentially transports di/tri-peptides composed of hydrophobic residues (branchedchain amino acids). DtpP is driven by ATP or a related energy-rich phophorylated
intermediate since the activity is inhibited by o-vanadate, an inhibitor of ATP production
in the glycolytic pathway. DtpP is induced by its own substrates such as in the presence
of di/tri-peptides with branched-chain amino acids (FOUCAUD et al. 1995). However, how
ATP is involved in the single protein peptide transport remains unknown.

Regulation of ABC transporter systems: ABC transporter systems are regulated by the
cell’s environment. Some small molecules in the media can even trigger the expression of
the entire transporter activity. For example, the Dpp transporter system is constitutively
expressed, but the transport ability is down-regulated when bacteria grow in phosphatelimited medium due to decreased expression of DppA (ABOUHAMAD et al. 1991). The
Opp transporter system is induced under anaerobic conditions, while the amino acids
leucine and alanine up-regulate peptide transport by increasing transcriptional expression
of OppA in E. coli and S. tryphimurium. In addition, some regulatory proteins have been
identified that are involved in the expression of the transporter system at the
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transcriptional level. For instance, the expression of the Opp operon is repressed by the
leucine-responsive regulatory protein (Lrp) in E. coli. Mutation of this gene results in
constitutive expression of the Opp system (CALVO and MATTHEWS 1994). However, how
the Opp system is regulated by Leu and how the Lrp repressor is related to leucine
upregulation remains unclear. It might be possible that a sensor system can detect leucine
which results in the regulation of Opp transcription. In L. lactis, CodY, a transcriptional
regulator, interacts with the upstream promoter of the Opp transport system, and
branched amino acids directly impact the binding of repressor CodY on the promoter
region of the Opp operon (DEN HENGST et al. 2005).

Proton-driven di/tri-peptide transport: The proton oligopeptide transporter (POT) or
PTR superfamily is another type of peptide transporter involved in the uptake of di/tripeptides. PTR transporters are symporters in that the influx of di/tri-peptides is coupled
with the uptake of protons. As a result, this process leads to a decrease in the pH in the
cytosol. The fluctuation of pH in the cytosol is regulated by an antiporter, Na+/H+
exchange transporter (NHE) in both prokaryotic and eukaryotic organisms (BOOTH 1985;
MADSHUS 1988). NHE exports the proton by uptaking Na+ across the plasma membrane
into the cytosol. Furthermore, Na+/K+ pump regulates Na+ intracellular concentration by
the exchange of K+ (Figure 1). In addition, H+-ATPase is also involved in the proton
homeostasis. H+-ATPase pumps protons out of the cell by hydrolysis of ATP.
PTR family members are present in all cells studied to date (HAUSER et al. 2001).
At least 40 members are classified into the PTR family in both prokaryotic and
eukaryotic organisms (SAIER et al. 2006). Among theses transporters, DtpT, Ptr2p, and
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PepT1/2 are the most studied peptide transporters in bacteria, yeast, and mammals,
respectively (Table 5).
In prokaryotic organisms, the DtpT transporter is predicted to contain 12
transmembrane domains and has high affinity for transporting hydrophilic and charged
peptides in L. lactis (HAGTING et al. 1997). DtpT is also identified in Listeria
monocytogenes, and is involved in salt stress protection and might also contribute to the
virulence of L. monocytogenes (WOUTERS et al. 2005). In addition, several
uncharacterized E.coli transporters including YhiP, f493 and Yjd also have the ability to
transport di/tri-peptides (SAIER 1999). Another type of peptide transporter, tripeptide
permease (Tpp) was identified in S. typhimurium, however, it does not carry the signature
sequence of PTR transport family nor is it an ABC transporter. The Tpp system has a
restricted range of tripeptide substrates containing hydrophobic residues and is not able to
transport substrates larger than tetrapeptides (SMITH et al. 1999). Expression of Tpp is
induced under anaerobic conditions and is positively regulated by the gene products of
ompR and anvZ (ABOUHAMAD et al. 1991).
In eukaryotic organisms, two distinct peptide transport systems have been
reported in a variety of organisms (Hauser et al. 2001): the PTR (Peptide TRansport)
system transports di/tri-peptides (STEINER et al. 1995) and the OPT (OligoPeptide
Transport) system highly favors the transport of peptides of four to five amino acid
residues and also glutathione (LUBKOWITZ et al. 1997; MIYAKE et al. 2002). Both the
PTR and OPT transport systems are predicted to contain twelve transmembrane domains,
and have specific signature sequences distinguishing them from one another as well as
from all other proteins in the database (HAUSER et al. 2001). Ptr2p, encoded by the PTR2
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Table 5 PTR (POT) transporter system in bacteria, yeast and mammalian organisms and the regulatory mechanisms
Transporter
Functions
DtpT

NHE activity

Gene expression or mRNA stability

Protein trafficking

Organism

Unknown

1) Induced in anaerobic condition;
2) Up-regulated by Leu and Ala

unknown

Bacteria

PTR2

Unknown

1) Poor nitrogen medium
2) N-end rule dipeptides enhance PTR2 expression
3) Ssy1p-Ptr3p-Ssy5p protein complex induces
PTR2 expression.
4) Stp1/2p is PTR2 transcriptional activation.
5) Cup9p represses PTR2 transcription
6) Ptr1p, Ubc2p and Ubc4p are involved in the
degradation of Cup9p.

1) Protein components of
ESCRT I, II, III complex

Yeast

1) High protein diet, fasting, or starvation increases
expression.
2) Presence of Phe,Arg, Lys and Gly-Sar, Gly-Phe,
Lys-Phe,Asp-Lys increases PEPT1/2 expression via
influence the level of transcriptional factor AP-1
3) Tissue specific expression
4) Epidermal growth hormone and thyroid hormone
5) Ligand of σ receptor
6) Organism development, injury and disease states

1) Insulin and leptin increase
the amount of transporters in
plasma membrane

PEPT1/2

Intracellular
Ca2+
concentration
decreases
uptake ability
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2) Npr1p, Lst4p

Mammalian organisms

gene, is the only member of the PTR system transporting di/tri-peptides in S. cerevisiae.
Highly conserved regions of the PTR family are located in TM2, TM3, and TM5 and the
intracellular loop between TM2 and TM3 (MEREDITH and BOYD 2000). Another di/tripeptide transporter Dal5p has been recently discovered in yeast but does not contain the
PTR signature sequence. Dal5p has di/tri-peptide transport activity, and additionally
transports allantoate/ureidosuccinate (HOMANN et al. 2005).
In mammals, two major di/tri-peptides transporters, PepT1 and PepT2 of the PTR
system have been utilized for drug delivery. PepT1 and PepT2 were first identified in the
intestine and kidney, respectively (FEI et al. 1994; LIU et al. 1995). PepT1 has a low
affinity but a high capacity for di/tri-peptide transport, while PepT2 has a low capacity
but high affinity. Expression and activity of these peptide transporters were also shown in
other organs such as lung, placenta, mammary gland, pancreas, pituitary gland,
reproductive organs, and the central nervous system (LU and KLAASSEN 2005). Two
other peptide transporters, PHT1 and PHT2, have also been identified to transport free
histine and certain di/tri-peptides (DANIEL and KOTTRA 2004; MEREDITH and BOYD 2000;
NIELSEN and BRODIN 2003). PepT1/2 transporters provide the means for absorption of
nutritional peptides and peptidomimetic drugs. Peptidomimetic substances such as betalactam antibiotics (Cefadroxil, Cefadrine, cyclacillin, Cefixime, cephalosporins and
Ceftibuten), the anticancer compound Bestatin, and angiotension-converting enzyme
(ACE) inhibitors (Captopril, Enalapril, and Fosinopril) can also be transported by peptide
transporters (RUBIO-ALIAGA and DANIEL 2002), and has been commercialized for
treating many diseases. The substrate specificity of these transporters has provided an
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mpetus to many pharmaceutical companies to develop peptide transporters as drug
delivery systems (HERRERA-RUIZ and KNIPP 2003; LEE 2000).

Regulation of PTR transport system: It is not clear whether the members of the PTR
transport system are regulated in a similar pattern, however understanding the regulation
of one peptide transporter might shed light on the study of another. In prokaryotic
organisms, DtpT expression is induced under anaerobic conditions, and growth medium
containing Leu or Ala up-regulates peptide transport (PAYNE and SMITH 1994). Further
research is needed on the regulation of DtpT expression and function since little
information is known for the mechanism of the regulation.
Among the peptide transporters of the PTR system, PTR2 transcriptional
regulation in yeast has been studied in a great detail at the molecular level due to the
simplicity of genetic manipulation. This research might provide clues for understanding
the genetic regulation of PEPT1/2 for drug delivery in mammalian organisms.

Regulation of di/tri-peptide utilization via transcriptional regulation of PTR2 in yeast:
Peptide transport is up-regulated by growth media containing poor nitrogen sources, such
as allantoin, isoleucine, or proline (ISLAND et al. 1991). Under poor nitrogen conditions,
PTR2 expression is highly upregulated and results in more efficient di/tri-peptide
transport. In media containing the rich nitrogen source ammonium, PTR2 expression is
down-regulated via nitrogen catabolite repression (MARZLUF 1997).
At least three pathways have been shown to be related to the transcriptional
regulation of PTR2 (Figure 2). First, specific amino acids regulate PTR2 expression via a
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Figure 2 The regulation of SPS protein complex on amino acid permeases and PTR2.
There are at least three types of sensors in the yeast plasmic membrane. Mep2p sensors
NH4+ concentration; Snf3/Rgt2p and Gpr1p sensor glucose; and Gap1p and Ssy1p sensor
amino acids in the extracellular environment. Ssy1p-Ptr3p-Ssy5p form a protein complex
and deliver signal to up-regulate the expression level of PTR2 encoding di/tri-peptide
tansporter, and other amino acid permeases such as AGP1, BAP2, and down-regulate the
expression level of GAP1. The regulation of PTR2 is involved in the modification of
Stp2p by trancating the N-terminal of Stp2p. The truncated Stp2p is translocated into
nucleus to regulate PTR2 transcription. SCF GRR1 protein complex is involved in the SPS
signal transduction pathway, but the role of this protein complex is not clear. In addition,
PTR2 transcription is also repressed by Cup9p. Cup9p is destabilized by the protein
complex of Ptr1p, Ubc2p, and Ubc4p via ubiquitination pathway. SPS protein complex
also regulates the release of amino acid from vacuole. The process remains unclear.

25

NH4

Glucose

Amino Acid

+

Mep2p

Gap1p

Snf3p/
Rgt2p

Ssy1p

Gpr1p

Ptr3p Ptr3p
Ssy5p

Stp1/2p

?
SCF GRR1
Ubc2p Ubc4p

Stp1/2p*

Ptr1p

Amino acid

Cup9p

Vacuole

Ub

Cup9p

Dal81p

Stp1/2p*

Stp1p*

Dal81p

Leu3p

Stp1/2p*

Tup1p

PTR2

AGP1

BAP2

….

?

GAP1

26

signal transduction pathway. Peptide utilization was markedly enhanced by addition of
micromolar amounts of certain amino acids, most notably leucine and tryptophan, to the
growth medium (BAETZ et al. 2004; ISLAND et al. 1987). The addition of these amino
acids has been shown to up-regulate the expression of PTR2 (PERRY et al. 1994). Amino
acids regulate PTR2 expression by the SPS (Ssy1p-Ptr3p-Ssy5p) signal transduction
pathway (BARNES et al. 1998; FORSBERG et al. 2001a; FORSBERG et al. 2001b; FORSBERG
and LJUNGDAHL 2001b). In the SPS complex, Ssy1p is a transmembrane receptor that
senses extracellular amino acids. Similar to the amino acid permeases, Ssy1p contains 12
predicted transmembrane domains and requires Shr3p function for its localization to the
cytoplasmic membrane (KLASSON et al. 1999). However Ssy1p is not able to transport
amino acids, but instead acts as a sensor for the induction of several permease genes and
a di/tri-peptide transporter gene PTR2. These permeases include branched-chain amino
acid permease (BAP2 and BAP3), tyrosine and tryptophan permease (TAT1), dicarboxylic
amino acid permease (DIP5), carnitine transporter (AGP2), methionine permease
(MUP1), broad-specificity amino acid permease (AGP1), tyrosine permease (TAT2),
glutamine permease (GNP1), gamma-aminobutyrate (GABA) and Delta-aminolevulinic
permease (UGA4), arginase gene (CAR1), nitrogen catabolite repression (NCR)-sensitive
genes (BERMUDEZ MORETTI et al. 2005; ECKERT-BOULET et al. 2004; FORSBERG et al.
2001a; KODAMA et al. 2002), reduction of the arginine permease gene (CAN1), highaffinity proline permease (PUT4), and the general amino acid permease gene (GAP1)
(FORSBERG et al. 2001a; KLASSON et al. 1999; KODAMA et al. 2002). Compared to other
amino acid permease, Ssy1p has a unique extended N-terminal region, which is essential
for its function. Plasmid-borne over-expression of this N-terminal region interferes with
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Ssy1p function in a dominant negative manner (BERNARD and ANDRE 2001b). The
mutation of threonine 382 of Ssy1p to other amino acids results in constitutive amino
acid signaling, which further supports that Ssy1p is a sensor responding to extracellular
amino acids (BERNARD and ANDRE 2001b; POULSEN et al. 2005). In addition to the
amino acid sensor Ssy1p, other sensor components, the glucose sensors Snf3/Rgt2p and
the ammonium sensor Mep2p have also been studied. Recently, the general amino acid
permease, Gap1p, has also been reported to act as an amino acid sensor for the activation
of protein kinase A targets, such as the activation of trehalase and repression of HSP12,
CTT1 and SSA3, which results in the fermentable growth (DONATON et al. 2003).
Ptr3p and Ssy5p are hydrophilic proteins, but are associated with the cytoplamic
side of the membrane. Yeast two hybrid experiments show protein-protein interactions of
Ptr3p-Ssy5p and Ptr3p-Ptr3p (BERNARD and ANDRE 2001a). Ptr3p and Ssy5p interact
with the cytoplasmically located N-terminus of Ssy1p, and are required for their function
(FORSBERG and LJUNGDAHL 2001a; POULSEN et al. 2005). Single and double deletion
mutations of these three components showed identical growth phenotypes (FORSBERG
and LJUNGDAHL 2001a), and overexpression of Ssy5p suppresses the growth defect
caused by the deletion of SSY5 and PTR3 (BERNARD and ANDRE 2001a). In addition, the
deletion of SSY1 and PTR3 caused a change in cell morphology with invasive growth and
accumulation of histidine and arginine in the vacuole (KLASSON et al. 1999). Two related
transcription factors, Stp1p and Stp2p, are downstream of the SPS complex and regulate
the expression of PTR2 and branched-chain amino acid permeases, BAP2, BAP3, and
AGP1 (DE BOER et al. 2000). Stp1p and Stp2p are synthesized in an inactive form and
were first identified as necessary for the maturation of pre-tRNAs. The activation of
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Stp1p and Stp2p depends on the endoproteolytic-processing of their N-terminal domain
mediated by Ptr3p and Ssy5p (ANDREASSON and LJUNGDAHL 2002; ANDREASSON and
LJUNGDAHL 2004). In the study of the SPS complex on the regulation of AGP1
expression, Ssy1p and Ptr3p are involved in signal sensing while Ssy5p is involved in the
activation of Stp1p. Ssy5p acts as an endoprotease catalyzing the cleavage of Stp1p in
response to extracellular amino acids. Likely Ptr3p self-association brings Ssy5p together,
which leads to Ssy5p undergoing Ptr3p-dependent self-processing (ABDEL-SATER et al.
2004a). Furthermore, casein kinase I is involved in the phosphorylation of the inactive
form of the membrane bound transcription factor Stp1p before undergoing an
endoproteolytic process (ABDEL-SATER et al. 2004a). The truncated forms of Stp1p and
Stp2p are translocated into the nucleus to up-regulate expression of down-stream genes
including PTR2 (ANDREASSON and LJUNGDAHL 2002; ANDREASSON and LJUNGDAHL
2004). The processing of Stp1p/2p is also required for the F-box protein Grr1p, which is
a component of the SCFGrr1 ubiquitin ligase complex (Skp1p, Hrt1p, Cdc34p, and
Cdc53p) that labels proteins for degradation by the proteasome. However, the detailed
process of the participants of this protein complex remains unclear in the SPS signal
transduction pathway (ABDEL-SATER et al. 2004a; ANDREASSON and LJUNGDAHL 2004;
BERNARD and ANDRE 2001b).
PTR2 expression is negatively regulated by the repressor Cup9p, which binds the
PTR2 promoter region between nucleotides -488 and -897 upstream of the PTR2 start
codon. In a cup9 null mutant, PTR2 is over-expressed and results in a marked increase in
dipeptide uptake (BYRD et al. 1998).

Cup9p is degraded by Ptr1p through the

ubiquitinylation pathway. In this pathway, Ptr1p acts as a scaffolding protein or ubiquitin
29

ligase (E3) for two other proteins, Ubc2p and Ubc4p, which serve as ubiquitinconjugating (E2) enzymes in the Cup9p degradation process (XIE and VARSHAVSKY
1999). Dipeptides containing N-terminal basic (Arg, Lys, His) or bulky hydrophobic (Phe,
Leu, Tyr, Trp and Ile) residues directly bind to two distinct binding sites of Ptr1p, and
accelerate the Ptr1p-dependent degradation of Cup9p (TURNER et al. 2000). Deletion of
PTR1 results in the stabilization of Cup9p, lack of expression of PTR2, and a null
peptide-uptake phenotype (DU et al. 2002; ISLAND et al. 1991; TURNER et al. 2000).
Other transcription factors, such as Dal81p/Uga35p, have also been reported to be
involved in PTR2 and AGP1 expression (ABDEL-SATER et al. 2004b; IRAQUI et al. 1999),
however it is not clear how Dal81p responds to the external amino acid sensing pathway
(IRAQUI et al. 1999). Obviously, the systems regulating PTR2 expression are complex,
and there has not been a systematic study to uncover other proteins involved in the
regulation of peptide utilization.
Regulation of di/tri-peptide utilization in mammals:

In the mammalian peptide

transport system, the mechanisms of the regulation on di/tri-peptide transport are still not
clear at the molecular level; however some studies have demonstrated several
physiological conditions and possible cellular processes that could impact di/tri-peptide
transport activity. These physiological conditions mainly impact di/tri-peptide transport
in three aspects (Table 3) (NIELSEN and BRODIN 2003). First, some factors that affect
NHE3 activity, defined as Na+/H+ exchanger, resulting from the alteration of pH will
indirectly alter di/tri-peptide uptake. For example, the uptake of di/tri-peptides is
regulated by the intracellular calcium concentration. The calcium concentration might
trigger the activation of protein kinase A (PKA) and C (PKC), which lead to alteration of
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NHE3 function. As a result, the calcium concentration will eventually influence dipeptide
influx via NHE3 activity, and the increase of calcium leads to a decrease of peptide
uptake through the PepT1 transporter (MEREDITH and BOYD 2000).
Second, alteration of hPepT1/2 trafficking system will change di/tri-peptide
transport. Several hormones such as insulin and leptin show significant alteration in the
capability of di/tri-peptides uptake. An increased insulin level immediately elevates the
rate of Gly-Gln influx in Caco-2 cells; increases Vmax two fold by increasing the amount
of transporters in the plasma membrane without a change in the Km value of the
transporter, suggesting peptide transporter activity remains the same (NIELSEN et al. 2003;
THAMOTHARAN et al. 1999).
Third, modification of transcriptional expression of the peptide transporter or its
mRNA stability leads to a change in di/tri-peptide transport. A high protein diet, fasting
or starvation increases the level of mRNAs of hPepT1 in the intestine (MEREDITH and
BOYD 2000; NIELSEN and BRODIN 2003). It is not clear how this diet condition triggers
the changes in expression level. In addition, the expression of hPepT1/2 is also upregulated in the presence of dietary amino acids (Phe, Arg, and Lys) and peptides (GlySar, Gly-Phe, Lys-Phe and Asp-Lys) possibly through the transcription factor AP-1 since
the PepT1 gene promoter contains its binding sequence. It is possible that high
concentrations of amino acids and peptides up-regulates the expression level of AP-1
(SHIRAGA et al. 1999; THAMOTHARAN et al. 1998). Expression of the peptide transporter
also varies in different tissues. hPEPT1 has higher expression in the small intestine and
lower in kidney and liver, and no expression in colon. However, how the expression is
changed in different tissues remains unsolved. Epidermal growth factor and thyroid
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hormone show a significant alteration in the uptake of di/tri-peptides by increasing the
PEPT1 expression (ADIBI 2003; ASHIDA et al. 2002). A ligand such as (+)pentazocine for
sigma receptor, the plasma membrane receptor binding with nonopiate and
nonphencyclidine, can also up-regulate the expression of PEPT1 (FUJITA et al. 1999). In
addition, the expression of the di/tri-peptide transporter also changes in the development
process, injury and disease states such as cancer, as well as diabetes and intestinal
inflammation (ADIBI 2003); the mechanisms of these conditions affecting the expression
level are largely unknown. Compared with the known gene products involved in the
regulation of PTR2 in yeast, such as SPS sensor, it is not known whether the counterparts
in mammals to regulate PEPT1/2 exist and play the similar role.
Rationale for this study:
This study was undertaken to identify possible genes involved in the regulation of
peptide utilization in yeast. In my study, I performed a genome-wide screen on a yeast
single gene deletion mutant library. In addition, we used high-throughput phenotyping in
which we grew yeast cells on 284 different dipeptides or 11 tripeptides as the sole
nitrogen source in several genetically diverse strains. Several gene products and signal
pathways involved in the regulation of di/tri-peptide utilization have been identified in
this study. The identified genes regulating dipeptide utilization represented a very wide
regulatory network involved in transport and utilization of dipeptides in yeast. The
identified components involved in dipeptide utilization may help understand the
regulation of peptide transport in mammals. This is the first such study of a membrane
transport system in any organism and initiates a systems biology approach to
understanding membrane transport in cells.
32

REFERENCES
ABDEL-SATER, F., M. EL BAKKOURY, A. URRESTARAZU, S. VISSERS and B. ANDRE,
2004a Amino acid signaling in yeast: casein kinase I and the Ssy5 endoprotease
are key determinants of endoproteolytic activation of the membrane-bound Stp1
transcription factor. Mol Cell Biol 24: 9771-9785.
ABDEL-SATER, F., I. IRAQUI, A. URRESTARAZU and B. ANDRE, 2004b The external amino
acid signaling pathway promotes activation of Stp1 and Uga35/Dal81
transcription factors for induction of the AGP1 gene in Saccharomyces cerevisiae.
Genetics 166: 1727-1739.
ABOUHAMAD, W. N., M. MANSON, M. M. GIBSON and C. F. HIGGINS, 1991 Peptide
transport and chemotaxis in Escherichia coli and Salmonella typhimurium:
characterization of the dipeptide permease (Dpp) and the dipeptide-binding
protein. Mol Microbiol 5: 1035-1047.
ADERMANN, K., H. JOHN, L. STANDKER and W. G. FORSSMANN, 2004 Exploiting natural
peptide diversity: novel research tools and drug leads. Curr Opin Biotechnol 15:
599-606.
ADIBI, S. A., 2003 Regulation of expression of the intestinal oligopeptide transporter
(Pept-1) in health and disease. Am J Physiol Gastrointest Liver Physiol 285:
G779-788.
ALONSO DE DIEGO, S. A., P. MUNOZ, R. GONZALEZ-MUNIZ, R. HERRANZ, M. MARTINMARTINEZ et al., 2005 Analogues of the neuroprotective tripeptide Gly-Pro-Glu
(GPE): synthesis and structure-activity relationships. Bioorg Med Chem Lett 15:
2279-2283.
ANAND, B. S., J. M. HILL, S. DEY, K. MARUYAMA, P. S. BHATTACHARJEE et al., 2003a In
vivo antiviral efficacy of a dipeptide acyclovir prodrug, val-val-acyclovir, against
HSV-1 epithelial and stromal keratitis in the rabbit eye model. Invest Ophthalmol
Vis Sci 44: 2529-2534.
ANAND, B. S., J. PATEL and A. K. MITRA, 2003b Interactions of the dipeptide ester
prodrugs of acyclovir with the intestinal oligopeptide transporter: competitive
inhibition of glycylsarcosine transport in human intestinal cell line-Caco-2. J
Pharmacol Exp Ther 304: 781-791.
ANDREASSON, C., and P. O. LJUNGDAHL, 2002 Receptor-mediated endoproteolytic
activation of two transcription factors in yeast. Genes Dev 16: 3158-3172.

33

ANDREASSON, C., and P. O. LJUNGDAHL, 2004 The N-terminal regulatory domain of
Stp1p is modular and, fused to an artificial transcription factor, confers full
Ssy1p-Ptr3p-Ssy5p sensor control. Mol Cell Biol 24: 7503-7513.
ASHIDA, K., T. KATSURA, H. MOTOHASHI, H. SAITO and K. INUI, 2002 Thyroid hormone
regulates the activity and expression of the peptide transporter PEPT1 in Caco-2
cells. Am J Physiol Gastrointest Liver Physiol 282: G617-623.
BAETZ, K., L. MCHARDY, K. GABLE, T. TARLING, D. REBERIOUX et al., 2004 Yeast
genome-wide drug-induced haploinsufficiency screen to determine drug mode of
action. Proc Natl Acad Sci U S A 101: 4525-4530.
BARNES, D., W. LAI, M. BRESLAV, F. NAIDER and J. M. BECKER, 1998 PTR3, a novel
gene mediating amino acid-inducible regulation of peptide transport in
Saccharomyces cerevisiae. Mol Microbiol 29: 297-310.
BECKER, J. M., F. NAIDER and E. KATCHALSKI, 1973 Peptide utilization in yeast. Studies
on methionine and lysine auxotrophs of Saccharomyces cerevisiae. Biochim
Biophys Acta 291: 388-397.
BERMUDEZ MORETTI, M., A. M. PERULLINI, A. BATLLE and S. CORREA GARCIA, 2005
Expression of the UGA4 gene encoding the delta-aminolevulinic and gammaaminobutyric acids permease in Saccharomyces cerevisiae is controlled by amino
acid-sensing systems. Arch Microbiol 184: 137-140.
BERNARD, F., and B. ANDRE, 2001a Genetic analysis of the signalling pathway activated
by external amino acids in Saccharomyces cerevisiae. Mol Microbiol 41: 489-502.
BERNARD, F., and B. ANDRE, 2001b Ubiquitin and the SCF(Grr1) ubiquitin ligase
complex are involved in the signalling pathway activated by external amino acids
in Saccharomyces cerevisiae. FEBS Lett 496: 81-85.
BINET, R., S. LETOFFE, J. M. GHIGO, P. DELEPELAIRE and C. WANDERSMAN, 1997 Protein
secretion by Gram-negative bacterial ABC exporters--a review. Gene 192: 7-11.
BOOTH, I. R., 1985 Regulation of cytoplasmic pH in bacteria. Microbiol Rev 49: 359-378.
BUENO, A. B., I. COLLADO, A. DE DIOS, C. DOMINGUEZ, J. A. MARTIN et al., 2005
Dipeptides as effective prodrugs of the unnatural amino acid (+)-2aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740), a selective group
II metabotropic glutamate receptor agonist. J Med Chem 48: 5305-5320.
BYRD, C., G. C. TURNER and A. VARSHAVSKY, 1998 The N-end rule pathway controls the
import of peptides through degradation of a transcriptional repressor. Embo J 17:
269-277.
34

CALVO, J. M., and R. G. MATTHEWS, 1994 The leucine-responsive regulatory protein, a
global regulator of metabolism in Escherichia coli. Microbiol Rev 58: 466-490.
CURINI, M., F. EPIFANO and S. GENOVESE, 2005 Synthesis of a novel prodrug of 3-(4'geranyloxy-3'-methoxyphenyl)-2-trans-propenoic acid for colon delivery. Bioorg
Med Chem Lett 15: 5049-5052.
DALPIAZ, A., S. SPISANI, C. BIONDI, E. FABBRI, M. NALLI et al., 2003 Studies on human
neutrophil biological functions by means of formyl-peptide receptor agonists and
antagonists. Curr Drug Targets Immune Endocr Metabol Disord 3: 33-42.
DANIEL, H., 2004 Molecular and integrative physiology of intestinal peptide transport.
Annu Rev Physiol 66: 361-384.
DANIEL, H., and G. KOTTRA, 2004 The proton oligopeptide cotransporter family SLC15
in physiology and pharmacology. Pflugers Arch 447: 610-618.
DE BOER, M.,

P. S. NIELSEN, J. P. BEBELMAN, H. HEERIKHUIZEN, H. A. ANDERSEN et al.,
2000 Stp1p, Stp2p and Abf1p are involved in regulation of expression of the
amino acid transporter gene BAP3 of Saccharomyces cerevisiae. Nucleic Acids
Res 28: 974-981.

DEN HENGST, C. D.,

P. CURLEY, R. LARSEN, G. BUIST, A. NAUTA et al., 2005 Probing
direct interactions between CodY and the oppD promoter of Lactococcus lactis. J
Bacteriol 187: 512-521.

DETMERS, F. J., E. R. KUNJI, F. C. LANFERMEIJER, B. POOLMAN and W. N. KONINGS,
1998 Kinetics and specificity of peptide uptake by the oligopeptide transport
system of Lactococcus lactis. Biochemistry 37: 16671-16679.
DEV, I. K., and P. H. RAY, 1990 Signal peptidases and signal peptide hydrolases. J
Bioenerg Biomembr 22: 271-290.
DOEVEN, M. K., R. ABELE, R. TAMPE and B. POOLMAN, 2004 The binding specificity of
OppA determines the selectivity of the oligopeptide ATP-binding cassette
transporter. J Biol Chem 279: 32301-32307.
DONATON, M. C., I. HOLSBEEKS, O. LAGATIE, G. VAN ZEEBROECK, M. CRAUWELS et al.,
2003 The Gap1 general amino acid permease acts as an amino acid sensor for
activation of protein kinase A targets in the yeast Saccharomyces cerevisiae. Mol
Microbiol 50: 911-929.
DU, F., F. NAVARRO-GARCIA, Z. XIA, T. TASAKI and A. VARSHAVSKY, 2002 Pairs of
dipeptides synergistically activate the binding of substrate by ubiquitin ligase
through dissociation of its autoinhibitory domain. Proc Natl Acad Sci U S A 99:
14110-14115.
35

ECKERT-BOULET, N., P. S. NIELSEN, C. FRIIS, M. M. DOS SANTOS, J. NIELSEN et al., 2004
Transcriptional profiling of extracellular amino acid sensing in Saccharomyces
cerevisiae and the role of Stp1p and Stp2p. Yeast 21: 635-648.
ERBELDINGER, M., X. NI and P. J. HALLING, 2001 Kinetics of enzymatic solid-to-solid
peptide synthesis: synthesis of Z-aspartame and control of acid-base conditions by
using inorganic salts. Biotechnol Bioeng 72: 69-76.
ERIKSSON, A. H., P. L. ELM, M. BEGTRUP, R. NIELSEN, B. STEFFANSEN et al., 2005
hPEPT1 affinity and translocation of selected Gln-Sar and Glu-Sar dipeptide
derivatives. Mol Pharm 2: 242-249.
FADEN, A. I., S. M. KNOBLACH, V. A. MOVSESYAN, P. M. T. LEA and I. CERNAK, 2005
Novel neuroprotective tripeptides and dipeptides. Ann N Y Acad Sci 1053: 472481.
FEI, Y. J., Y. KANAI, S. NUSSBERGER, V. GANAPATHY, F. H. LEIBACH et al., 1994
Expression cloning of a mammalian proton-coupled oligopeptide transporter.
Nature 368: 563-566.
FORSBERG, H., C. F. GILSTRING, A. ZARGARI, P. MARTINEZ and P. O. LJUNGDAHL, 2001a
The role of the yeast plasma membrane SPS nutrient sensor in the metabolic
response to extracellular amino acids. Mol Microbiol 42: 215-228.
FORSBERG, H., M. HAMMAR, C. ANDREASSON, A. MOLINER and P. O. LJUNGDAHL, 2001b
Suppressors of ssy1 and ptr3 null mutations define novel amino acid sensorindependent genes in Saccharomyces cerevisiae. Genetics 158: 973-988.
FORSBERG, H., and P. O. LJUNGDAHL, 2001a Genetic and biochemical analysis of the
yeast plasma membrane Ssy1p-Ptr3p-Ssy5p sensor of extracellular amino acids.
Mol Cell Biol 21: 814-826.
FORSBERG, H., and P. O. LJUNGDAHL, 2001b Sensors of extracellular nutrients in
Saccharomyces cerevisiae. Curr Genet 40: 91-109.
FOUCAUD, C., E. R. KUNJI, A. HAGTING, J. RICHARD, W. N. KONINGS et al., 1995
Specificity of peptide transport systems in Lactococcus lactis: evidence for a third
system which transports hydrophobic di- and tripeptides. J Bacteriol 177: 46524657.
FRIEDRICHSEN, G. M., P. JAKOBSEN, M. TAUB and M. BEGTRUP, 2001 Application of
enzymatically stable dipeptides for enhancement of intestinal permeability.
Synthesis and in vitro evaluation of dipeptide-coupled compounds. Bioorg Med
Chem 9: 2625-2632.
36

FUJITA, T., Y. MAJIKAWA, S. UMEHISA, N. OKADA, A. YAMAMOTO et al., 1999 sigma
Receptor ligand-induced up-regulation of the H(+)/peptide transporter PEPT1 in
the human intestinal cell line Caco-2. Biochem Biophys Res Commun 261: 242246.
GEUEKE, B., K. NAMOTO, D. SEEBACH and H. P. KOHLER, 2005 A novel beta-peptidyl
aminopeptidase (BapA) from strain 3-2W4 cleaves peptide bonds of synthetic
beta-tri- and beta-dipeptides. J Bacteriol 187: 5910-5917.
GONZALES, T., and J. ROBERT-BAUDOUY, 1996 Bacterial aminopeptidases: properties and
functions. FEMS Microbiol Rev 18: 319-344.
HAGTING, A., J. VD VELDE, B. POOLMAN and W. N. KONINGS, 1997 Membrane topology
of the di- and tripeptide transport protein of Lactococcus lactis. Biochemistry 36:
6777-6785.
HAUSER, M., V. NARITA, A. M. DONHARDT, F. NAIDER and J. M. BECKER, 2001
Multiplicity and regulation of genes encoding peptide transporters in
Saccharomyces cerevisiae. Mol Membr Biol 18: 105-112.
HERRERA-RUIZ, D., and G. T. KNIPP, 2003 Current perspectives on established and
putative mammalian oligopeptide transporters. J Pharm Sci 92: 691-714.
HOMANN, O. R., H. CAI, J. M. BECKER and S. L. LINDQUIST, 2005 Harnessing natural
diversity to probe metabolic pathways. PLoS Genet 1: e80.
HUBE, B., and J. NAGLIK, 2001 Candida albicans proteinases: resolving the mystery of a
gene family. Microbiology 147: 1997-2005.
IRAQUI, I., S. VISSERS, F. BERNARD, J. O. DE CRAENE, E. BOLES et al., 1999 Amino acid
signaling in Saccharomyces cerevisiae: a permease-like sensor of external amino
acids and F-Box protein Grr1p are required for transcriptional induction of the
AGP1 gene, which encodes a broad-specificity amino acid permease. Mol Cell
Biol 19: 989-1001.
ISLAND, M. D., F. NAIDER and J. M. BECKER, 1987 Regulation of dipeptide transport in
Saccharomyces cerevisiae by micromolar amino acid concentrations. J Bacteriol
169: 2132-2136.
ISLAND, M. D., J. R. PERRY, F. NAIDER and J. M. BECKER, 1991 Isolation and
characterization of S. cerevisiae mutants deficient in amino acid-inducible peptide
transport. Curr Genet 20: 457-463.
ITO, K., M. UNO and Y. NAKAMURA, 2000 A tripeptide 'anticodon' deciphers stop codons
in messenger RNA. Nature 403: 680-684.
37

JAIN, R., S. AGARWAL, S. MAJUMDAR, X. ZHU, D. PAL et al., 2005 Evasion of P-gp
mediated cellular efflux and permeability enhancement of HIV-protease inhibitor
saquinavir by prodrug modification. Int J Pharm 303: 8-19.
JIA, J., R. LU, S. QIU, H. LI, X. CHE et al., 2005 Preliminary Investigation of the
Inhibitory Effects of the Tyroservaltide (YSV) Tripeptide on Human
Hepatocarcinoma BEL-7402. Cancer Biol Ther 4: 993-997.
KLASSON, H., G. R. FINK and P. O. LJUNGDAHL, 1999 Ssy1p and Ptr3p are plasma
membrane components of a yeast system that senses extracellular amino acids.
Mol Cell Biol 19: 5405-5416.
KODAMA, Y., F. OMURA, K. TAKAHASHI, K. SHIRAHIGE and T. ASHIKARI, 2002 Genomewide expression analysis of genes affected by amino acid sensor Ssy1p in
Saccharomyces cerevisiae. Curr Genet 41: 63-72.
KOLAKOVICH, K. A., I. Y. GLUZMAN, K. L. DUFFIN and D. E. GOLDBERG, 1997
Generation of hemoglobin peptides in the acidic digestive vacuole of Plasmodium
falciparum implicates peptide transport in amino acid production. Mol Biochem
Parasitol 87: 123-135.
KORHONEN, H., and A. PIHLANTO, 2003 Food-derived bioactive peptides--opportunities
for designing future foods. Curr Pharm Des 9: 1297-1308.
KRAINER, E., J. M. BECKER and F. NAIDER, 1991 Synthesis and biological evaluation of
dipeptidyl and tripeptidyl polyoxin and nikkomycin analogues as anticandidal
prodrugs. J Med Chem 34: 174-180.
KUMAR, D., and T. C. BHALLA, 2005 Microbial proteases in peptide synthesis:
approaches and applications. Appl Microbiol Biotechnol 68: 726-736.
KUNJI, E. R., I. MIERAU, A. HAGTING, B. POOLMAN and W. N. KONINGS, 1996a The
proteolytic systems of lactic acid bacteria. Antonie Van Leeuwenhoek 70: 187221.
KUNJI, E. R., I. MIERAU, B. POOLMAN, W. N. KONINGS, G. VENEMA et al., 1996b Fate of
peptides in peptidase mutants of Lactococcus lactis. Mol Microbiol 21: 123-131.
LAMARQUE, M., P. CHARBONNEL, D. AUBEL, J. C. PIARD, D. ATLAN et al., 2004 A
multifunction ABC transporter (Opt) contributes to diversity of peptide uptake
specificity within the genus Lactococcus. J Bacteriol 186: 6492-6500.
LARSEN, S. D., T. BARF, C. LILJEBRIS, P. D. MAY, D. OGG et al., 2002 Synthesis and
biological activity of a novel class of small molecular weight peptidomimetic
competitive inhibitors of protein tyrosine phosphatase 1B. J Med Chem 45: 598622.
38

LEE, V. H., 2000 Membrane transporters. Eur J Pharm Sci 11 Suppl 2: S41-50.
LI, Y., Y. SAITO, M. SUZUKI, H. UEDA, M. ENDO et al., 2006 Kyotorphin has a novel
action on rat cardiac muscle. Biochem Biophys Res Commun 339: 805-809.
LIN, B., S. A. SHORT, M. ESKILDSEN, M. S. KLEMPNER and L. T. HU, 2001 Functional
testing of putative oligopeptide permease (Opp) proteins of Borrelia burgdorferi: a
complementation model in opp(-) Escherichia coli. Biochim Biophys Acta 1499:
222-231.
LIU, W., R. LIANG, S. RAMAMOORTHY, Y. J. FEI, M. E. GANAPATHY et al., 1995
Molecular cloning of PEPT 2, a new member of the H+/peptide cotransporter
family, from human kidney. Biochim Biophys Acta 1235: 461-466.
LU, H., and C. KLAASSEN, 2005 Tissue distribution and thyroid hormone regulation of
Pept1 and Pept2 mRNA in rodents. Peptides.
LUBKOWITZ, M. A., L. HAUSER, M. BRESLAV, F. NAIDER and J. M. BECKER, 1997 An
oligopeptide transport gene from Candida albicans. Microbiology 143 ( Pt 2):
387-396.
MADSHUS, I. H., 1988 Regulation of intracellular pH in eukaryotic cells. Biochem J 250:
1-8.
MARZLUF, G. A., 1997 Genetic regulation of nitrogen metabolism in the fungi. Microbiol
Mol Biol Rev 61: 17-32.
MEISEL, H., and W. BOCKELMANN, 1999 Bioactive peptides encrypted in milk proteins:
proteolytic activation and thropho-functional properties. Antonie Van
Leeuwenhoek 76: 207-215.
MEREDITH, D., and C. A. BOYD, 2000 Structure and function of eukaryotic peptide
transporters. Cell Mol Life Sci 57: 754-778.
MIYAKE, T., M. KANAYAMA, H. SAMMOTO and B. ONO, 2002 A novel cis-acting
cysteine-responsive regulatory element of the gene for the high-affinity
glutathione transporter of Saccharomyces cerevisiae. Mol Genet Genomics 266:
1004-1011.
MONETON, P., P. SARTHOU and F. LE GOFFIC, 1986 Transport and hydrolysis of peptides
in Saccharomyces cerevisiae. J Gen Microbiol 132: 2147-2153.

39

NAGLIK, J. R., S. J. CHALLACOMBE and B. HUBE, 2003 Candida albicans secreted aspartyl
proteinases in virulence and pathogenesis. Microbiol Mol Biol Rev 67: 400-428,
table of contents.
NAKAMURA, Y., and K. ITO, 2002 A tripeptide discriminator for stop codon recognition.
FEBS Lett 514: 30-33.
NIELSEN, C. U., J. AMSTRUP, R. NIELSEN, B. STEFFANSEN, S. FROKJAER et al., 2003
Epidermal growth factor and insulin short-term increase hPepT1-mediated
glycylsarcosine uptake in Caco-2 cells. Acta Physiol Scand 178: 139-148.
NIELSEN, C. U., and B. BRODIN, 2003 Di/tri-peptide transporters as drug delivery targets:
regulation of transport under physiological and patho-physiological conditions.
Curr Drug Targets 4: 373-388.
PAYNE, J. W., and M. W. SMITH, 1994 Peptide transport by micro-organisms. Adv Microb
Physiol 36: 1-80.
PELLEGRINI, A., 2003 Antimicrobial peptides from food proteins. Curr Pharm Des 9:
1225-1238.
PERRY, J. R., M. A. BASRAI, H. Y. STEINER, F. NAIDER and J. M. BECKER, 1994 Isolation
and characterization of a Saccharomyces cerevisiae peptide transport gene. Mol
Cell Biol 14: 104-115.
PODBIELSKI, A., and B. A. LEONARD, 1998 The group A streptococcal dipeptide permease
(Dpp) is involved in the uptake of essential amino acids and affects the expression
of cysteine protease. Mol Microbiol 28: 1323-1334.
POULSEN, P., B. WU, R. F. GABER, K. OTTOW, H. A. ANDERSEN et al., 2005 Amino acid
sensing by Ssy1. Biochem Soc Trans 33: 261-264.
PRITCHARD, G. G., and T. COOLBEAR, 1993 The physiology and biochemistry of the
proteolytic system in lactic acid bacteria. FEMS Microbiol Rev 12: 179-206.
ROSE, B., J. M. BECKER and F. NAIDER, 1979 Peptidase activities in Saccharomyces
cerevisiae. J Bacteriol 139: 220-224.
RUBIO-ALIAGA, I., and H. DANIEL, 2002 Mammalian peptide transporters as targets for
drug delivery. Trends Pharmacol Sci 23: 434-440.
SAIER, M. H., JR., 1999 A functional-phylogenetic system for the classification of
transport proteins. J Cell Biochem Suppl 32-33: 84-94.

40

SAIER, M. H., JR., C. V. TRAN and R. D. BARABOTE, 2006 TCDB: the Transporter
Classification Database for membrane transport protein analyses and information.
Nucleic Acids Res 34: D181-186.
SARIC, T., C. I. GRAEF and A. L. GOLDBERG, 2004 Pathway for degradation of peptides
generated by proteasomes: a key role for thimet oligopeptidase and other
metallopeptidases. J Biol Chem 279: 46723-46732.
SHIOMI, H., Y. KURAISHI, H. UEDA, Y. HARADA, H. AMANO et al., 1981 Mechanism of
kyotorphin-induced release of Met-enkephalin from guinea pig striatum and
spinal cord. Brain Res 221: 161-169.
SHIRAGA, T., K. MIYAMOTO, H. TANAKA, H. YAMAMOTO, Y. TAKETANI et al., 1999
Cellular and molecular mechanisms of dietary regulation on rat intestinal
H+/Peptide transporter PepT1. Gastroenterology 116: 354-362.
SMITH, M. W., D. R. TYREMAN, G. M. PAYNE, N. J. MARSHALL and J. W. PAYNE, 1999
Substrate specificity of the periplasmic dipeptide-binding protein from
Escherichia coli: experimental basis for the design of peptide prodrugs.
Microbiology 145 ( Pt 10): 2891-2901.
SOLOMON, J., L. SU, S. SHYN and A. D. GROSSMAN, 2003 Isolation and characterization
of mutants of the Bacillus subtilis oligopeptide permease with altered specificity
of oligopeptide transport. J Bacteriol 185: 6425-6433.
STEINER, H. Y., F. NAIDER and J. M. BECKER, 1995 The PTR family: a new group of
peptide transporters. Mol Microbiol 16: 825-834.
TAMAI, I., T. NAKANISHI, H. NAKAHARA, Y. SAI, V. GANAPATHY et al., 1998
Improvement of L-dopa absorption by dipeptidyl derivation, utilizing peptide
transporter PepT1. J Pharm Sci 87: 1542-1546.
TEMSAMANI, J., and P. VIDAL, 2004 The use of cell-penetrating peptides for drug delivery.
Drug Discov Today 9: 1012-1019.
THAMOTHARAN, M., S. Z. BAWANI, X. ZHOU and S. A. ADIBI, 1998 Mechanism of
dipeptide stimulation of its own transport in a human intestinal cell line. Proc
Assoc Am Physicians 110: 361-368.
THAMOTHARAN, M., S. Z. BAWANI, X. ZHOU and S. A. ADIBI, 1999 Hormonal regulation
of oligopeptide transporter pept-1 in a human intestinal cell line. Am J Physiol
276: C821-826.
TOMKINSON, B., and A. C. LINDAS, 2005 Tripeptidyl-peptidase II: a multi-purpose
peptidase. Int J Biochem Cell Biol 37: 1933-1937.
41

TROITSKAYA, L. A., and T. KODADEK, 2004 Peptides as modulators of enzymes and
regulatory proteins. Methods 32: 406-415.
TURNER, G. C., F. DU and A. VARSHAVSKY, 2000 Peptides accelerate their uptake by
activating a ubiquitin-dependent proteolytic pathway. Nature 405: 579-583.
VABENO, J., T. LEJON, C. U. NIELSEN, B. STEFFANSEN, W. CHEN et al., 2004a Phe-Gly
dipeptidomimetics designed for the di-/tripeptide transporters PEPT1 and PEPT2:
synthesis and biological investigations. J Med Chem 47: 1060-1069.
VABENO, J., C. U. NIELSEN, T. INGEBRIGTSEN, T. LEJON, B. STEFFANSEN et al., 2004b
Dipeptidomimetic ketomethylene isosteres as pro-moieties for drug transport via
the human intestinal di-/tripeptide transporter hPEPT1: design, synthesis, stability,
and biological investigations. J Med Chem 47: 4755-4765.
VERMA, V., A. MANN, W. COSTAIN, G. PONTORIERO, J. M. CASTELLANO et al., 2005
Modulation of agonist binding to human dopamine receptor subtypes by L-prolylL-leucyl-glycinamide and a peptidomimetic analog. J Pharmacol Exp Ther 315:
1228-1236.
WANDERSMAN, C., 1998 Protein and peptide secretion by ABC exporters. Res Microbiol
149: 163-170.
WOUTERS, J. A., T. HAIN, A. DARJI, E. HUFNER, H. WEMEKAMP-KAMPHUIS et al., 2005
Identification and characterization of Di- and tripeptide transporter DtpT of
Listeria monocytogenes EGD-e. Appl Environ Microbiol 71: 5771-5778.
XIE, Y., and A. VARSHAVSKY, 1999 The E2-E3 interaction in the N-end rule pathway: the
RING-H2 finger of E3 is required for the synthesis of multiubiquitin chain. Embo
J 18: 6832-6844.
XIE, Y., and A. VARSHAVSKY, 2000 Physical association of ubiquitin ligases and the 26S
proteasome. Proc Natl Acad Sci U S A 97: 2497-2502.
YAMAMOTO, N., 1997 Antihypertensive peptides derived from food proteins.
Biopolymers 43: 129-134.
YAMAMOTO, N., M. EJIRI and S. MIZUNO, 2003 Biogenic peptides and their potential use.
Curr Pharm Des 9: 1345-1355.
YAO, Z., R. LU, J. JIA, P. ZHAO, J. YANG et al., 2005 The effect of tripeptide
tyroserleutide (YSL) on animal models of hepatocarcinoma. Peptides.

42

PART II

GENOME-WIDE SCREEN REVEALS A WIDE REGULATORY NETWORK
FOR DI/TRI-PEPTIDE UTILIZATION IN Saccharomyces cerevisiae
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ABSTRACT
Small peptides of two to six residues serve as important sources of amino acids
and nitrogen required for growth by a variety of organisms. In the yeast Saccharomyces
cerevisiae, the membrane transport protein Ptr2p, encoded by PTR2, mediates the uptake
of di/tri-peptides. To identify genes involved in regulation of dipeptide utilization, we
performed a systematic, functional examination of this process in a haploid, non-essential,
single-gene deletion mutant library. We have identified 103 candidate genes: 57 genes
whose deletion decreased dipeptide utilization and 46 genes whose deletion enhanced
dipeptide utilization. Based on Ptr2p-GFP expression studies, together with PTR2
expression analysis and dipeptide uptake assays, 42 genes were ascribed to the regulation
of PTR2 expression, 37 genes were involved in Ptr2p localization, and 24 genes did not
apparently affect Ptr2p-GFP expression or localization. The 103 genes regulating
dipeptide utilization were distributed among most of the Gene Ontology functional
categories indicating a very wide regulatory network involved in transport and utilization
of dipeptides in yeast. It is anticipated that further characterization of how these genes
affect peptide utilization should add new insights into the global mechanisms of
regulation of transport systems in general and peptide utilization in particular.
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INTRODUCTION
Peptides can serve as a major nutritional source of amino acids and nitrogen for
microbial cell growth and for human nutrition as well (DANIEL 2004; PRITCHARD and
COOLBEAR 1993). Peptides are generated by the action of proteases and peptidases in
environments where microbes reside (DANIEL 2004; GONZALES and ROBERT-BAUDOUY
1996). All cellular organisms from bacteria to fungi, plants and mammals are capable of
taking up small peptides (two to six amino acids) through a system mediated by
cytoplasmic membrane transporters specific for peptides (HAUSER et al. 2001). In
mammalian systems, two major peptide transporters, PepT1 and PepT2, have been found
in the intestine and kidney, respectively (FEI et al. 1994; LIU et al. 1995). The PepT1
transporter provides the means for absorption of nutritional peptides and peptidomimetic
drugs, such as beta-lactam antibiotics, angiotensin converting enzyme inhibitors, renin
inhibitors, and antivirals. The substrate specificity of these transporters has provided an
impetus to many pharmaceutical companies to develop peptide transporters as drug
delivery systems (HERRERA-RUIZ and KNIPP 2003; LEE 2000).
Two peptide transport systems have been characterized in the model eukaryote
Saccharomyces cerevisiae: the PTR (Peptide TRansport) system transports di/tri-peptides
(STEINER et al. 1995) and the OPT (OligoPeptide Transport) system highly favors
transport of peptides of four to five amino acid residues and glutathione (LUBKOWITZ et
al. 1997; MIYAKE et al. 2002). While PTR family members are present in all cells studied
to date and are in the same family as the mammalian transporters PepT1 and PepT2, OPT
family members have been found only in plants and fungi (HAUSER et al. 2001). Both
The PTR and OPT transport systems are dependent on the proton-motive force, are
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predicted to have twelve transmembrane domains, and have specific signature sequences
distinguishing them from one another and from all other proteins in the database
(HAUSER et al. 2001). Yet the amino acid sequence of the PTR and OPT members places
them in different, unrelated families of transport proteins with presumably totally
separate evolutionary origins. The only S. cerevisiae member of the PTR system is Ptr2p,
encoded by the PTR2 gene. Di/tri-peptide utilization is regulated by a number of means
including PTR2 transcriptional regulation.
In early studies pre-dating the cloning of PTR2, peptide utilization was shown to
be up-regulated by growing cells on organic nitrogen sources such as allantoin, isoleucine,
or proline defined as poor nitrogen sources in comparison to the rich nitrogen source
ammonium sulfate (ISLAND et al. 1991). Peptide utilization was also stimulated markedly
by addition of micromolar amounts of certain amino acids, most notably leucine and
tryptophan, to the growth medium (BAETZ et al. 2004; ISLAND et al. 1987). These
environmental conditions were later shown to up-regulate the expression of PTR2 (PERRY
et al. 1994). Although nitrogen source apparently regulates PTR2 expression via nitrogen
catabolite repression (MARZLUF 1997), amino acids regulate PTR2 expression via the
SPS (Ssy1p-Ptr3p-Ssy5p) signal transduction pathway (BARNES et al. 1998; FORSBERG et
al. 2001a; FORSBERG et al. 2001b; FORSBERG and LJUNGDAHL 2001b).
In the SPS complex, Ssy1p is a transmembrane receptor that senses extracellular
amino acids. Ptr3p and Ssy5p interact with the cytoplasmically located N-terminus of
Ssy1p (FORSBERG and LJUNGDAHL 2001a; POULSEN et al. 2005). Two related
transcription factors, Stp1p and Stp2p, are down-stream of the SPS complex and regulate
the expression of PTR2 and branched-chain amino acid permeases (DE BOER et al. 2000).
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Stp1p and Stp2p are synthesized in an inactive form, and the activation of Stp1p and
Stp2p depends on the endoproteolytic-processing of their N-terminus domain mediated
by Ptr3p and Ssy5p. The truncated forms of Stp1p and Stp2p are translocated into the
nucleus to up-regulate expression of down-stream genes including PTR2 (ANDREASSON
and LJUNGDAHL 2002; ANDREASSON and LJUNGDAHL 2004).
In addition to the SPS complex regulation, PTR2 expression is positively
regulated by the import of di/tri-peptides with basic (Arg, His, or Lys) and bulky (Ile, Leu,
Phe, Trp, or Tyr) N-terminal residues that bind to Ubr1p to allosterically activate Ubr1pmediated degradation of the PTR2 repressor Cup9p (BYRD et al. 1998; DU et al. 2002;
TURNER et al. 2000). Relief of Cup9p repression of PTR2 results in enhanced PTR2
expression. In a cup9 null mutant strain, PTR2 is over-expressed, resulting in a marked
increase in dipeptide uptake (BYRD et al. 1998). Cup9p is degraded by Ptr1p through the
ubiquitinylation pathway. In this pathway, Ptr1p acts as a scaffolding protein or ubiquitin
ligase (E3) for two other proteins, Ubc2p and Ubc4p, which serve as ubiquitinconjugating (E2) enzymes in the Cup9p degradation process (XIE and VARSHAVSKY
1999). Deletion of PTR1 results in the stabilization of Cup9p, lack of expression of PTR2,
and a null peptide-uptake phenotype (DU et al. 2002; ISLAND et al. 1991; TURNER et al.
2000). Other transcription factors, such as Dal81p/Uga35p, have also been reported to be
involved in PTR2 expression, in ways apparently different from their involvement in the
SPS or Cup9p pathways (IRAQUI et al. 1999). Obviously, the systems regulating PTR2
expression are numerous and complex, and there has not been a systematic study to
uncover other proteins involved in the regulation of peptide utilization.
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Systematic screening of yeast deletion mutant collections has been successfully
applied in identifying genes related to drug resistance (AOUIDA et al. 2004; BAETZ et al.
2004; PAGE et al. 2003), human disease (STEINMETZ et al. 2002), telomere function
(ASKREE et al. 2004), centromeric cohesion (MARSTON et al. 2004), vacuolar protein
sorting (BONANGELINO et al. 2002), and other biological processes (SCHERENS and
GOFFEAU 2004). In order to identify other gene products involved in the regulation of
peptide utilization in yeast, we conducted a genome-wide screen using the haploid, nonessential, single-gene deletion strain library. We have identified a total of 103 Open
Reading Frames (ORFs), accounting for about 2 percent of the non-essential deletion
mutants as being involved in causing increased or decreased utilization of peptides for
growth. We monitored Ptr2p-GFP expression in the identified 103 deletion mutant
strains, and genes involved in multiple cellular functions including transcriptional
regulation and membrane trafficking were revealed as being involved in dipeptide
utilization. The data generated provide a global view of molecular components regulating
dipeptide utilization by S. cerevisiae.
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MATERIAL AND METHODS
Strains, media, and mutant library growth assay screen: A yeast haploid, nonessential, single-gene deletion mutant strain library was purchased from Open
Biosystems (Huntsville, AL) containing 4827 deletion strains, 4750 in the BY4742
(MATα his3∆1 leu2∆0 lys2∆0 ura3∆0) background, and 77 strains in the BY4739 (MATα
leu2∆0 lys2∆0 ura3∆0) strain background. The list of strains contained in the library is
available at the company’s website (http://openbiosystems.com/yeast_knock_outs.php).
The deletion mutants were arrayed in 96-well microtiter plates kept at -80˚C in YPD
broth containing G418 and glycerol (1% yeast extract, 2% peptone, 2% dextrose, 200
μg/mL G418, and 15% glycerol). After thawing, the deletion mutants were inoculated
into minimal medium supplemented with amino acids to satisfy the auxotrophic
requirements using a 96-well plate replicator. The minimal medium used in this study is
referred to as MM+HLKU and contained (per liter) 20g dextrose, 1.7g Yeast Nitrogen
Base (Difco) without (NH4)2SO4 and amino acids, 1g allantoin as nitrogen source,
supplemented with 20μg/mL His (H), 30μg/mL Leu (L), 30μg/mL Lys (K), and 20μg/mL
Ura (U). The plates were incubated at 30˚C for 2 days, then the liquid medium growth
assay was performed as follows. Five microliters from each well were inoculated into
200μL of three different liquid media: (1) MM+HLKU medium as described above, (2)
MM+(H-L)HKU medium, or (3) MM+(H-L)HKU+Trp medium. The MM+(H-L)HKU
and MM+(H-L)HKU+Trp media contained 80μM His-Leu dipeptide (H-L) in place of
leucine with all other components identical to the MM+HLKU medium, except that
tryptophan (30μg/mL) was added to the MM+(H-L)HKU+Trp medium. The purpose of
the tryptophan addition was to induce PTR2 expression as shown in previous studies
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(ISLAND et al. 1987). The efficiency of the utilization of His-Leu was reflected in cell
growth. The mini-cultures in the microtiter plates were grown at 30˚C with shaking at
200 rpm. The OD620 was measured at incubation times of 0, 12, 24, 48, and 72 hours with
a 96-well plate reader (Labsystems Multiskan MCC/340, Finland). In some
circumstances, growth at incubation times of 36, 60, 84, and 96 hours were also recorded.
The ptr2 deletion mutant was not able to grow in the His-Leu supplemented medium,
although its growth in the medium MM+HKLU was excellent. Strains either defective in
peptide utilization (ptr1 deletion) or over-expressing PTR2 (cup9 deletion) were
inoculated into wells of each plate as controls showing defective or enhanced dipeptide
utilization, respectively. In this manner, deletion strains were identified that grew more,
or less, efficiently than wild-type in MM+(H-L)HKU or MM+(H-L)HKU+Trp medium.

Solid medium growth assay: Using the same principle as that employed in the liquid
medium growth assay, a solid medium growth assay was used to determine whether the
candidate gene deletion strains obtained from the liquid medium growth screen could
utilize dipeptide on solid medium as their substrate to satisfy auxotrophic requirements.
The deletion mutant candidates from the screen, wild type BY4742, cup9, and ptr1
deletion mutants were grown overnight in MM+HLKU liquid medium at 30˚C while
shaking at 200rpm. Cells were harvested by centrifugation and washed three times with
sterile, distilled water. Cells were then counted by hemacytometer and adjusted to the cell
number of 5x106/mL. Five microliters of a suspension containing 2.5x104 and 2.5x103
yeast cells were spotted onto agar plates containing one of three different media: (1)
MM+HLKU, (2) MM+(H-L)HKU, or (3) MM+(H-L)HKU+Trp. The plates were
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incubated at 30˚C, and growth was recorded after 2 days. A score was given to the
growth of each strain compared to the growth of wild-type, cup9, and ptr1 deletion
mutant strains.

Toxic halo assays and osmotic sensitivity assay: For the toxic dipeptide halo assay, the
sensitivity of deletion mutants to the toxic dipeptide Ala-Eth was measured as previously
described (ISLAND et al. 1987). Ethionine (Eth) is an analog of methionine, and
utilization of Eth causes cell death. This assay is more sensitive than the previously
described dipeptide growth assays. Yeast cells having a functional dipeptide transport
system will take up the toxic dipeptide and die (indicated by a clear halo of growth
inhibition on plates spotted with ethioninyl-containing peptides). Cells with a defective
dipeptide uptake system will not take up the dipeptide efficiently and will survive (as
indicated by a small halo or no halo). Cells were grown overnight in MM+HLKU
medium, then harvested and washed three times with sterile, distilled water. Yeast cells
were counted and adjusted to the cell number of 5x106/mL. One milliliter of the cell
suspension was added to 0.8% noble agar (3mL) and plated onto solid MM+HLKU
medium. Two 6mm sterile paper disks containing either 0.2 or 0.1µmoles of Ala-Eth
were placed on the lawn of cells. The halo size was measured after two days of
incubation at 30˚C. The halo size formed by each deletion mutant was compared to the
halo size of the wild-type strain by dividing the halo size of the mutant by the halo size of
the wild-type strain and multiplied by 100 to get a percentage. A strain that gave a higher
than 100% value was considered to be deleted for a gene that would was involved in
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down-regulation of peptide utilization, whereas a strain deleted for a gene involved in upregulation would give a lower than 100% value in this test.
For the canavanine toxicity assay, the procedure was the same as the toxic
dipeptide halo assay. Two 6 mm sterile paper disks containing 1µg of canavanine were
placed on the lawn of cells. The size of halo was measured and the image was taken after
two days incubation at 30˚C.
For the osmotic sensitivity assay, the wild type and deletion mutant strains were
grown overnight in MM+HLKU medium, then harvested and washed three times with
sterile, distilled water. Yeast cells were counted and adjusted to the cell number of
5x106/mL, then cells were further diluted to 5x105/mL, 5x104/mL, and 5x103/mL.Ten
microliters of each cell suspension was spotted into MM+HLKU media containing 0M,
0.4M, and 1.0M NaCl.

Uptake assays: The strains were grown overnight in MM+HLKU, then sub-cultured
into a fresh medium. Cells were harvested in log phase, washed with 2% glucose and
adjusted to a final concentration to 2x108 cells/mL. The uptake assay was initiated by
combining equal volumes of pre-warmed (30˚C) cells and uptake assay mixture [2%
glucose, 20mM sodium citrate/potassium phosphate, pH 5.5, 320µM Leu-Leu (Sigma),
and 2µCi/ml [3H]Leu-Leu (ISLAND et al. 1987)]. After 10 minutes, portions (100µL)
were removed onto a membrane filter and washed four times by vacuum filtration with
1mL ice cold water. The radioactivity retained on the filter was determined by liquid
scintillation spectrometry, and results were reported as nmol Leu-Leu uptake/1x109
cells/10 min. The accumulation of [3H]Leu-Leu in ptr2 strain was subtracted from that of
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the tested strains, and the percentage of the accumulation of [3H]Leu-Leu in each deletion
mutant vs the wild-type was calculated.

Reporter gene assay: The centromeric plasmid pRD1, which contained a selectable
URA3 marker and the lacZ gene under the control of the PTR2 promoter was transformed
into the tested deletion mutant strains. The reporter gene assay was performed using a
protocol adapted from Hoffman (HOFFMAN et al. 2002). The strains were grown
overnight in MM+HLK, and sub-cultured into a fresh medium. Cells were harvested in
log phase, washed with sterile water and adjusted to a final concentration to 1x108
cells/mL. Cell suspension (100µL) was added to a well of a 96-well plate, then 20µl FDG
(Fluorescein di-β-D-galactopyranoside) solution was added. The FDG solution was
prepared by mixing solution 1 (0.1mM FDG diluted in 25mM PIPES, pH7.2) and
solution 2 (5% Triton X-100 diluted in 250mM PIPES, pH7.2) in equal amounts just
prior to use. The plate was incubated at 37˚C for 1.5 hours, then read with a fluorescence
multi-well plate reader (Wallac Victor2, 1420 multilabel counter, PerkinElmer Life and
Analytical Sciences, Inc., MA) using 485nm and 530nm as excitation and emission
wavelengths, respectively.

Classification of the obtained genes: The classification of the 103 genes identified
through this screen was based on the Gene Ontology (GO) annotation found in the
Saccharomyces

Genome

Database

(SGD)

(http://db.yeastgenome.org/cgi-

bin/GO/goTermMapper) (CHRISTIE et al. 2004), where 34 functional categories of
biological process were given. Among the 103 genes, some genes fell into several
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categories due to their multiple known functions. The detailed gene function could also
be

referenced

from

Yeast

Proteome

Database

(YPD)

database

(https://proteome.incyte.com/control /tools/ proteome) (HODGES et al. 1999).

Northern analysis of PTR2 mRNA in deletion mutant strains: Approximately 3x108
cells of select candidate deletion mutant strains were harvested after overnight growth in
MM+HLKU medium. Yeast total RNA was isolated using an extraction kit (RiboPureTMyeast, Ambion, Austin, TX). Total RNA was quantified by monitoring absorbance at
260nm, and 20µg was loaded per lane into a formaldehyde-reducing gel. Gels were run in
buffer containing MOPS (pH 7.0) for 5 hours at 75V and then transferred by capillary
action onto a nylon hybridization membrane in 20x SSC. Total RNA was UV crosslinked to the membrane with a Stratalinker UV source. The blot was prehybridized at
65ºC in Church buffer (7% SDS, 1% BSA, 1mM EDTA, and 250 mM Na2HPO4, pH 7.2)
for 2 hours and hybridized overnight in the same buffer containing radioactive probes at
65ºC. Radioactive probes were prepared as follows. A 1.7kb fragment of PTR2 was
obtained by PCR amplification using the primers PTR2-F (Northern) and PTR2-R
(Northern), and a 0.92 kb fragment of ACT1 was obtained by PCR amplification using
the primers ACT1-F (Northern) and ACT1-R (Northern) (primer sequences are
represented in Supplemental Table S1). DNA fragments were labeled with (α-32P)-dATP
by random-primed probe synthesis. Blots were rinsed with post-hybridization buffer
(0.1X SSC, 0.1% SDS) at 65ºC, and the RNA images were developed with a Storm 840
phosphoimager (Molecular Dynamics, Sunnyvale, CA). The expression of PTR2 in each
mutant was analyzed at least twice in separate experiments, with similar expression found
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in each experiment. The quantification of PTR2 and ACT1 mRNA was performed using
the software ImageQuant5.0 (GE Healthcare, Technologies, Waukesha, Wisconsin).

Real-Time RT PCR: Approximately 3 x 108 cells of the tested deletion mutant strains
were harvested after overnight growth in MM+HLKU medium. Yeast total RNA was
isolated using RiboPureTM-Yeast extraction kit (Ambion, Austin, TX), and then treated
with TURBO DNA-freeTM Kit to eliminate the genomic DNA contamination (Ambion,
Austin, TX). The amount of total RNA was quantified by monitoring absorbance at
260nm. To check that the genomic DNA had been eliminated, the obtained total RNA
was used for the template to PCR amplify the target genes, and no PCR product was
obtained. cDNA was synthesized using M-MLV RT (Invitrogen; 400 U reverse
transcriptase) in a reaction mixture containing 1µg Oligo(dT), 1 mM deooxynucleoside
triphosphates, 14 U anti-RNase and 1µg of total RNA at 42°C for 45min, and the reaction
was stopped after 5 minutes by incubation at 72°C.
Real-Time PCR analysis was performed in the DNA Engine OpticonTM (MJ
Research, Boston, MA). QuantiTectTM SYBR Green PCR Kit (Qiagen, Valencia, CA)
and the primers (the sequences are presented in Supplemental Table S1) resulting in
about 100bp amplicon were applied in the PCR reaction. The reaction contained 12.5 µl
of 2x qPCR reaction mix, 15pmol of Primers, and run with a cycle of 50ºC for 2min,
95ºC for 15 min, followed by 40 cycles of 95ºC for 15s, 54ºC for 30s, and 72ºC for 15s.
A standard curve for each primer set was performed with 1, 1:10, 1:100, 1:1000, 1:10000,
1:100000 dilutions of the wild type cDNA. The CT value, the cycle when sample
fluorescence exceeds a chosen threshold above background fluorescence, was determined
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using the software program. The copy number of PTR2, PMA1, and ACT1 genes in each
deletion mutant strain was calculated based on the standard curve. The ratio of the fold
change of target genes (PTR2 and PMA1) vs the fold change of the internal control gene
(ACT1) in the tested mutant strains was calculated to show up-regulation or downregulation. The ratio of the fold change in the wild type was standardized as 1.0.

Ptr2p localization in deletion mutant strains:

In order to trace the localization of

Ptr2p, a Ptr2p-GFP construct was created as follows. The primers PTR2-FLAG-GFP-F
and PTR2-Flag-GFP-R (see Supplemental Table S1 for the sequence) were used to PCR
amplify two tandem copies of the GFP gene using pKW430 [a gift of Dr. Mary Miller,
Rhodes College, Memphis, TN (STADE et al. 1997)] as the template. The amplified PCR
product (1.5kb) had two copies of GFP sequence with 40bp of flanking sequence
homologous to pMS2, which contained PTR2 with its endogenous promoter and
terminator sequences and both FLAG and His tags located at the C terminus. The plasmid
was linearized with AgeI at a unique restriction site located between the FLAG and His
tags. The centromeric plasmid pMS4, containing Ptr2p-FLAG-GFP2-His6 and the
selectable marker URA3, was created by homologous recombination.
To test the localization of Ptr2p-GFP in different yeast strains, the pMS4
construct was transformed into each deletion mutant of interest and transformants
selected by growth in the absence of uracil. Yeast strains carrying pMS4 were pre-grown
in MM+HLK overnight, then inoculated into fresh MM+HLK at an initial cell
concentration of 2x106 cells/mL. Cells were concentrated by centrifugation and observed
at 10 hours after inoculation by fluorescence microscopy using a 470-490nm excitation
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wavelength and 515nm emission filter fitted to an Olympus microscope. Images were
taken with a MicroFireTM camera (Model S99809, Olympus). All mutants were in the log
phase at the 10 hour time point as ascertained by the high proportion of cells with buds
and the low density of cells under the experimental conditions used. To visualize the
amount of GFP expression, each image was captured with the same exposure time.
Significantly higher and lower GFP signal could be distinguished from the captured
images. For those images with higher GFP signal, the images were taken with a
decreased exposure time to be visualized clearly.
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RESULTS
Primary Screening of Deletion Mutants to Identify Strains Demonstrating Increased
or Decreased Dipeptide Utilization
In order to identify genes involved in dipeptide utilization, we screened a library
of 4826 haploid, single-gene deletion strains for mutants with an altered dipeptide
utilization profile. The leucine auxotrophic marker in the BY4742 strain background
(MATα his3∆1 leu2∆0 lys2∆0 ura3∆0) was used to monitor how well each strain was
able to utilize the dipeptide His-Leu. Under the conditions of the screen, cells could grow
only if they were able to take up the dipeptide His-Leu from the medium and release
leucine from the peptide intracellularly. Numerous previous studies have shown that there
is no extracellular peptidase or protease in S. cerevisiae able to catalyze the hydrolysis of
dipeptides under the growth conditions used. In this screening, any mutant strain
demonstrating either an enhanced or decreased growth was considered to have a deletion
in a gene involved in dipeptide utilization. Since Ptr2p is the only dipeptide transporter
expressed in this yeast under the conditions used for the screen, we expected that genes
related to the regulation of PTR2 expression or Ptr2p function would comprise the list of
candidates. The yeast deletion mutant library was generated by the Saccharomyces
Genome Deletion Project, which involved several laboratories (WINZELER et al. 1999).
Only non-essential genes are represented in this deletion mutant collection.
In the primary screening, yeast deletion mutants were grown in a poor nitrogen
medium with allantoin as the nitrogen source. These conditions are known to partially upregulate PTR2 expression (ISLAND et al. 1991). All deletion mutant strains not capable of
growing in allantoin as the sole nitrogen source were necessarily excluded from this
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study. One hundred and nine strains of the haploid collection were identified in this
category. For a full list of the 109 strains see supplemental data Table S2. The rest of the
deletion series, including strains known to be deficient (ptr1) and hyper-active (cup9) for
dipeptide utilization, grew similarly in the MM+HLKU medium.
A screen was performed to the mutant collection in medium [MM+(HL)HKU+Trp] containing His-Leu as the only leucine source. Tryptophan up-regulates
PTR2 expression via the SPS system over the enhancement induced by growth on MM
alone thus providing the maximal dipeptide utilization phenotype (FORSBERG and
LJUNGDAHL 2001b; ISLAND et al. 1987). The screen was also performed without
tryptophan addition with identical results observed (data not shown). Two hundred
seventy-eight deletion mutants were obtained from the primary screening that showed
either enhanced dipeptide utilization (the deleted genes are “negative regulator genes”) or
decreased dipeptide utilization (the deleted genes are “positive regulator genes”). As
controls for comparison of strains that show increased or decreased dipeptide utilization,
cup9 and ptr1 mutants were used. Cup9p is a repressor of PTR2 transcriptional
expression; the cup9 deletion mutant strain has a higher expression level of PTR2 in
comparison to that of the wild-type (BYRD et al. 1998), therefore the hyper-active strain
(cup9) grew better than wild-type on dipeptide (Figure 1 A). Ptr1p is required for
degradation of Cup9p; in the ptr1 deletion mutant strain Cup9p is stabilized (DU et al.
2002; ISLAND et al. 1991), and there is an undetectable level of PTR2 expression
preventing this strain from growing on dipeptide (Figure 1 A). For clarity of presentation
and to present data representative of the phenotypes among the mutants identified, we
highlight in the Results section of this paper eighteen deletion mutant strains (bud32,
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Figure 1 Growth patterns of various selected strains that demonstrate increased or
decreased dipeptide utilization. A) The growth pattern of wild-type (BY4742), ptr1,
cup9, and eight other deletion mutant strains in MM+H(H-L)KU+Trp medium. B) The
growth pattern of wild-type (BY4742), ptr1, cup9, and nine other deletion mutant strains
in MM+H(H-L)KU+Trp medium.
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cup9, dal81, gcv3, hal9, kem1, lpd1, npr1, ptr1, reg1, rpn4, ssn3, srn2, ubc2, ubp14,
ubr2, vps8, and ybt1).
Growth patterns of deletion mutant strains hal9, kem1, npr1, srn2, ssn3, ubr2,
vps8, and ybt1 were similar to that of the cup9 deletion mutant in that they had a shorter
lag phase and a higher growth rate compared to the wild type (Figure 1A). Therefore,
these deletion strains were considered to carry a deletion in a gene involved in decreasing
dipeptide utilization. Growth patterns of deletion mutants bud32, dal81, gcv3, lpd1, reg1,
rpn4, ubc2, and ubp14, had a similar growth pattern to the ptr1 deletion strain which did
not grow in MM+(H-L)HKU+Trp medium (Figure 1 B). These deletion mutants were
considered to carry a deletion in a gene involved in increasing dipeptide utilization.

Verification of Candidate Genes: Solid Media Growth Assay and Toxic Dipeptide
Halo Assay
The candidate mutants were further tested in a solid medium growth assay and a
toxic dipeptide halo assay. The deletion mutant strains were grown on solid medium
plates containing MM+HLKU, MM+(H-L)HKU, or MM+(H-L)HKU+Trp. Eighteen
representative deletion mutant strains with enhanced or decreased dipeptide utilization
are shown in Figure 2. All the tested deletion mutant strains grew to a similar extent as
compared to that of the wild type in MM+HLKU. The deletion mutants hal9, kem1, npr1,
srn2, ssn3, ubr2, vps8, and ybt1 had a similar growth pattern to the cup9 deletion mutant
strain, which grew better than wild-type in both MM+(H-L)HKU+Trp (Figure 2) and
MM+(H-L)HKU (data not shown). In contrast, the deletion mutants bud32, dal81, gcv3,
lpd1, reg1, rpn4, ubc2, and ubp14 had a similar growth pattern to the ptr1 deletion
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Figure 2 Growth of selected strains on solid medium. Two cell dilutions, 3x104 cells /mL, and 3x103 cells/mL were tested on
MM+HLKU and MM+(H-L)HKU+Trp media.
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mutant strain, which could not grow in MM+(H-L)HKU+Trp medium (Figure 2) or in
MM+(H-L)HKU (data not shown). The growth phenotype found in the liquid growth
screening of these chosen candidate mutants with respect to the regulation of dipeptide
utilization was therefore confirmed in this solid medium test.
The mutants identified in the initial screen were also subjected to a toxic dipeptide
assay for further verification of the peptide transport phenotype. In this assay, cells were
grown on MM+HLKU and tested for their sensitivity to Ala-Eth. The halo size of each
deletion mutant strain was measured and compared to that of wild-type. A larger halo
indicated that the deletion mutant strain was more sensitive to Ala-Eth toxic dipeptide
than the wild-type, while a smaller halo indicated less sensitivity. As expected, cup9
developed a larger halo than that of wild-type and ptr1 was not sensitive to the toxic
dipeptide. Similar to that of cup9, deletion strains hal9, kem1, npr1, srn2, ssn3, ubr2,
vps8, and ybt1 developed a larger halo than that of wild-type (Table 1), indicating the
deleted genes negatively regulated dipeptide utilization. Conversely, similar to that of
ptr1, deletion strains bud32, dal81, gcv3, lpd1, reg1, rpn4, ubc2, and ubp14 were not
sensitive to toxic dipeptide (Table 2), indicating that the deleted genes positively
regulated dipeptide utilization.
Of the 278 strains identified in the initial liquid growth screen, 103 strains showed
increased or decreased peptide utilization in all three assays: liquid and solid media
growth and the toxic dipeptide halo assay (Table S3 and S4 listed in order of biological
process according to Gene Ontology annotation). These 103 genes were considered to be
the set of genes involved as either negative or positive regulators of peptide utilization as
determined by the three experimental tests. As expected, five genes (PTR1, CUP9,
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Table 1 The response of deletion mutants with increased dipeptide utilization to Ala-Eth, NaCl, and canavanine.a
Gene name

Description of gene product

Wild-type

Toxicity of Ala-Eth
(% of wild type)b

NaCl
Sensitivityc

Canavanine toxicity
(% of the wild type)d

100

KEM1

Specific RNA polymerase II transcription
factor activity
Specific RNA polymerase II transcription
factor activity
5'-3' exoribonuclease activity

120

-

-

131

-

-

135

More sensitive

Less sensitive

NPR1

Serine/threonine protein kinase

129

-

Less sensitive

SRN2

Class E vacuolar sorting protein

109

More sensitive

More sensitive

SSN3

Cyclin-dependent protein kinase activity

114

-

-

UBR2
VPS8

Ubiquitin-protein ligase activity
Vacuolar sorting

129
121

More sensitive

More sensitive

YBT1

Bile acid transporter activity

156

-

-

CUP9
HAL9

a

These data are also presented in supplementary Table S3, Figure S4, and Figure S5.
The halo size formed by each deletion mutant was compared to the halo size of the wild-type strain by dividing the halo size of the mutant by the halo size of
the wild-type strain and multiplied by 100 to get a percentage.
c
“-” indicates that the deletion strain had no difference in its sensitivity to NaCl compared to that of the wild-type. A strain that was more sensitive exhibited
greater growth inhibition to 1.0 M NaCl in comparison to that shown by the wild-type.
d
“-” indicates that the deletion strain had no difference in sensitivity to canavanine compared to that of the wild-type.
b
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Table 2 The response of deletion mutants with decreased dipeptide utilization to Ala-Eth, NaCl, and canavanine.a
Gene name

Description of gene product

Wild-type

NaCl
Sensitivityc

Canavanine toxicity
(% of the wild type)d

100

PTR1
BUD32

Ubiquitin-protein ligase activity
Protein serine/threonine kinase activity

DAL81

LPD1

Specific RNA polymerase II transcription
factor activity
Glycine dehydrogenase (decarboxylating)
activity
Dihydrolipoyl dehydrogenase activity

REG1

Protein phosphatase type 1 activity

RPN4
UBC2
UBP14

GCV3

Toxicity of Ala-Eth
(% of wild type)b

0
0 (Fuzzy halo)

More sensitive

Less sensitive

0

-

More sensitive

0

-

More sensitive

0

-

More sensitive

0 (Fuzzy halo)

-

More sensitive

Transcriptional activator activity

0

-

-

Ubiquitin conjugating enzyme activity
Ubiquitin-specific protease activity

0
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-

-

a

These data are also presented in supplementary Table S3, Figure S4, and Figure S5.
The halo size formed by each deletion mutant was compared to the halo size of the wild-type strain by dividing the halo size of the mutant by the halo size of
the wild-type strain and multiplied by 100 to get a percentage.
c
“-” indicates that the deletion strain had no difference in its sensitivity to NaCl compared to that of the wild-type. A strain that was more sensitive exhibited
greater growth inhibition to 1.0 M NaCl in comparison to that shown by the wild-type.
d
“-” indicates that the deletion strain had no difference in sensitivity to canavanine compared to that of the wild-type.
b
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UBC2, DAL81/UGA35, and STP2) previously known to be involved in dipeptide
utilization were identified among the 103 genes, which validated the utility of the
screening method. Three other genes (SSY1, PTR3, and SSY5), known to affect dipeptide
utilization via the regulation of PTR2 mRNA expression, were not found in the screen
since they are not included in the deletion mutant library. The number of deletion mutant
strains found by our methods to modulate dipeptide utilization accounted for about 2% of
the entire collection. Of the 46 genes whose deletion mutant strains enhanced dipeptide
utilization (Table S3), 20 encoded proteins with more than a 30% protein sequence
identity to a human protein (Table S3, footnote a). Additionally, of the 57 genes whose
deletion mutant strain decreased dipeptide utilization (Table S4), 33 encoded proteins
with more than a 30% sequence identity to a human protein (Table S4, footnote a).
According to Gene Ontology (GO) annotation in SGD, the 103 genes covered 29 out of
the 34 given categories in the Biological Processes GO categories. The categories of each
gene are indicated in Table S3 and S4.
Ptr2p-GFP Expression and Localization in the Identified Deletion Strains
In order to further explore the impact of the identified 103 genes on dipeptide
utilization, we measured Ptr2p expression and localization using a Ptr2p-GFP chimera.
This construct (pMS4), which encoded Ptr2p-GFP under the control of its native
promoter, was transformed into the 103 deletion strains, and Ptr2p-GFP in log phase cells
was observed by fluorescence microscopy. The addition of the GFP tag did not affect the
function of Ptr2p as demonstrated by halo and uptake assays (data not shown). Ptr2p-GFP
was primarily localized to the plasma membrane in wild-type log-phase cells (Figure 3).
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Figure 3 Ptr2p-GFP expression and localization in the wild-type (WT) and 9
deletion strains that demonstrated increased dipeptide utilization. The right-hand
panel of each strain shows phase microscopy of the same field as the left-hand panel
which shows the fluorescently-labeled Ptr2p-GFP. Deletion strain ssn3 showed a very
high amount of GFP signal under the same exposure time as that of the wild-type.
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The amount of the Ptr2p-GFP expression signal and its localization in the 103 deletion
mutant strains revealed seven phenotypic patterns (Table 3).

Ptr2p-GFP expression and localization in deletion strains with increased dipeptide
utilization: The Ptr2p-GFP expression signal and localization in 46 deletion strains with
increased dipeptide utilization are shown in Figure S1 (9 deletion strains and wild type
are shown in Figure 3 as representative of the full set).
Strains with enhanced Ptr2p-GFP expression signal: A higher level of Ptr2p-GFP
expression signal in the plasma membrane was observed in the cup9 deletion strain as
compared to the wild-type (Figure 3 and Table 3). The enhanced Ptr2p-GFP expression
level corresponded with the phenotype of increased dipeptide utilization as reflected in
growth on dipeptide in liquid and solid medium and toxicity to Ala-Eth (Figure 1, Figure
2, and Table 1). In addition, Ptr2p-GFP was also observed in the vacuole, possibly due to
the over-expressed PTR2 in the cup9 strain. Similar to the cup9 strain, the deletion of
HAL9, KEM1, SSN3, and UBR2 showed an increased Ptr2p-GFP expression signal in
both the plasma membrane and the vacuole. Enhanced Ptr2p-GFP expression signal was
also observed in 18 other deletion strains including four unknown gene deletion mutants,
yfr044c, ylr114c, ynl123w, and yor322c (Table 3 and Figure S1). Consistently, the
increased Ptr2p-GFP expression agreed with increased sensitivity to toxic dipeptide and
better growth on dipeptide substrate (Table S3).
Strains with altered Ptr2p-GFP localization: Fourteen deletion strains with increased
dipeptide utilization showed altered localization of Ptr2p-GFP (Table 3 and Figure S1).
An example of three deletion mutants, npr1, srn2, and vps8 is shown in Figure 3. These
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Table 3 Ptr2p-GFP expression and localization in 103 identified strains with decreased or increased dipeptide utilization.a
Phenotypic Category
Strains with enhanced Ptr2p-GFP
expression
Strains with altered Ptr2p-GFP
localization
Strains with no apparent effect on
Ptr2p-GFP localization or
expression
Strains with decreased Ptr2p-GFP
expression

Increased dipeptide utilization
(46 strains)
arp5, arp8, cup9, csm1, dbr1, eaf3, hal9,
ies6, kem1, mrps9, pat1, sfp1, srb8, ssd1,
ssn2, ssn3, ssn8, tom72, ubr2, yor322c,
ynl123w, yfr044c, ylr114c
bni1, def1, eaf7, lst4, npr1, sac6, snf7, srn2,
tpm1, vam10, vps8, vps36, ypl073c, ynl295w
cik1, kti12, mlh1, mrp17, pho2, rim101, tif3,
ybt1, ydr417c
No mutant strains were found in this
category.

a

Decreased dipeptide utilization
(57 strains)
asm4, ydr015c, ydr290w

bem4, bud32 , csf1, etr1, gcv2, gcv3, hfm1,
ilm1, isa1, isa2, mck1, mre11, npl3, shp1,
reg1, rmd12, rps9b, tsa1, vbm1, ydr433w,
yjl046w, ydr157w, yjl175w
bud28, bye1, elf1, hfa1, ira2, lat1, lpd1,
mct1, oar1, pdb1, pdx1, prd1, rad23, spo21,
ypl098c
dal81, hof1, ipk1, nfu1, pho85, ptr1, rpl21a,
rpn4, shm2, stp2, taf14, thp1, uba3, ubp14,
ubc2, ypr174c

Ptr2p-GFP expression and localization in the underlined strains are shown in Figures 3 and 4. The underlined strains were the representatives chosen to highlight
in the Results section of this paper. Ptr2p-GFP expression and localization of all the listed strains are shown in supplemental data (Figures S1 and S3). The
strains in bold (cup9, dal81, ptr1, stp2, and ubc2) contain the deleted genes previously identified as being involved in regulation of PTR2 transcription.
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gene products had GO annotations of transport, vesicle-mediated transport, cytokinesis,
or related to protein modification. Ptr2p-GFP signal in the srn2 and vps8 deletion mutants
was mainly localized to the plasma membrane and the endosome. In addition, Ptr2p-GFP
remained in the endosome in stationary phase cells and targeting of Ptr2p-GFP to the
vacuole was defective (data not shown). Similar to srn2 and vps8 strains, the deletion
strains eaf7, sac6, snf7, vps36, and ypl073c exhibited Ptr2p-GFP localization to the
plasma membrane and to the endosome (Figure S1), suggesting that these gene products
are involved in a similar cellular process regulating dipeptide utilization. Snf7p, Srn2p,
and Vps36p are three key proteins involved in ESCRT protein complexes required for
endocytotic degradation of membrane proteins (BOWERS et al. 2004).
To further characterize the ESCRT protein complexes involved in Ptr2p
endocytotic degradation, deletion mutant strains of other components of the ESCRT
protein complexes (vps2, vps20, vps22, vps23, vps24, vps25, and vps28) were also
transformed with the pMS4 construct. The localization of Ptr2p-GFP in these strains was
similar to that in snf7, srn2, and vps36 strains (Figure S2). Additionally, vps2, vps20,
vps22, vps23, vps24, vps25, and vps28 strains were more sensitive to toxic dipeptide as
compared to the wild type (Table S5), confirming the role of the ESCRT protein complex
in dipeptide utilization.
The deletion strain npr1 showed an accumulation of Ptr2p-GFP signal in both
endosomal vesicles and the vacuole in addition to the plasma membrane localization
(Figure 3). The Ptr2p sorting process is likely regulated by Npr1p, a protein kinase
involved in the regulation of vesicle transport systems (Table S3). Similar to Ptr2p-GFP
localization in the npr1 strain, deletion strains bni1, def1, lst4, and tpm1 showed Ptr2p72

GFP localization to the plasma membrane and the vacuole (Figure S1), implicating them
as well as being involved in the protein trafficking of Ptr2p.
Strains with no apparent effect on Ptr2p-GFP expression or localization: The deletion
strain ybt1 showed no apparent difference in the expression level of Ptr2p-GFP signal in
the cytoplasmic membrane (Figure 3), although there was an increase in the Ptr2p-GFP
signal in the vacuole. In this strain dipeptide utilization was increased (Figure 1, Figure
2, and Table 1). In addition, seven other deletion strains, cik1, kti12, mlh1, mrp17, pho2,
rim101, tif3, and ydr417c demonstrated increased dipeptide utilization with no apparent
effect on Ptr2p-GFP expression in the cytoplasmic membrane (Table 3 and Figure S1).
These gene products might impact dipeptide utilization independently of Ptr2p function.
For example, Ybt1p, known as an ABC transporter and localized on the vacuolar
membrane, may be involved in the uptake of dipeptides into the vacuole. The deletion of
this gene resulted in increased growth response and dipeptide toxicity.

Ptr2p-GFP expression and localization in deletion strains with decreased dipeptide
utilization: The expression level of Ptr2p-GFP signal and localization of nine
representative strains are shown in Figure 4, and all 57 deletion strains listed in Table 3
with decreased dipeptide utilization are shown in Figure S3.
Gene deletion enhanced the expression level of Ptr2p-GFP signal: The deletion strains
asm4, ydr015c and ydr290w showed an enhanced expression level of Ptr2p-GFP at the
cytoplasmic membrane and the vacuole (Figure S4). These strains showed a decreased
sensitivity to toxic dipeptide, however, with no growth change on dipeptide (Table S4).
In the asm4 strain, a fuzzy halo was observed in the toxic dipeptide halo assay indicating
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Figure 4 Ptr2p-GFP expression and localization in 9 selected deletion strains that
demonstrated decreased dipeptide utilization. The right-hand panel of each strain
shows phase microscopy of the same field as the left-hand panel which shows the
fluorescently-labeled Ptr2p-GFP.
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a transient growth inhibition. ASM4 encodes a component of the karyopherin docking
complex of the nuclear pore (MARELLI et al. 1998) indicating that some cellular protein
involved in ethionine toxicity requires Asm4p for its full expression.
Strains with altered Ptr2p-GFP localization: Compared to the wild-type, deletion strains
bud32 and reg1 showed higher expression level of Ptr2p-GFP signal at the vacuole and
less expression in the plasma membrane (reg1) or no visible plasma membrane
expression (bud32) (Figure 4). In addition, deletion strain gcv3 showed Ptr2p-GFP
localization both at the vacuole and plasma membrane (Figure 4). Similar to the Ptr2pGFP localization at the vacuole in bud32, reg1, or gcv3 strains, the deletion strains bem4,
csf1, etr1, gcv2, hfm1, ilm1, isa1, isa2, mck1, mre11, npl3, rps9b, rmd12, shp1, tsa1,
vbm1, and four unknown gene deletion strains (ydr157w, ydr433w, yjl046w, and yjl175w)
resulted in Ptr2p-GFP localization both at the vacuole and plasma membrane (Table S4
and Figure S3).
Strains with no apparent effect on the expression or localization of Ptr2p-GFP: No
apparent change in the expression or localization of Ptr2p-GFP was observed in the lpd1
deletion strain (Figure 4). Similarly, Ptr2p-GFP localization and expression level was not
different in the deletion strains bye1, bud28, elf1, hfa1, ira2, lat1, mct1, oar1, pdb1, pdx1,
rad23, and ypl098c as compared to the wild-type (Table S4 and Figure S3).
Strains with decreased expression of Ptr2p-GFP: The expression level of Ptr2p-GFP
signal was lower in the ptr1, dal81, rpn4, ubc2, and ubp14 deletion strain as compared to
the wild-type (Figure 4). A decreased Ptr2p-GFP expression signal was also observed in
the deletion strains hof1, ipk1, nfu1, pho85, rpl21a, shm2, stp2, taf14, thp1, uba3, and
ypr174c (Table S4 and Figure S3). The decreased Ptr2p-GFP expression signal in these
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strains was consistent with a decrease of dipeptide utilization which was previously
documented (Table S4) and is consistent with the observation that Ptr1p, Stp2p, Ubc2p,
and Dal81p positively regulate PTR2 transcription (ANDREASSON and LJUNGDAHL 2002;
BERNARD and ANDRE 2001; DU et al. 2002).

Transcriptional Regulation of PTR2
In order to explore whether strains with enhanced or reduced expression level of
Ptr2p-GFP showed a change in the transcriptional regulation of PTR2, the fold change of
PTR2 mRNA compared to that of the wild type was measured by Real-Time reverse
transcription PCR in the eighteen representative deletion strains. In control experiments,
PTR2 mRNA expression level in the cup9 strain was up-regulated more than nine times
that of the wild-type (Table 4). This result also agreed with the increased PTR2 mRNA
level in Northern analysis and lacZ activity as compared to the wild-type (data not
shown). The increase in PTR2 mRNA expression in the cup9 strain is consistent with the
increased expression level of Ptr2p-GFP signal (Figure 3). Similar to that of the cup9
strain, PTR2 mRNA expression level was highly up-regulated in ssn3 and kem1. PTR2
mRNA expression was up-regulated in ubr2, hal9, ybt1, vpc8, and gcv3 less than twofold. In contrast to the cup9, hal9, kem1, ssn3, ubr2, vps8, and ybt1 strains, which showed
increased dipeptide utilization, the gcv3 strain exhibited a decrease in peptide utilization
(Table S4). The apparent discrepancy between decrease in utilization and robust
expression in gcv3 strain could result from a post-translational alteration of Ptr2p
function or the alteration of the metabolic pathway(s) of dipeptide utilization.
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Table 4 The expression of PTR2 and PMA1 in various strains.

ubc2

PTR2
expressiona
0.06 (0.02)

PMA1
Expressiona
0.94 (0.50)

ptr1

0.07 (0.03)

1.08 (0.40)

ubp14

0.08 (0.04)

1.09 (0.48)

rpn4

0.21 (0.02)

1.23 (0.25)

npr1

0.48 (0.1)

1.33 (0.08)

dal81

0.79 (0.07)

1.70 (0.31)

reg1

0.88 (0.06)

1.03 (0.31)

lpd1

0.82 (0.19)

2.30 (0.03)

srn2

0.92 (0.05)

0.87 (0.08)

bud32

0.94 (0.10)

1.44 (0.44)

ubr2

1.23 (0.62)

2.95 (0.35)

hal9

1.37 (0.21)

1.93 (0.35)

ybt1

1.51 (0.14)

2.37 (0.25)

vps8

1.66 (0.22)

2.09 (0.44)

gcv3

1.93 (0.56)

1.22 (0.33)

ssn3

5.00 (1.17)

2.41 (0.47)

cup9

9.36 (2.60)

0.98 (0.21)

kem1

12.12 (1.47)

3.06 (0.24)

Strains

a

Expression level measured by Real-Time RT-PCR analysis is shown as a ratio calculated by the fold
change of the target gene (PTR2 or PMA1) in the mutant compared to that of the wild-type divided by the
fold change of ACT1 in the mutant compared to that of the wild-type. The datum in the bracket is the
standard deviation.
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PTR2 mRNA expression level in the ptr1 strain was only 7% that of the wild type
(Table 4) in accordance with the known requirement of Ptr1p for PTR2 transcription
(BYRD et al. 1998; TURNER et al. 2000). This result also agreed with the decreased PTR2
mRNA level in Northern analysis and lacZ activity as compared to the wild-type (data
not shown). The decrease in PTR2 mRNA expression in the ptr1 strain is consistent with
the decreased expression level of Ptr2p-GFP signal (Figure 4). Similar to the ptr1 strain,
PTR2 mRNA expression was highly down-regulated in ubc2, ubp14, and rpn4 strains.
The expression of PTR2 mRNA in npr1, dal81, reg1, lpd1, srn2, and bud32 strains was
not more than two-fold less than that of the wild-type.
Dipeptide Uptake Capability
In order to explore whether altered dipeptide utilization was correlated directly to
flux of dipeptide, the accumulation of [3H]Leu-Leu dipeptide was measured in the
eighteen representative strains (Figure 5). In a control experiment, the accumulation of
[3H]Leu-Leu increased remarkably in the cup9 strain as compared to the wild-type
(Figure 5). Similar to the cup9 strain, the accumulation of [3H]Leu-Leu was higher in the
hal9, kem1, npr1, srn2, ssn3, ubr2, vps8, and ybt1 strains as compared to that of the wildtype. The increased uptake in these strains was reflected in their increased ability to
utilize dipeptide. In contrast to the increased accumulation of dipeptide in hal9, kem1,
npr1, srn2, ssn3, ubr2, vps8, and ybt1 strains, the accumulation of [3H]Leu-Leu in gcv3
was not significantly different as compared to the wild-type, suggesting that deletion of
this gene did not impact the import of dipeptide even though dipeptide utilization was
decreased.
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Figure 5 The uptake of [3H]Leu-Leu dipeptide in log phase cells of the wild-type,
cup9, ptr1, and the 16 deletion strains bud32, dal81, gcv3, hal9, kem1, lpd1, npr1,
reg1, rpn4, srn2, ssn3, ubc2, ubr2, ubp14, vps8, and ybt1. The percentage of the
accumulation of [3H]Leu-Leu for each deletion mutant was calculated as [(the
accumulation of [3H]Leu-Leu in each mutant strain)/(the accumulation of [3H]Leu-Leu in
the wild-type) X 100].
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The accumulation of [3H]Leu-Leu in the ptr1 strain was lower than that of the
wild-type. The reduced accumulation of dipeptide was consistent with the decreased
expression level of PTR2 mRNA and Ptr2p-GFP in the ptr1 strain. Similar to the ptr1
strain, the accumulation of [3H]Leu-Leu was lower in the bud32, dal81, lpd1, reg1, rpn4,
ubc2, and ubp14 strains as compared to that of the wild-type (Figure 5). The decreased
uptake in these strains was reflected in their decreased expression of PTR2 in dal81,
rpn4, ubc2, and ubp14 strains (Table 4), decreased amount of Ptr2p-GFP in the
cytoplasmic membrane (Figure 4) and the alteration localization of Ptr2p in bud32 and
reg1 strains (Figure 4). In contrast, although the transport of dipeptide was reduced in the
lpd1 strain, the expression level of Ptr2p-GFP remained similar to that in the wild-type
(Figure 4).

Effects of Gene Deletions on Osmotic and Canavanine Sensitivity and PMA1
Expression
In order to determine whether gene deletions also affected general membrane
properties, additional assays were performed. Osmotic sensitivity, toxicity of canavanine,
and the expression level of PMA1 encoding a proton transporter localized in the
cytoplasmic membrane were examined. NaCl at 1.0 M inhibits the growth of wild type S.
cerevisiae by causing osmotic de-stabilization of the cell membrane (HOHMANN 2002).
NaCl at 1.0 M significantly inhibited the growth of all strains on MM+HLKU plates.
Fourteen deletion mutant strains, cup9, dal81, gcv3, hal9, lpd1, npr1, ptr1, reg1, rpn4,
ssn3, ubc2, ubp14, ubr2, and ybt1, showed similar effects to NaCl as that of the wild type
(Table 1 and 2, and Figure S4) suggesting that the deletion of those genes did not change
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the osmotic sensitivity of the deletion mutant strains. In contrast, four deletion mutant
strains, bud32, kem1, srn2, and vps8, showed greater sensitivity to 1.0 M NaCl than that
of the wild-type (Tables 1 and 2 and Figure S4).
Canavanine is transported by the arginine permease, and changes in canavanine
toxicity have been correlated directly to arginine permease function (HAMPSEY 1997). In
the canavanine toxicity assay, nine deletion mutant strains, cup9, hal9, ptr1, rpn4, ssn3,
ubc2, ubp14, ubr2, and ybt1, did not show significant alteration in the canavanine
sensitivity as compared with that of the wild-type. In contrast, six deletion mutants, dal81,
gcv3, lpd1, reg1, srn2, and vps8 were more sensitive to canavanine, and three deletion
mutant strains, bud32, kem1, and npr1 were less sensitive than the wild type (Table 1 and
2 and Figure S5).
To examine whether the gene representative deletion mutants were also affected
in the expression of other transport proteins, the expression level of PMA1 encoding a
proton transporter was measured. PMA1 mRNA expression level in cup9 and ptr1 strains
was similar to that of the wild type (Table 4). In contrast, PMA1 mRNA level was upregulated more than two-fold in kem1, lpd1, ssn3, ubr2, vps8, and ybt1 strains, and less
than two-fold in bud32, dal81, gcv3, hal9, npr1, reg1, rpn4, srn2, ubc2, and ubp14
strains (Table 4). Overall these changes in expression levels of PMA1 in the various
mutant strains did not correlate with the changes in expression in PTR2 except for upregulation of both genes in the ssn3 and kem1 strains.
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DISCUSSION
We have systematically screened a haploid, single-gene, deletion mutant library
and identified 103 genes involved in dipeptide utilization. To our knowledge, this is the
first such screen for a membrane transport system. PTR2 expression is known to be
regulated by amino acids via the Ssy1p-Ptr3p-Ssy5p (SPS) protein complex and by
dipeptides themselves (Figure 6). Import of di/tri-peptides containing basic or bulky
hydrophobic N-terminal residues (N-end Rule peptides) induces PTR2 by reducing
cellular levels of the PTR2 repressor Cup9p (BYRD et al. 1998; DU et al. 2002; TURNER
et al. 2000). In the SPS complex regulatory pathway a few down-stream proteins, such
as STP2 and components of SCFGrr1 ubiquitin ligase complex (Skp1p, Hrt1p, Cdc34p,
and Cdc53p), are involved in the Ssy1p-induced signal transduction pathway via
proteolytic processing of Stp2p (ANDREASSON and LJUNGDAHL 2002; BERNARD and
ANDRE 2001). Due to the complex nature of signal transduction pathways, such as the
well-studied pheromone-mediated mitogen-activated protein (MAP) kinase pathway in
yeast (GUSTIN et al. 1998), we expected that other regulatory proteins would be identified
in this screen.
The 103 genes identified in the screen cover a number of different Biological
Processes based on the Gene Ontology annotation. It is clear from the broad range of
mutants identified that genes involved in both direct and indirect regulation of peptide
utilization were discovered. Such a global array of genes supports the inter-connectivity
of networks involved in regulating biological processes (CHEN et al. 2003; LEE et al.
2002), but such a heterogeneous collection of interacting genes has not previously
identified as specifically regulating membrane transport systems.
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Figure 6 A hypothetical model for the regulation of dipeptide utilization in S. cerevisiae. The proteins with clear background
represent those that have been reported previously to be involved in PTR2 regulation. Grey background represents those proteins that
have been determined in this study. The SPS protein complex (Ssy1p-Ptr3p-Ssy5p) is an amino acid sensor, which leads to a cleavage
of the N-terminal of Stp2p. The activated form of Stp2p is localized to the nucleus and regulates PTR2 expression. In addition, Dal81p
synergistically regulates PTR2 expression together with Stp2p. Other proteins, Rpn4p, a positive regulator, and Cup9p, a negative
regulator, bind at the PTR2 promoter region and are also involved in PTR2 transcription. The stability of Rpn4p is modulated by
Ubr2p and Ubc2p, and the stability of Cup9p by Ptr1p, Ubc2p, and Ubc4p via the ubiquitination pathway. Binding of N-end Rule
dipeptides to Ptr1p/Ubr1p results in ubiquitin-mediated degradation of Cup9p. Ubr2p competes with Ptr1p for the degradation of
Cup9p. Arp5p, Arp8p, Ies6p, and Taf14p (components of the INO80 complex) together with Eaf3p possibly negatively regulates
PTR2 transcription via repressing the acetylation of histones in the PTR2 coding region. The transcription of PTR2 is negatively
regulated by a RNA polymerase mediator protein complex, which includes Ssn2p, Ssn3p, Ssn8p, and Srb8p. Thp1p might be involved
in the translocation of PTR2 mRNA from the nucleus to the cytosol. The interaction between Kem1p and Pat1p is potentially involved
in the degradation of PTR2 mRNA. Dipeptide utilization is also modulated by the Ptr2p trafficking system; ESCRT-I, -II, III, together
with Vps8p and Eaf7p, appear to regulate Ptr2p internalization from the endosome to the vacuole. In addition, Npr1 and Lst4p are also
involved in Ptr2p trafficking and affect the retention of Ptr2p in the plasma membrane.
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Genes that regulate PTR2 transcription: In this study we have considerably expanded
the identification of genes involved in PTR2 transcriptional regulation. The deletion of
these genes results in the alteration of dipeptide utilization.
First, we have shown that dipeptide utilization can be affected by gene products
involved in the modification of the nucleosome, namely Arp5p, Arp8p, Ies6p and Taf14p.
These proteins belong to the components of the chromatin remodeling INO80 protein
complex that carries ATPase activity, DNA binding, and nucleosome mobilization
(SANDERS et al. 2002), and that preferentially interacts with histones H3 and H4 (SHEN et
al. 2003). Another histone- modification-related gene product, Eaf3p, was also identified
in our screen. Eaf3p is a component of the NuA4 histone acetyltransferase complex
which maintains the acetylation of histone H3 and H4 (REID et al. 2004). It is possible
that these chromatin remodeling proteins negatively regulate PTR2 transcription via the
modification of histones. A model representing the potential involvement of these
proteins and others is shown (Figure 6).
Second, four gene products with transcription factor activity, Cup9p, Dal81p,
Stp2p, and Rpn4p were shown to regulate PTR2 expression and affected dipeptide
utilization. Cup9p binds the region between -488 and -897 upstream of the PTR2 start
codon (BYRD et al. 1998), while Rpn4p may bind between -610 and -603 due to the
existence of the Rpn4p binding consensus sequence (5’-GGTGGAAA-3’) present at this
location (MANNHAUPT et al. 1999). Cup9p is a repressor of PTR2, whereas Rpn4p is a
“positive-regulator” as reflected in the observation that the cup9 deletion strain showed
an increase in peptide utilization and the rpn4 strain has decreased peptide utilization.
Subsequent to amino acid induction via the SPS system and its conversion into the active
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form after proteolytically processing and translocation into the nucleus (ANDREASSON
and LJUNGDAHL 2002; ANDREASSON and LJUNGDAHL 2004), the active form of Stp2p
(truncated at the N-terminus) binds to the upstream activation sequence (UAS) of the
promoter region of BAP2 and BAP3 (DE BOER et al. 2000; NIELSEN et al. 2001). Because
BAP2, BAP3 and PTR2 are simultaneously regulated in response to amino acid induction
via the SPS-Stp2p system, the active form of Stp2p likely also binds to the PTR2
promoter region and regulates its transcription. Dal81p is a transcriptional activator
essential for PTR2 expression under the induction by the SPS signal pathway as well
(BERNARD and ANDRE 2001). Dal81p acts synergistically with Stp1p to regulate the
transcription of AGP1 in response to the amino acid induction, and the sequence 5’CGGC-3’ of a UAS element is important for AGP1 transcriptional regulation (ABDELSATER et al. 2004). Since the PTR2 promoter region has this consensus sequence and
because Dal81p was identified as important for PTR2 transcription and dipeptide
utilization in our screening, we speculate that Dal81p and Stp2p act synergistically in
PTR2 transcription in a similar manner.
Third, other gene products identified in this screen such as Ubr2p, Ptr1p, and
Ubc2p regulate PTR2 expression by modulating the stability of Rpn4p and Cup9p (Figure
6). Cup9p stability is regulated by Ptr1p, Ubc2p, and Ubc4p (DU et al. 2002). Ubr2p is
associated with Rpn4p to regulate proteasome gene expression through the ubiquitination
pathway (WANG et al. 2004). In addition, Ubr2p has high amino acid sequence similarity
to Ptr1p presumably allowing a competition with Ptr1p for the stabilization of Cup9p
(BARTEL et al. 1990). Therefore, Ubr2p probably regulates PTR2 transcription by
impacting the stability of both Rpn4p and Cup9p (Figure 6).
87

Fourth, we identified one other gene product (SSN3) involved in PTR2
transcription that is known to be general transcription factor, which also affected PMA1
expression. Ssn3p/Srb10p, Ssn8p/Srb11p, Ssn2p/Srb9p, and Srb8p have been identified
as a cyclin-dependent serine/threonine protein kinase complex that functions as a
mediator of RNA polymerase (KORNBERG 2005). This complex is also involved in
glucose signaling pathway (BALCIUNAS and RONNE 1995; KUCHIN et al. 1995). Deletion
of these genes leads to de-repression of a wide variety of down-stream genes, including
GAL and SUC, which are important for galactose and raffinose metabolism, respectively
(KUCHIN et al. 2000; MYER and YOUNG 1998). The deletion of SSN3 resulted in a change
of PMA1 and PTR2 expression level.
Finally, we identified gene products involved in PTR2 transcription by means that
are not clear. For example, UBP14 was important for PTR2 expression since deletion of
these genes significantly decreased PTR2 mRNA level (Table 4), and the strain carrying
deletion of this gene exhibited decreased peptide utilization. Ubp14p has ubiquitinspecific protease activity (Table S4). It is probably modulating PTR2 transcription via the
ubiquitination pathway. In addition, the deletion of UBP14 had no effect on the
expression of PMA1 or on sensitivity to NaCl and canavanine. Further experiments are
needed to provide some insight into whether the gene product acts directly or indirectly to
control PTR2 expression.

Genes involved in PTR2 mRNA maturation: Gene products (Kem1p, Pat1p, and
Thp1p) involved in post-transcriptional regulation impacting the stability and transport of
PTR2 mRNA also affected dipeptide utilization (Figure 6). Both Kem1p and Pat1p
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belong to an mRNA decay protein complex (BONNEROT et al. 2000; BOUVERET et al.
2000). PTR2 mRNA was highly up-regulated in the kem1 strain (Table 4). It is likely
that PTR2 mRNA was more stable in kem1 and pat1 strains, which resulted in more Ptr2p
being synthesized leading to enhanced Ptr2p-GFP expression (Figure 3) and increased
dipeptide utilization (Table 1 and Figure 1 and 2). The deletion of KEM1 resulted as also
an increased expression level of PMA1 and changes sensitivity to NaCl and canavanine
(Table 1). It is not surprising that the deletion of this gene affected several phenotypes
related to membrane function, since a deletion in this gene would impact gene expression
of many different genes. Another gene shown to impacting dipeptide utilization was
Thp1p, which is involved in mRNA export from the nucleus to the cytoplasm (FISCHER et
al. 2002). The thp1 strain probably has a defect in transporting PTR2 mRNA into the
cytoplasm for protein synthesis. Therefore this mutant demonstrated a decrease in peptide
utilization.

Genes that regulate Ptr2p trafficking: This screen revealed that dipeptide utilization is
regulated by the trafficking system. Deletion of components of ESCRT-I, ESCRT-II, and
ESCRT-III protein complexes showed a defect in Ptr2p-GFP trafficking from the
endosome to the vacuole (Figure 6 and Figure S2). These protein complexes are essential
for sorting ubiquitinylated membrane proteins from the plasma membrane to the
multivesicular body and to the vacuole for further degradation (RAIBORG et al. 2003).
Ptr2p has been shown to be ubiquitinylated (HITCHCOCK et al. 2003). Strains srn2, vps36
and snf7 demonstrated increased dipeptide utilization perhaps due to an increased
residence time of Ptr2p at the cytoplasmic membrane. In addition, the eaf7 and vps8
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strains showed Ptr2p localization similar to that of the ESCRT protein mutants.
Surprisingly, Eaf7p is annotated as a component of the NuA4 HAT complex, which is an
essential histone acetyltransferase complex that acetylates the N-terminal tails of histones
H4 and H2A (KROGAN et al. 2004). It is possible that Eaf7p has dual functions or
indirectly affects Ptr2p localization through other proteins. Both srn2 and vps8 strains
showed an altered sensitivity to NaCl and canavanine. It has been reported that the
osmotic sensitivity changes if vacuolar development is affected (HAMPSEY 1997). Thus a
disruption of the protein sorting process that affects the vacuole could lead to alteration of
osmotic sensitivity.

Deletion mutants (npr1, lst4) with increased dipeptide utilization and mutants
(bud32, reg1) with decreased utilization showed an accumulation of Ptr2p-GFP in
vesicles. NPR1 encodes a Ser/Thr protein kinase, involved in post-translational control of
Gap1p. Npr1p is required for Gap1p to be targeted to the plasma membrane, and an npr1
deletion mutant loses Gap1p function by sorting Gap1p from the Golgi into the vacuole
by-passing the plasma membrane (DE CRAENE et al. 2001). Similarly, mutations in LST4
reduced the function of Galp1p and other amino acid permeases by the interruption of
sorting of these transporters to the cell surface (ROBERG et al. 1997). Our observations
indicated that NPR1 and LST4 regulate Ptr2p differently from the way they regulate
Gap1p. It is not clear how Lst4p and Npr1p regulate Ptr2p in a manner opposite to that
of their regulation of Gap1p. Bud32p is a Ser/Thr protein kinase involving in polar bud
site selection and changing the vacuolar morphology (BONANGELINO et al. 2002). Reg1p
is a regulatory subunit for protein phosphatase Glc7p involved in the repression of many
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glucose-regulated genes and vesicular trafficking (CUI et al. 2004). The involvement of
Bud32p and Reg1p in dipeptide utilization reflects their roles in Ptr2p trafficking.

Genes that regulate dipeptide utilization independent of Ptr2p: The alteration of
dipeptide utilization also results from Ptr2p-independent metabolic processes as indicated
by the observation of no apparent phenotypic change in expression or localization of
Ptr2p-GFP in a number of mutants (Table 3). Mutation in genes encoding a variety of
cellular metabolic processes (Figure S6) (NAGARAJAN and STORMS 1997; SCHNEIDER et
al. 1997; STOOPS et al. 1997), such as the conversion of pyruvate into acetyl-CoA by
pyruvate dehydrogenase complex (Pdx1p, Lpd1, Pdb1p, and Lat1p), the conversion of
acetyl-CoA to malonyl-CoA by Hfa1p, fatty acid synthesis by fatty acid synthase
complex (Oar1p, Mct1p, and Etr1p), glycine degradation (Gcv2p, Gcv3p, and Lpd1p),
and a peptidase activity (Prd1p) resulted in a decrease of dipeptide utilization (Table 3).
In these mutants the impairment of the dipeptide utilization appeared to be independent
of Ptr2p transport activity since Ptr2p-GFP could be observed at the plasma membrane
(Figure S3). The assay of [3H]Leu-Leu uptake in gcv3 strains suggested that the import of
dipeptide was still maintained at wild-type level which showed that Ptr2p was functional
(Figure 5), indicating that the decrease of dipeptide utilization resulted from the inability
of the mutant to release amino acid from accumulated dipeptide or from a metabolic
block in using the released amino acid for protein biosynthesis. Prd1p is a
metalloendoproteinase (BUCHLER et al. 1994). The deletion mutant might be impaired in
the degradation of intracellularly transported dipeptide which would result in a decrease
of dipeptide utilization.
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Deletion strains cik1, kti12, mlh1, mrp17, pho2, rim101, tif3, ybt1 and ydr417c
showed no apparent effect on Ptr2p-GFP localization or expression but demonstrated
increased dipeptide utilization. The utilization of dipeptide in these strains appears to
involve Ptr2p-independent cellular processes as well. For example, Ybt1p belongs to the
ABC transporter family exhibiting ATP-dependent bile acid transport (ORTIZ et al. 1997;
PAULSEN et al. 1998). As expected for an ABC transporter, the ybt1 mutant was not only
more sensitive to the toxic dipeptide Ala-Eth, but also this strain was more sensitive to
ethionine and Lys-Ala-Eth (data not shown). We speculate that this protein might be
involved in the transport of dipeptide into the vacuole. In the deletion mutant the defect in
the uptake of dipeptide into the vacuole would lead to an increase of dipeptide
availability in the cytoplasm. It is also possible that the deletion of a gene might result in
a de-repression or change in function of other transport systems that may mediate
dipeptide utilization in the mutant without alteration of PTR2 expression or Ptr2p
function. We are currently working on unraveling the involvement of these metabolic
genes in dipeptide utilization.
Unknown genes that regulate dipeptide utilization: Fifteen unknown gene deletion
mutant strains were identified in this screen, including seven strains exhibiting increased
and eight strains showing decreased dipeptide utilization (Table 3). Deletion mutants
yor322c, ynl123w, yfr044c, and ylr114c showed enhanced expression level of Ptr2p-GFP
signal compared to wild-type, and ypr174c had reduced expression of Ptr2p-GFP; these
results were consistent with dipeptide utilization in these strains, suggesting these
unknown genes products are involved in the regulation of PTR2 expression. Deletion
mutants ynl295w, ypl073c, yjl175w, ydr157w, and ydr433w showed accumulation of
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Ptr2p-GFP signal in the vesicles or the vacuole, suggestion these unknown gene products
are involved in Ptr2p trafficking and localization. Similar to the expression level of Ptr2pGFP in the asm4 strain, enhanced Ptr2p-GFP expression was observed in the deletion
mutant strains of unknown function ydr015c and ydr290w. These two mutants, however,
showed a decreased sensitivity to toxic dipeptide and no growth change on dipeptide; it is
not clear how these genes regulate dipeptide utilization.

Overall, this investigation has provided a list of genes involved directly and
indirectly in the utilization of dipeptides in yeast. In our screen, 53 genes encoding
proteins with more than 30% identity to human genes have been identified (See Tables
S3 and S4, footnote a). To date no genes have been reported in the regulation of the
human PTR2 homologs PEPT1 and PEPT2 (DANIEL 2004). Further investigation of these
human genes may promote understanding of the regulation of dipeptide utilization in
mammalian systems. This study represents the first such global analysis of a membrane
transport process and as such provides a rich starting ground for future investigations.
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APPENDIX
Supplement Table S1: The sequence of the primers used in the construction of PTR2-GFP, Northern analysis, and Real-Time PCR
Primers
PTR2-FLAG-GFP-F
PTR2-Flag-GFP-R
PTR2-F (Northern)
PTR2-R (Northern)
ACT1-F (Northern)
ACT1-R (Northern)
PTR2 (F)
PTR2 (R)
ACT1 (F)
ACT1 (R)
PMA1 (F)
PMA1 (R)

Sequence
(5’- gatccaccaccaaatatGACTACAAGGACGACGATGACAAGcttgatatcaacaagacaggg-3’)
(5’-GATGATGATGACTGCTGCCGCTGCCGCGCGGCACACCGGTcctcgagccgcttttcttgtac-3’)
(5’-TTCCGCACCATTCCAAAACTACAT-3’)
(5’-GCAGCACAGAAAACTCCCGTAAAC-3’)
(5’-GCCGGTTTTGCCGGTGACGAC-3’)
(5’-GGAAGATGGAGCCAAAGCGTG-3’).
(5’-cagtgaccgttgatcctaaat-3’)
(5’-ctgaagcacaaccagaacaaa-3’)
(5’-ccaccatgttcccaggtatt-3’)
(5’-ccaatccagacggagtactt-3’)
(5’-ctggtccattctggtcttcta-3’)
(5’-ccaccaaccgaataaggtaaa-3’)
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Supplement Table S2 One hundred and nine strains of the haploid, deletion mutant collection were not capable of growing in
MM+HLKU with allantoin as the sole nitrogen source. These deletion mutant strains were excluded from this study. The strains
are listed alphabetically by gene name.
ORF name
YLR304C
YAR015W

Gene
Name
ACO1
ADE1

YOR128C

ADE2

YGR204W

ADE3

YMR300C

ADE4

YGL234W

ADE5,7

YGR061C

ADE6

YDR408C
YNL220W
YOL058W

ADE8
ADE12
ARG1

YJL071W

ARG2

YJL088W

ARG3

YHR018C
YER069W

ARG4
ARG5,6

YDR127W

ARO1

YGL148W

ARO2

Gene description in SGD
Mitochondrial aconitase, required for the tricarboxylic acid (TCA) cycle; mutation leads to glutamate auxotrophy
N-succinyl-5-aminoimidazole-4-carboxamide ribotide (SAICAR) synthetase, required for 'de novo' purine nucleotide
biosynthesis; red pigment accumulates in mutant cells deprived of adenine
Phosphoribosylaminoimidazole carboxylase, catalyzes a step in the 'de novo' purine nucleotide biosynthetic pathway; red
pigment accumulates in mutant cells deprived of adenine
Cytoplasmic trifunctional enzyme C1-tetrahydrofolate synthase, involved in single carbon metabolism and required for
biosynthesis of purines, thymidylate, methionine, and histidine
Phosphoribosylpyrophosphate amidotransferase (PRPPAT; amidophosphoribosyltransferase), catalyzes first step of the 'de
novo' purine nucleotide biosynthetic pathway
Bifunctional enzyme of the 'de novo' purine nucleotide biosynthetic pathway, contains aminoimidazole ribotide synthetase
and glycinamide ribotide synthetase activities
Formylglycinamidine-ribonucleotide (FGAM)-synthetase, catalyzes a step in the 'de novo' purine nucleotide biosynthetic
pathway
Phosphoribosyl-glycinamide transformylase, catalyzes a step in the 'de novo' purine nucleotide biosynthetic pathway
Adenylosuccinate synthase, catalyzes the first committed step in the 'de novo' biosynthesis of adenosine
Arginosuccinate synthetase, catalyzes the formation of L-argininosuccinate from citrulline and L-aspartate in the arginine
biosynthesis pathway; potential Cdc28p substrate
Acetylglutamate synthase (glutamate N-acetyltransferase), mitochondrial enzyme that catalyzes the first step in the
biosynthesis of the arginine precursor ornithine; forms a complex with Arg5,6p
Ornithine carbamoyltransferase (carbamoylphosphate:L-ornithine carbamoyltransferase), catalyzes the sixth step in the
biosynthesis of the arginine precursor ornithine
Argininosuccinate lyase, catalyzes the final step in the arginine biosynthesis pathway
Bifunctional enzyme with N-acetyl-gamma-glutamyl-phosphate reductase and acetylglutamate kinase activities, catalyzes
the second and third steps in the biosynthesis of the arginine precursor ornithine; forms a complex with Arg2p
Pentafunctional arom protein, catalyzes steps 2 through 6 in the biosynthesis of chorismate, which is a precursor to aromatic
amino acids
Bifunctional chorismate synthase and flavin reductase, catalyzes the conversion of 5-enolpyruvylshikimate 3-phosphate
(EPSP) to form chorismate, which is a precursor to aromatic amino acids
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Supplement Table S2 Continued
ORF name
YEL029C

Gene
Name
BUD16

YER014C-A

BUD25

YLR226W
YJR122W

BUR2
CAF17

YJR060W

CBF1

YDR364C

CDC40

YGL029W
YGL206C
YOR303W

CGR1
CHC1
CPA1

YJR109C
YML112W

CPA2
CTK3

YGR155W
YDR294C

CYS4
DPL1

YJR137C
YJL201W
YHL030W

ECM17
ECM25
ECM29

YFR019W

FAB1

YPR062W
YER060W-A

FCY1
FCY22

Gene description in SGD
Protein involved in bud-site selection; diploid mutants display a random budding pattern instead of the wild-type bipolar
pattern; has similarity to pyridoxal kinases
Protein involved in bud-site selection; diploid mutants display a random budding pattern instead of the wild-type bipolar
pattern
Bypass UAS Requirement; involved in transcriptional regulation
Mitochondrial protein that interacts with Ccr4p in the two-hybrid system; 3'-untranslated region contains a putative mRNA
localization element common to genes encoding mitochondrial proteins
Helix-loop-helix protein that binds the motif CACRTG (R=A or G), which is present at several sites including MET gene
promoters and centromere DNA element I (CDEI); required for nucleosome positioning at this motif; targets Isw1p to DNA
Pre-mRNA splicing factor, important for catalytic step II of pre-mRNA splicing and plays a role in cell cycle progression;
required for DNA synthesis during mitosis and meiosis; has WD repeats
Coiled-coil protein that may contribute to compartmentalization of nucleolar constituents; expression is growth-regulated
Vesicle coat protein; presumed vesicle coat protein
Small subunit of carbamoyl phosphate synthetase, which catalyzes a step in the synthesis of citrulline, an arginine precursor;
translationally regulated by an attenuator peptide encoded by YOR302W within the CPA1 mRNA 5'-leader
Large subunit of carbamoyl phosphate synthetase, which catalyzes a step in the synthesis of citrulline, an arginine precursor
Gamma subunit of C-terminal domain kinase I (CTDK-I), which phosphorylates the C-terminal repeated domain of the RNA
polymerase II large subunit (Rpo21p) to affect both transcription and pre-mRNA 3' end processing
Cystathionine beta-synthase, catalyzes the first committed step of transsulfuration in cysteine biosynthesis
Dihydrosphingosine phosphate lyase, regulates intracellular levels of sphingolipid long-chain base phosphates (LCBPs),
degrades phosphorylated long chain bases, prefers C16 dihydrosphingosine-l-phosphate as a substrate
Sulfite reductase beta subunit, involved in amino acid biosynthesis, transcription repressed by methionine
Non-essential protein of unknown function; promoter contains a consensus binding sequence for factor Abf1p
Major component of the proteasome; tethers the proteasome core particle to the regulatory particle, and enhances the
stability of the proteasome
1-phosphatidylinositol-3-phosphate 5-kinase; vacuolar membrane kinase that generates phosphatidylinositol (3,5)P2, which
is involved in vacuolar sorting and homeostasis
Cytosine deaminase, involved in salvage pathways of pyrimidine metabolism
Putative purine-cytosine permease, very similar to Fcy2p but cannot substitute for its function
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Supplement Table S2 Continued
ORF name
YOR382W

Gene
Name
FIT2

YOR381W
YDL198C

FRE3
GGC1

YHR183W

GND1

YJL184W

GON7

YER057C

HMF1

YDR158W

HOM2

YJR139C

HOM6

YER086W

ILV1

YJR050W

ISY1

YDR017C

KCS1

YFR001W
YKR069W

LOC1
MET1

YJR010W

MET3

YER091C

MET6

YOR241W

MET7

Gene description in SGD
Mannoprotein that is incorporated into the cell wall via a glycosylphosphatidylinositol (GPI) anchor, involved in the
retention of siderophore-iron in the cell wall
Ferric reductase, reduces siderophore-bound iron prior to uptake by transporters; expression induced by low iron levels
Mitochondrial GTP/GDP transporter, essential for mitochondrial genome maintenance; has a role in mitochondrial iron
transport; member of the mitochondrial carrier family; (putative) mitochondrial carrier protein
6-phosphogluconate dehydrogenase, decarboxylating; converts 6-phosphogluconate + NADP to ribulose-5-phosphate +
NADPH + CO2; Phosphogluconate Dehydrogenase (Decarboxylating)
Protein of unknown function, proposed to be involved in the transfer of mannosylphosphate groups onto N-linked
oligosaccharides; also proposed to be involved in responding to osmotic stress
Member of the p14.5 protein family with similarity to Mmf1p, functionally complements Mmf1p function when targeted to
mitochondria; heat shock inducible; high-dosage growth inhibitor; forms a homotrimer in vitro
Aspartic beta semi-aldehyde dehydrogenase, catalyzes the second step in the common pathway for methionine and threonine
biosynthesis; expression regulated by Gcn4p and the general control of amino acid synthesis
Homoserine dehydrogenase (L-homoserine:NADP oxidoreductase), dimeric enzyme that catalyzes the third step in the
common pathway for methionine and threonine biosynthesis; enzyme has nucleotide-binding, dimerization and catalytic
regions
Threonine deaminase, catalyzes the first step in isoleucine biosynthesis; expression is under general amino acid control;
ILV1 locus exhibits highly positioned nucleosomes whose organization is independent of known ILV1 regulation
Component of the spliceosome complex involved in pre-mRNA splicing, auxiliary splicing factor that may modulate Syf1p
activity and help optimize splicing; isy1 syf2 double mutation activates the spindle checkpoint, causing cell cycle arrest
Inositol hexaphosphate kinase, phosphorylates inositol hexakisphosphate (InsP6) to diphosphoinositol polyphosphates,
required for proper vacuole morphology and involved in salt stress response, contains two leucine heptad repeats
Nuclear protein involved in asymmetric localization of ASH1 mRNA; binds double-stranded RNA in vitro
S-adenosyl-L-methionine uroporphyrinogen III transmethylase, involved in sulfate assimilation, methionine metabolism, and
siroheme biosynthesis
ATP sulfurylase, catalyzes the primary step of intracellular sulfate activation, essential for assimilatory reduction of sulfate
to sulfide, involved in methionine metabolism
Cobalamin-independent methionine synthase, involved in amino acid biosynthesis; also called N5-methyltetrahydrofolate
homocysteine methyltransferase or 5-methyltetrahydropteroyltriglutamate homocysteine methyltransferase
Folylpolyglutamate synthetase, catalyzes extension of the glutamate chains of the folate coenzymes, required for methionine
synthesis and for maintenance of mitochondrial DNA, present in both the cytoplasm and mitochondria
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Supplement Table S2 Continued
ORF name
YBR213W

Gene
Name
MET8

YFR030W
YKL001C
YPR167C

MET10
MET14
MET16

YLR303W
YIL128W

MET17
MET18

YIR017C
YML128C

MET28
MSC1

YMR091C
YJR073C

NPL6
OPI3

YOR130C

ORT1

YDR323C

PEP7

YNL316C
YPL188W

PHA2
POS5

YGR006W

PRP18

YHR001W-A
YOL143C

QCR10
RIB4

YER070W

RNR1

YBL093C

ROX3

Gene description in SGD
Bifunctional dehydrogenase and ferrochelatase, involved in the biosynthesis of siroheme; also involved in the expression of
PAPS reductase and sulfite reductase
Subunit alpha of assimilatory sulfite reductase, which is responsible for the conversion of sulfite into sulfide
Adenylylsulfate kinase, required for sulfate assimilation and involved in methionine metabolism
3'-phosphoadenylsulfate reductase, reduces 3'-phosphoadenylyl sulfate to adenosine-3',5'-bisphosphate and free sulfite using
reduced thioredoxin as cosubstrate, involved in sulfate assimilation and methionine metabolism
O-acetyl homoserine-O-acetyl serine sulfhydrylase, required for sulfur amino acid synthesis
DNA repair and TFIIH regulator, required for both nucleotide excision repair (NER) and RNA polymerase II (RNAP II)
transcription; possible role in assembly of a multiprotein complex(es) required for NER and RNAP II transcription
Transcriptional activator in the Cbf1p-Met4p-Met28p complex, participates in the regulation of sulfur metabolism
Protein of unknown function, green fluorescent protein (GFP)-fusion protein localizes to the endoplasmic reticulum; msc1
mutants are defective in directing meiotic recombination events to homologous chromatids
Nuclear protein that may have a role in nuclear protein import
Phospholipid methyltransferase (methylene-fatty-acyl-phospholipid synthase), catalyzes the last two steps in
phosphatidylcholine biosynthesis
Ornithine transporter of the mitochondrial inner membrane, exports ornithine from mitochondria as part of arginine
biosynthesis; human ortholog is associated with hyperammonaemia-hyperornithinaemia-homocitrullinuria (HHH) syndrome
Multivalent adaptor protein that facilitates vesicle-mediated vacuolar protein sorting by ensuring high-fidelity vesicle
docking and fusion, which are essential for targeting of vesicles to the endosome; required for vacuole inheritance
Prephenate dehydratase
Mitochondrial NADH kinase, phosphorylates NADH; also phosphorylates NAD(+) with lower specificity; required for the
response to oxidative stress
Splicing factor involved in the positioning of the 3' splice site during the second catalytic step of splicing, recruited to the
spliceosome by Slu7p
8.5 kDa subunit of the ubiqunol-cytochrome c oxidoreductase complex
Lumazine synthase (6,7-dimethyl-8-ribityllumazine synthase, also known as DMRL synthase); catalyzes synthesis of
immediate precursor to riboflavin
Ribonucleotide-diphosphate reductase (RNR), large subunit; the RNR complex catalyzes the rate-limiting step in dNTP
synthesis and is regulated by DNA replication and DNA damage checkpoint pathways via localization of the small subunits
RNA polymerase II holoenzyme component
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Supplement Table S2 Continued
ORF name
YIL069C

Gene
Name
RPS24B

YOR184W
YGR208W
YJR104C
YHR178W
YDL185W

SER1
SER2
SOD1
STB5
TFP1

YHR025W
YCR053W
YJL138C
YPR074C
YGR260W
YJL129C
YDR120C

THR1
THR4
TIF2
TKL1
TNA1
TRK1
TRM1

YER090W
YKL211C
YDR354W
YGL026C
YBR166C
YDL077C
YPR036W
YBR127C
YPL065W

TRP2
TRP3
TRP4
TRP5
TYR1
VAM6
VMA13
VMA2
VPS28

YDR495C
YLR240W

VPS3
VPS34

Gene description in SGD
Protein component of the small (40S) ribosomal subunit; identical to Rps24Ap and has similarity to rat S24 ribosomal
protein
Phosphoserine transaminase
Phosphoserine phosphatase
Cu, Zn superoxide dismutase
Binds Sin3p in two-hybrid assay; Zinc finger
Vacuolar ATPase V1 domain subunit A; protein precursor is spliced to yield the extein Tfp1p and the intein Vde (PI-SceI),
which is a site-specific endonuclease
Homoserine kinase
Threonine synthase
Translation initiation factor eIF4A
Transketolase 1
High affinity nicotinic acid plasma membrane permease
180 kDa high affinity potassium transporter
tRNA methyltransferase, localizes to both the nucleus and mitochondrion to produce the modified base N2,N2dimethylguanosine in tRNAs in both compartments
Anthranilate synthase Component I
Anthranilate synthase Component II and indole-3-phosphate (multifunctional enzyme)
Anthranilate phosphoribosyl transferase
Tryptophan synthetase
Step of tyrosine biosynthesis pathway; Prephenate dehydrogenase (NADP+)
Protein involved in vacuolar morphogenesis
Vacuolar ATPase V1 domain subunit H (54 kDa)
Vacuolar H+ ATPase regulatory subunit (subunit B) of the catalytic (V1) sector
Soluble, hydrophilic protein involved in transport of precursors for soluble vauolar hydrolases from the late endosome to the
vacuole; involved in vacuolar protein targeting
Vacuolar sorting protein
Phosphatidylinositol 3-kinase
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Supplement Table S2 Continued
ORF name
YGL095C

Gene
Name
VPS45

YLR322W

VPS65

YML097C
YEL004W

VPS9
YEA4

YNL241C
YOR302W
YOR302W
YHR039C-B
YER068C-A
YER091C-A
YIL039W
YDR008C
YOL125W
YDR442W
YER137C

ZWF1

Gene description in SGD
Protein of the Sec1p family, essential for vacuolar protein sorting; required for the function of both Pep12p and the early
endosome/late Golgi SNARE Tlg2p
Dubious open reading frame, unlikely to encode a protein; not conserved in closely related Saccharomyces species; 75% of
ORF overlaps the verified gene SFH1; deletion causes a vacuolar protein sorting defect
Protein required for Golgi to vacuole trafficking, has similarity with mammalian ras inhibitors
Shows sequence similarity to GOG5, a gene involved in vanadate resistance; similar to Gog5, which is involved in vanadate
resistance
Glucose-6-phosphate dehydrogenase
CPA1 uORF , Arginine attenuator peptide, regulates translation of the CPA1 mRNA
CPA1 uORF , Arginine attenuator peptide, regulates translation of the CPA1 mRNA
Slow growth
Questionable ORF from MIPS
Hypothetical ORF
Hypothetical ORF
Hypothetical ORF
Hypothetical ORF
Hypothetical ORF
Hypothetical ORF

107

Supplement Table S3 List of 46 genes whose deletion mutant strain enhanced dipeptide utilization. In the solid medium plate,
deletion strains were grown in MM+(H-L)HKU with or without Trp. In the toxicity halo assay, deletion strains were grown in
MM+HLKU medium supplied with 0.1µmol Ala-Eth in the disk. According to the Gene Ontology (GO) in SGD
(http://db.yeastgenome.org/cgi-bin/GO/goTermMapper), these genes cover 23 out of 34 categories of “Biological Processes”. A given
gene is only listed once, although based on its functions some genes are classified into multiple categories. The gene in bold (CUP9)
was previously identified as being involved in the regulation of PTR2 transcription.
Gene name

Description of gene product

Growth in solid medium plate with
His-Leu
No inducer
Inducer
(Without Trp)
(With Trp)

Wild-type
RIM101
SSN3 a
SSN8 a
BNI1
CIK1
CSM1
MLH1 a
PAT1
SRB8
SSN2
VPS36
HAL9
PHO2 a
EAF3 a
CUP9 a
ARP5 a
ARP8
LST4

a

Specific transcriptional repressor activity
Cyclin-dependent protein kinase activity
Cyclin-dependent protein kinase regulator activity
Cytoskeletal regulatory protein binding
Microtubule motor activity
Required for monopolar attachment of homologous
chromosomes to the spindle
DNA binding; ATPase activity
Required for faithful chromosome transmission and
normal translation initiation
RNA polymerase II transcription mediator activity
General RNA polymerase II transcription factor activity
Regulator of G-protein signaling activity
Specific RNA polymerase II transcription factor activity
Transcription factor activity
Histone acetyltransferase activity
Specific RNA polymerase II transcription factor activity
Actin-related protein
Actin-related protein
Protein transporter activity
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Toxicity of AlaEth (% of the
wild type)

Functional
categories
of Biological
Processesb

-

+

100

++
++
++
++
++
+

++
++
++
++
++
++

109
114
106
109
124
109

1 2 8 20
1268
128
1 4 5 9 10 17 21
1489
178

+
+

++
++

106
121

178
1 13

++
++
+
+
++
++
++
++
++
-

++
++
++
++
++
++
++
++
++
+++

109
123
116
131
121
133
120
139
126
116

2
2
2 3 14
25
2 5 26
2 6 7 19
2 23
3
3
3

Supplement Table S3 Continued
Gene name

YBT1 a
SRN2
SAC6 a
TPM1
SNF7 a
VPS8 a
VAM10
DEF1
UBR2
DBR1 a
SFP1 a
KEM1 a
MRP17 a
MRPS9 a
TIF3
IES6
NPR1 a
KTI12
SSD1
TOM72 a
YDR417C
YFR044C a
YLR114C
YNL123W
YNL136W
YNL295W
YOR322C
YPL073C

Description of gene product

Bile acid transporter activity
Class E vacuolar sorting protein
Actin filament binding
Actin lateral binding
Protein sorting in the pre-vacuolar endosome
Vacuolar sorting
Involved in early stages of vacuolar fusion
Involved in vacuolar import and degradation
Ubiquitin-protein ligase activity
RNA lariat debranching enzyme activity
Transcription factor activity
5'-3' exoribonuclease activity
Structural constituent of ribosome
Structural constituent of ribosome
Translation initiation factor activity
Involved in secretion and vacuolar trafficking and
maintenance
Serine/threonine protein kinase
Enzyme regulator activity
Maintenance of cellular integrity
Minor import receptor of the mitochondrial outer
membrane
Unknown
Unknown
Unknown
Putative serine protease
Unknown
Unknown
Unknown
Unknown

Growth in solid medium plate with
His-Leu
No inducer
Inducer
(Without Trp)
(With Trp)
+
++
+
+
+
++
++
++
+++
+++
+
++
+
++
++
+++
+++
+++
+
+++
++
++
++
++
++
++
++
++
+
++
++
++
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Toxicity of AlaEth (% of the
wild type)
156
109
118
119
114
121
107
113
129
109
168
135
146
170
124
132

Functional
categories
of Biological
Processesb
3
3
3 4 5 9 14 21
3 4 9 10 14 21
3 4 14
3 4 14
4
5 12
6
7 27
10
10 27 28
13
13
13
14

+
++
+
++

+
+++
++
++

129
109
107
108

14
19
25
29

++
++
+
+
++
+
+

++
++
++
++
++
++
+
++

139
112
143
106
123
106
122
114

29
29
29
29
29
29
29
29

a

These genes encode proteins with more than 30% sequence identity to a human protein.
The functional categories found for each gene according to the gene annotation in SGD Gene Ontology (GO) (http://db.yeastgenome.org/cgibin/GO/goTermMapper) are listed. Many genes have multiple listings in GO. The GO functional categories are listed as follows, with the number of genes
identified in this screen belonging to each category shown in parentheses taking into account the multiple functional categories found for many genes: 1) Cell
cycle (8 genes); 2) Transcription (10 genes); 3) Transport (10 genes); 4) Organelle organization and biogenesis (8 genes); 5) Response to stress (6 genes); 6)
Protein modification (3 genes); 7) DNA metabolism (4 genes); 8) Meiosis (6 genes); 9) Cytoskeleton organization and biogenesis (5 genes); 10) Morphogenesis
(4 genes); 11) Energy pathways (0 gene); 12) Protein catabolism (1 genes); 13) Protein biosynthesis (4 genes); 14) Vesicle-mediated transport (8 genes); 15)
Carbohydrate metabolism (0 gene); 16) Lipid metabolism (0 gene); 17) Signal transduction (2 genes); 18) Cytokinesis (0 gene); 19) Nuclear organization and
biogenesis (2 genes); 20) Sporulation (1 gene); 21) Budding (3 genes); 22) Cellular respiration (0 gene); 23) Cell homeostasis (1 gene); 24) Coenzyme and
prosthetic group metabolism (0 gene); 25) Cell wall organization and biogenesis (2 genes); 26) Amino acid and derivative metabolism (1 gene); 27) RNA
metabolism (2 genes); 28) Ribosome biogenesis and assembly (1 gene); 29) Biological process unknown (9 genes); 30) Membrane organization and biogenesis
(0 gene); 31) Electron transport (0 gene); 32) Pseudohyphal growth (0 gene); 33) Vitamin metabolism (0 gene); 34) Conjugation (0 gene).
b
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Supplement Table S4 List of 57 genes whose deletion mutant strain decreased dipeptide utilization. In the solid medium plate,
deletion strains were grown in MM+(H-L)HKU with or without Trp. In the toxicity halo assay, deletion strains were grown in
MM+HLKU medium supplied with 0.1µmol Ala-Eth in the disk. According to the Gene Ontology (GO) in SGD
(http://db.yeastgenome.org/cgi-bin/GO/goTermMapper), these genes cover 25 out of 34 categories of “Biological Processes”. A given
gene is only listed once, although based on its functions some genes are classified into multiple categories. The genes in bold (DAL81,
STP2, UBC2, and PTR1) were previously identified as being involved in the regulation of PTR2 transcription.
Gene name

Wild-type
TAF14 a
MCK1a
MRE11a
PHO85 a
HFM1 a
SPO21
RPN4 a
BYE1 a
DAL81
STP2 a
THP1
REG1
ISA1 a
ISA2
NPL3 a
VBM1
ASM4
BUD32 a
BEM4

Description of gene product

General RNA polymerase II transcription factor activity
Protein kinases, positive regulator of meiosis and spore
formation
3'-5' exonuclease activity
Cyclin-dependent protein kinase activity
DNA helicase activity
Structural molecule activity
Transcriptional activator activity
Transcriptional elongation regulator activity
Specific RNA polymerase II transcription factor activity
Specific RNA polymerase II transcription factor activity
Protein binding
Protein phosphatase type 1 activity
Mitochondrial protein required for normal iron
metabolism
Mitochondrial protein required for iron metabolism
mRNA binding
Fatty acid elongase activity
Structural molecule activity
Protein serine/threonine kinase activity
Rho-type GTPases

Growth in solid medium plate
with His-Leu
No inducer
Inducer
(Without Trp)
(With Trp)
+
+
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Toxicity of Ala-Eth

Functional
categories of
Biological
Processesb

100
0 (Fuzzy halo)
83

1 2 7 19
1 5 6 7 8 20

-

+
-

82
0
0 (Fuzzy halo)
0 (Fuzzy halo)
0
85
0
61
88
0 (Fuzzy halo)
0

1578
1 6 11 15
178
1 8 20
1 12
2
2
2
2 3 4 7 9 10 18
2 11 15
3

-

+
-

0
90
93
0 (Fuzzy halo)
0 (Fuzzy halo)
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3
3
3 14 16
3 19
4 6 9 10 18
4 9 10 17

Supplement Table S4 Continued
Gene name

BUD28
UBC2 a
RAD23 a
TSA1 a
PTR1
UBA3 a
UBP14
ELF1 a
CSF1
SHP1 a
ETR1 a
MCT1
OAR1
PRD1 a
RPL21A a
RPS9B a
IPK1
LAT1 a
PDB1 a
HFA1 a
IRA2
HOF1 a
RMD12
NFU1 a
PDX1 a
LPD1 a
GCV2 a

Description of gene product

Bud site selection
Ubiquitin conjugating enzyme activity
Damaged DNA binding
Thioredoxin peroxidase activity
Ubiquitin-protein ligase activity
NEDD8 activating enzyme activity
Ubiquitin-specific protease activity
Molecular function unknown
Required for normal growth rate
Ubiquitin binding; Enzyme regulator activity
Enoyl-[acyl-carrier protein] reductase activity
[acyl-carrier protein] S-malonyltransferase activity
3-oxoacyl-[acyl-carrier protein] reductase activity
Metalloendopeptidase activity
Structural constituent of ribosome
Structural constituent of ribosome
Inositol or phosphatidylinositol kinase activity
Dihydrolipoyllysine-residue acetyltransferase activity
Pyruvate dehydrogenase (acetyl-transferring) activity
Acetyl-CoA carboxylase activity
Ras GTPase activator activity
Cytoskeletal protein binding
3-hydroxyacyl-[acyl-carrier protein] dehydratase activity
Involved in maturation of mitochondrial iron-sulfur
proteins
Protein binding
Dihydrolipoyl dehydrogenase activity
Glycine dehydrogenase (decarboxylating) activity

Growth in solid medium plate
with His-Leu
No inducer
Inducer
(Without Trp)
(With Trp)
+
+
-
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+

Toxicity of Ala-Eth

75
0
84
88
0
0
73
94
90
74
0
0
0
84
0
65
67
0
0
0
86
0
0
0

Functional
categories of
Biological
Processesb
4 9 10 18
5 6 7 12 19
5 7 12
5 23
6
6
6 11 15
10
11
11 12 15 20
11 16 22
11 16 22
11 16 22
12
13
13
15
15
15
16
17
18
20
23

0
0
0

24
24 26
26

Supplement Table S4 Continued
Gene name

GCV3 a
SHM2 a
ILM1
YDR015C
YDR157W
YDR290W
YDR433W
YJL046W a
YJL175W
YPL098C a
YPR174C

Description of gene product

Glycine dehydrogenase (decarboxylating) activity
Glycine hydroxymethyltransferase activity
Mitochondrial DNA maintenance
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown

Growth in solid medium plate
with His-Leu
No inducer
Inducer
(Without Trp)
(With Trp)
+
+
+

a

Toxicity of Ala-Eth

0
89
85
82
0
85
79
0
0
82
79

Functional
categories of
Biological
Processesb
26
26
29
29
29
29
29
29
29
29
29

These genes encode proteins with more than 30% sequence identity to a human protein.
The functional categories found for each gene according to the gene annotation in SGD Gene Ontology (GO) (http://db.yeastgenome.org/cgibin/GO/goTermMapper) are listed. Many genes have multiple listings in GO. The GO functional categories are listed as follows with the number of genes
identified in this screen belonging to each category shown in parentheses taking into account the multiple functional categories found for many genes: 1) Cell
cycle (8 genes); 2) Transcription (6 genes); 3) Transport (7 genes); 4) Organelle organization and biogenesis (5 genes); 5) Response to stress (5 genes); 6) Protein
modification (8 genes); 7) DNA metabolism (7 genes); 8) Meiosis (4 genes); 9) Cytoskeleton organization and biogenesis (5 genes); 10) Morphogenesis (5
genes); 11) Energy pathways (8 genes); 12) Protein catabolism (5 genes); 13) Protein biosynthesis (2 genes); 14) Vesicle-mediated transport (1 gene); 15)
Carbohydrate metabolism (7 genes); 16) Lipid metabolism (5 genes); 17) Signal transduction (2 genes); 18) Cytokinesis (4 genes); 19) Nuclear organization and
biogenesis (3 genes); 20) Sporulation (4 genes); 21) Budding (0 gene); 22) Cellular respiration (3 genes); 23) Cell homeostasis (2 genes); 24) Coenzyme and
prosthetic group metabolism (2 genes); 25) Cell wall organization and biogenesis (0 gene); 26) Amino acid and derivative metabolism (4 genes); 27) RNA
metabolism (0 gene); 28) Ribosome biogenesis and assembly (0 gene); 29) Biological process unknown (10 genes); 30) Membrane organization and biogenesis
(0 gene); 31) Electron transport (0 gene); 32) Pseudohyphal growth (0 gene); 33) Vitamin metabolism (0 gene); 34) Conjugation (0 gene).
b
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Supplement Table S5 Halo assay of mutants in components of the ESCRT protein
complex.
Protein complex Strains

Halo size (Ala-Eth)

WT (BY4742)
ptr2
ESCRT I
ESCRT II
ESCRT III

vps23
vps28
srn2
vps22
vps25
vps36
vps2 (Sub-complexes 1)
vps24 (Sub-complexes 1)
vps20 (Sub-complexes 2)
snf7 (Sub-complexes 2)
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0.2µmol
28
0

0.1µmol
23
0

33
32
31
33
36
33
34
33
38
32

28
27.5
23
28.5
31
31
30
29
34
34

Supplement Figure S1: Ptr2p-GFP expression signal and localization in deletion
strains with increased dipeptide utilization. Some strains (underlined) are also shown
in Figure 3 as examples of the expression level and localization of Ptr2p-GFP.
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1)

WT

ssn2

cup9

srb8

kem1

eaf3

csm1

arp8

ssn8

ssn3

pat1

ubr2

hal9

dbr1

sfp1

ssd1

arp5

ies6

mrps9
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tom72

yor322c

yfr044c

ynl123w

ylr114c

2)

srn2

vps8

tpm1

vam10

vps36

snf7

eaf7

npr1

bni1

lst4

def1

sac6

Supplement Figure S1 Continued
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ypl073c

ynl295w

3)

ybt1

mlh1

rim101

kti12

pho2

cik1

tif3

ydr417c

mrp17

Supplement Figure S1 Continued
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vps23

Components of ESCRT I
vps28

srn2

vps22
Components of ESCRT II

vps25

vps36
vps2

vps24

Components of ESCRT III

vps20

snf7

Supplement Figure S2 Ptr2p-GFP localization in mutants of the ESCRT complex.
Strains srn2 is also shown in Figure 3.
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Supplement Figure S3: Ptr2p-GFP expression signal and localization in deletion
strains with decreased dipeptide utilization. Some strains (underlined) are also shown
in Figure 4 as examples of the expression level and localization of Ptr2p-GFP.
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1)

asm4

ydr015c

ydr290w

2)

bud32

reg1

csf1

shp1

mck1

vbm1

rps9b

hfm1

mre11

gcv3

npl3

tsa1

bem4

gcv2

etr1
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rmd12

ilm1

isa2

ydr433w

ydr157w

isa1

yjl046w

yjl175w

3)

spo21

prd1

elf1

bud28

pdx1

bye1

ira2

rad23

lpd1

pdb1

oar1

lat1

Supplement Figure S3 Continued
122

mct1

hfa1

ypl098c

4)

ptr1

ubc2

dal81

stp2

rpn4

shm2

hof1

rpl21a

uba3

ipk1

thp1

nfu1

pho85

ubp14

ypr174c

taf14
Supplement Figure S3 Continued
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Supplement Figure S4 The osmotic sensitivity of selected deletion mutants. The
selected strains were grown in either 0 or 1.0 M of NaCl. In panel A, deletion strains
showed a similar sensitivity to 1.0 M NaCl in comparison to that of the wild-type strain;
in panel B panel, deletion strains bud32, kem1, srn2, and vps8 were more sensitive to 1.0
M NaCl.
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NaCl
Cell number

0M

1.0 M

WT
cup9

(A)

ptr1
ubp14
ubr2
rpn4
ssn3
reg1
npr1
ybt1
hal9
ubc2
lpd1
gcv3
dal81

(B)

vps8
kem1
srn2
bud32
125

Supplement Figure S5 The canavanine sensitivity to the selected deletion mutants. The selected strains were grown in medium
MM+HLKU and canavanine (1.0 μg) was added to each disk. In panel A, nine deletion strains showed a similar sensitivity to
canavanine sensitivity in comparison to that of the wild-type. In panel B, the six deletion strains demonstrated a greater sensitivity to
canavanine. In panel C, the three deletion strains were less sensitive to canavanine.
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Halo size same as wild-type

W
WT
T

ptr
ptr1
1

cup
cup9
9

hal9

rpn4

ssn3

ubc2

ubp14

ubr2

ybt1

Halo size larger than wild-type

Halo size less than wild-type

dal8
dal81
1

gcv3

bud3
bud32
2

lpd1
lpd

reg1

npr1npr

1

vps8

1

srn2
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kem1

Pyruvate
PDH

H4folate
SHMT

Acetyl-CoA
serine
glycine

5,10-CH2-H4folate

Hfa1p

malonyl-CoA
FAS
Etr1p

GDC
CO2, NH4+

Mitochondrial fatty
acid synthesis

PDH (Pyruvate dehydrogenase complex): Pdx1p, Lpd1p, Pdb1p, and Lat1p
GDC (Glycine decarboxylase multienzyme complex): Gcv2p, Gcv3p, and Lpd1p
FAS (Fatty acid synthase): Oar1p and Mct1p
SHMT (Serine hydroxymethyltransferase): Shm2p

Supplement Figure S6 Proteins involved in cellular metabolic processes impacted in
dipeptide utilization. These proteins include the components of pyruvate dehydrogenase
complex (Pdx1p, Lpd1p, Pdb1p, and Lat1p), the components of GDC [Glycine
decarboxylase multienzyme complex (GCV2, GCV3, LPD1)], the components of FAS
[Fatty acid synthase (Oar1p, Mct1p)], SHMT [Serine hydroxymethyltransferase
(Shm2p)], Hfa1p, and Etr1p.
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PART III

PROBING METABOLIC PATHWAYS OF DI/TRI-PEPTIDE UTILIZATION
BASED OB NATURAL DIVERSITY
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Part III was published in its entirety as Oliver R. Homann, Houjian Cai, Jeffrey M.
Becker, and Susan L. Lindquist 2005. Harnessing Natural Diversity to Probe Metabolic
Pathways. PLoS Genetics 1(6):715-729. Houjian Cai was responsible for Ptr2p-GFP
expression analysis and toxic dipeptide halo assay, and proposed a research on a second
peptide transporter related to dipeptide utilization.

ABSTRACT
Analyses of cellular processes in the yeast Saccharomyces cerevisiae primarily
rely upon a small number of highly domesticated laboratory strains, leaving the extensive
natural genetic diversity of the model organism largely unexplored and unexploited. We
asked if this diversity could be used to enrich our understanding of basic biological
processes. As a test case, we examined a simple trait: the utilization of di/tri-peptides as
nitrogen sources. The capacity to import small peptides is likely to be under opposing
selective pressures (nutrient utilization versus toxin vulnerability) and may therefore be
sculpted by diverse pathways and strategies.

Hitherto, dipeptide utilization in S.

cerevisiae was solely ascribed to the activity of a single protein, the Ptr2p transporter.
Using high-throughput phenotyping and several genetically diverse strains, we identified
previously unknown cellular activities that contribute to this trait. We find that the Dal5p
allantoate/ureidosuccinate permease is also capable of facilitating di/tri-peptide transport.
Moreover, even in the absence of Dal5p and Ptr2p, an additional activity - almost
certainly the periplasmic asparaginase II Asp3p - facilitates the utilization of dipeptides
with C-terminal asparagine residues by a different strategy. Another, as yet unidentified
activity, enables the utilization of dipeptides with C-terminal arginine residues. The
relative contributions of these activities to the utilization of di/tri-peptides vary among the
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strains analyzed, as does the vulnerability of these strains to a toxic dipeptide. Only by
sampling the genetic diversity of multiple strains were we able to uncover several
previously unrecognized layers of complexity in this metabolic pathway.
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INTRODUCTION

Our understanding of the inner workings of eukaryotic cells owes much to the
yeast Saccharomyces cerevisiae. The application of powerful genetic and molecular
tools to this model organism has yielded an extensively annotated proteome. These
analyses have benefited greatly from the engineering of experimentally tractable strains
of S. cerevisiae, but an unintended consequence of this focus has been a tendency to
ignore the vast wealth of natural genetic variation found in diverse strains of this
organism. Following the “gold rush” ushered in by the sequencing of the S. cerevisiae
genome, efforts are being made to revisit this natural diversity. Phenotypic analyses of
diverse yeast strains (MORTIMER et al. 1994; TRUE and LINDQUIST 2000) and the
application of microarray technology to the analysis of allelic variation (BREM and
KRUGLYAK 2005; BREM et al. 2002; STEINMETZ et al. 2002; WINZELER et al. 1999;
WINZELER et al. 1998; YVERT et al. 2003) and population genetic variation in gene
expression (CAVALIERI et al. 2000; FAY et al. 2004; TOWNSEND et al. 2003) are
providing new insights into the ecology and diversity of the species. Such analyses
should also be applicable to the elucidation of pathways that face strong diversifying
selection, such as those governing uptake and metabolism of nutrients. As a test case, we
employed high-throughput phenotyping of diverse S. cerevisiae strains to dissect the
multiple activities contributing to the utilization of di/tri-peptides as a nitrogen source.
The capacity to import small peptides is a ubiquitous cellular function, found in
bacteria, fungi, plants, and animals (HAUSER et al. 2001; HERRERA-RUIZ and KNIPP 2003;
PAYNE and SMITH 1994; STACEY et al. 2002; STEINER et al. 1995). While small peptides
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have clear nutritional value as a source of amino acids, carbon, and nitrogen, they can
have additional beneficial functions. For example, studies in bacteria have demonstrated
a link between peptide transport and chemotaxis (MANSON et al. 1986), sporulation
(MATHIOPOULOS et al. 1991; PEREGO et al. 1991), and the recycling of cell wall peptides
(GOODELL and HIGGINS 1987).
Peptide transport systems, however, can also be a source of biological
vulnerability. A variety of antimicrobial and antifungal agents utilize the di/tri-peptide
transport machinery to gain entry into the cell (RINGROSE 1980; ST GEORGIEV 2000).
Thus, the benefits and risks associated with peptide import represent conflicting
evolutionary pressures that may help shape the regulation and substrate specificity of
peptide transporters. In a similar vein, transporters of small peptides are also of great
interest for their medical applications, as routes for delivery of peptidomimetic drugs
(BECKER and NAIDER 1995; NIELSEN and BRODIN 2003).
Members of the PTR family of peptide transporters transport a variety of
substrates, including nitrates, amino acids, and di/tri-peptides (GRAUL and SADEE 1997;
STEINER et al. 1995). All PTR members contain 12 predicted transmembrane helices,
and transport a variety of substrates by means of proton-motive force (CHIANG et al. 2004;
MACKENZIE et al. 1996). While many organisms, such as humans and plants, contain
multiple PTR2 family members, the yeast S. cerevisiae contains only one, the di/tripeptide transporter Ptr2p (Swiss-Prot: P32901).
The regulation of PTR2 expression in S. cerevisiae is strongly influenced by the
composition of the extra-cellular environment.

PTR2 expression is induced in the

absence of preferred nitrogen sources (ALAGRAMAM et al. 1995) - even more so when the
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medium contains particular amino acids (ISLAND et al. 1987). Import of di/tri-peptides
containing basic or bulky hydrophobic N-terminal residues also induces PTR2 by
reducing cellular levels of the PTR2 repressor Cup9p (Swiss-Prot: P41817). Specifically,
these di/tri-peptides serve both as ligands and as regulators of the E3 ubiquitin ligase
Ubr1p (Swiss-Prot:P19812), which mediates a protein degradation system that is
governed by the identity of N-terminal amino acids (VARSHAVSKY 1996; VARSHAVSKY
1997) (Figure 1). These peptides are too small to serve as targets for degradation by the
proteasome and they are assimilated as nutrients via other peptidases in the cells.
However, di/tri-peptides with basic (Type 1: Arg, His, or Lys) and bulky (Type 2: Ile,
Leu, Phe, Trp, or Tyr) N-terminal residues can compete with larger protein substrates for
binding at the type 1 and type 2 Ubr1p substrate binding sites. Upon binding, these
peptides allosterically activate Ubr1p-mediated degradation of Cup9p (Swiss-Prot:
P41817) by release of the Ubr1p autoinhibitory domain, thus exposing a substrate
binding domain that binds an internal degron in Cup9p (DU et al. 2002). Relief of Cup9p
repression of PTR2 results in enhanced PTR2 expression.

This initiates a positive

regulatory feedback loop in which di/tri-peptide uptake perpetuates Ubr1p-mediated
degradation of Cup9p, upregulation of PTR2, and additional di/tri-peptide uptake (BYRD
et al. 1998; DU et al. 2002; TURNER et al. 2000).
Investigations of di/tri-peptide import in S. cerevisiae have typically been limited
to the analysis of a small number of substrates through complementation of auxotrophies
or the use of radiolabeled dipeptides. The recent development of the Biolog system of
“Phenotype MicroArrays™” (PM; (BOCHNER 2003; BOCHNER et al. 2001)) provides the
opportunity to dramatically expand the scope of these analyses. The PM system
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Figure 1 Di/tri-peptide uptake is enhanced by a positive feedback loop governed by
the N-end rule pathway. The E3 ubiquitin ligase Ubr1p contains binding sites for
proteins containing Type 1 (Arg, His, Lys) and Type 2 (Ile, Leu, Phe, Trp, Tyr) Nterminal amino acids. In the absence of di/tri-peptides, the PTR2 repressor Cup9p is
abundant and PTR2 expression is minimal. Upon binding of Type 1 and/or Type 2 di/tripeptides to Ubr1p, an autoinhibitory domain blocking the recognition of an internal
Cup9p degron dissociates from the Cup9p binding site, and Cup9p turnover is accelerated.
Consequently, PTR2 repression is relieved and elevated levels of Ptr2p enhance di/tripeptide uptake, initiating a positive feedback loop. This figure was adapted from the
diagram of Turner et al. (TURNER et al. 2000), with the authors’ permission.
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facilitates the classification of bacterial and fungal species by generating a characteristic
phenotypic profile, which reflects the metabolic capabilities and chemical sensitivities of
different species. The strong representation of peptides in the PM assay plates – 284 of
the 400 possible dipeptide permutations and 11 tripeptides – provides a unique
opportunity to assay the capacity of different S. cerevisiae strains to import and utilize
dipeptides as nitrogen sources.
Using a combination of high-throughput data from the PM assays, we uncovered
extensive variation in dipeptide utilization in different strains of S. cerevisiae.

We

exploited this variation to uncover a diversity of strategies that may serve to balance the
opposing selection pressures of nutrient utilization and toxin vulnerability. We find that
Ptr2p provides only one of at least four distinct molecular activities that facilitate the
utilization of dipeptides in S. cerevisiae. The varying strengths of these activities in
different strains were key to their identification. No single strain would have revealed the
full complexity of dipeptide utilization, underscoring the importance of natural genetic
variation for developing a comprehensive understanding of cellular processes.
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MATERIALS AND METHODS

Media and reagents: Synthetic defined (SD), YPD, and 5-FOA (BioVectra)
media were made using standard formulations (AUSUBEL et al. 1988). When needed,
G418 (Gibco) was added to the YPD media at 200 µg/ml to select for Kanr. To select for
HygBr, Hygromycin B (American Bioanalytical) was added to YPD at 250 µg/ml. All
dipeptides used outside of the PM assays were obtained from Bachem. A minimal media
(MM), supplemented with the indicated nitrogen sources, was utilized for the Bioscreen
C growth curve assays. MM media contained 2% glucose, 0.17% yeast nitrogen base
without (NH4)2SO4 and amino acids (Bio101), 18 mg/L uracil (omitted for URA3
plasmid-bearing strains), and 2% agar (for solid media). The MMA medium used in the
halo and GFP assays was identical to the MM media, except that it contained 1 g/L
allantoin as a nitrogen source and a slightly different concentration of uracil (20 mg/L).
The Biolog PM media contained 50 mM glucose, 1 mM disodium pyrophosphate, 2 mM
sodium sulfate, and a proprietary tetrazolium dye mix and “IFY-0” media. IFY-0 is a
basal media, lacking nitrogen, carbon, phosphate, and sulfur sources, which are
supplemented as needed.
Plasmid construction:
(HAUSER et al. 2005).

Construction of the pMS2 plasmid is described in

The plasmid pPTR2-2xGFP-SFH-KanR was constructed by

addition of tandem copies of GFP (2xGFP) and a kanr selectable marker into plasmid
pMS2.

First, primers PTR2-FLAG-GFP-F and PTR2-FLAG-GFP-R (all primer

sequences are supplied in supplemental Table S1) were used to amplify a 1.5kb fragment
containing 2xGFP from plasmid pKW430 (a gift of Dr. Mary Miller, Rhodes University
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(STADE et al. 1997)) and an additional 40 bp of flanking sequence homologous to pMS2.
The plasmid pMS2 was then linearized at the unique restriction site AgeI, located
between the FLAG and His tags. 2xGFP was then inserted between these two tags by
homologous recombination, creating pMS4. A HincII fragment containing kanMX4 from
pFA6a-kanMX4 (WACH et al. 1997) was then inserted into the NaeI site of pMS4, which
lies beyond the stop codon following the 6xHis tag, creating the final pPTR2-2xGFPSFH-KanR plasmid.
The plasmid pRS426-DAL5 was created by cloning an EcoRV genomic fragment
from a plasmid recovered in the genomic screen (see below) into the 2µ vector pRS426
(ATCC#77107; (CHRISTIANSON et al. 1992)). This fragment spans a region from -1334
to +2908, relative to the start codon of the DAL5 gene.
pUG6-HygB was created by replacement of the kanMX marker in pUG6
(GULDENER et al. 1996) with a hphMX cassette from pAG32 (GOLDSTEIN and
MCCUSKER 1999). First, a PCR fragment containing the hphMX cassette was amplified
from pAG32 using primers O-199 and O-200 and digested with MluI and BsmI. The
resulting fragment was then inserted into the similarly digested pUG6.
Strain construction: The source and origins of the strains used in this study are
indicated in Table 1. To make all strains MATa ura3, some modifications were made to
eliminate amino acid auxotrophies, mutate URA3, and change mating types (described in
detail in Protocol S1). All transformations were conducted using the standard lithium
acetate technique (ITO et al. 1983).
PTR2 was deleted with a short-flanking homology (SFH) cassette amplified from
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Table 1 Strains used in this study
Straina
W303-x

Genotype
MATa ura3 can1-100 ho

Type
laboratory

YAT7-x

MATa ura3 ho::MX3

RM8-x

MATa ura3Δ0 ho::loxP

RM3-x

MATa ura3Δ0 ho::loxP

S288c-x
Y55-x
YAT17-x

MATa ura3 ho
MATa ura3 ho::KAN-MX3
MATa ura3 ho::KAN-MX3

YAT21-x

MATa ura3 ho::KAN-MX3

clinical
(peritoneal fluid)
vineyard
(California)
vineyard
(California)
laboratory
vineyard (France)
clinical
(broncheolar)
clinical
(vaginal)

a

Source(s)
G. Fink/
R. Rothstein
J. McCusker
B. Garvik/
R. Mortimer
B. Garvik/
R. Mortimer
B. Garvik
J. McCusker
J. McCusker
J. McCusker

When additional deletions were introduced into the strains, these modifications were appended to the
strain name (i.e. “x”= ptr2Δ, cup9Δ, dal5Δ or ptr2Δdal5Δ.)
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plasmid pFA6a-GFP(S65T)-kanMX6 (WACH et al. 1997) (pAG32 (GOLDSTEIN and
MCCUSKER 1999) in the case of Y55; the GFP portion of the plasmid was not amplified).
This deletion cassette replaced the PTR2 region spanning +77 to +1781, relative to the
start codon, with a kanMX marker (hphMX in the case of Y55). CUP9 was deleted with a
SFH cassette amplified from plasmid pFA6a-GFP(S65T)-kanMX6, removing the CUP9
region spanning +41 to +878, relative to the start codon. DAL5 was deleted with a
hphMX marker from a SFH cassette amplified from pAG32. This deletion cassette
eliminated the DAL5 region spanning -70 to +1594, relative to the start codon.
Addition of a FLAG-2xGFP-6xHis tag to the C-terminus of endogenous PTR2
was accomplished with a SFH cassette amplified from plasmid pPTR2-2xGFP-SFHKanR. Proper integration was ensured by selection on G418 media and verification by
colony PCR. Final confirmation of proper integration was obtained by observation of
membrane-localized GFP fluorescence in MMA+Leu media.
PM assays of nitrogen source utilization (BOCHNER et al. 2001; TANZER et al.
2003): A full list of the nitrogen sources tested in the PM assay plates is provided in
Dataset S1. Each well of the PM plates contains a very low micromolar amount of amino
acids, at a level insufficient to complement auxotrophies or serve as an adequate nitrogen
source. All dipeptides are present at the same concentration (between 1-4 mM, the
precise concentration is proprietary information), with the exception of the small set of
dipeptides present in PM03, which are present at double the concentration of the others
(these are notated as “(2x)” when presented in the figures).
Strains were prepared for inoculation into the PM assay plates as follows.
Glycerol stocks were streaked to YPD plates and incubated at 30 °C for ~48 h. Next, 2-3
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colonies from each strain were restreaked to one section of a fresh YPD plate and
incubated overnight at 30 °C. In the morning, cells on each YPD plate were spread over
the plate to form a thin layer and incubated an additional 4-6 h to ensure that most cells
were actively growing. This technique also served to avoid the late-growth clumping
encountered with some wild strains. In the case of strains containing plasmids, standard
SD –ura dropout plates were used in place of YPD.
Cells were then inoculated into sterile water in 20x100 mm test tubes and adjusted
to a transmittance of 63% (~5x106 cells/ml). This 48x concentration cell suspension also
contained 14.4 mM uracil, except when plasmids were used. The cell suspension was
then reduced to 1x concentration by dilution into the Biolog PM media. 100 µl of this
mix were then inoculated into each well of the PM assay plates PM03, PM06, PM07, and
PM08. The plates were then sealed with sterile Axygen SealPlate film, placed in the
OmniLog reader, and incubated for 48 h at 30 °C. The OmniLog reader photographs the
plates at 15-min intervals, converting the pixel-density in each well to a signal value
reflecting cell growth and dye-conversion.
After completion of the run, the signal data were compiled and analyzed. Signal
data were exported from the Biolog software, compiled using Microsoft Excel, and then
visually represented using Java TreeView v1.0.8 (SALDANHA 2004) and Adobe Illustrator.
We chose to export the average and maximum signal value for each well and then
average the two values. In doing so, we were able to represent the full time course by a
single number and weight the value towards latter time points. Shadows cast over
perimeter wells in the OmniLog machine sometimes raised the basal signal level of these
wells. This was accounted for by determining a “baseline” signal level for each well by
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calculating the average signal level for the first two hours of the run. This value was then
subtracted from the previously calculated signal value, yielding a final signal value.
These calculations can be summarized as follows:

Signal value = [((average signal over 48 h) + (maximum signal over 48 h)) / 2)
- (average signal over first 2 h)]

In all cases, a minimum of two replicate PM assay runs were conducted, and the average
of the signal values was used. Additionally, when non-wild-type strains were assayed,
two independently constructed deletion strains were always tested. The PM assay data
used to calculate the signal values presented in this study are provided in Dataset S1.
Images of all signal curves are provided in Datasets S2-S4.
To ensure that dye reduction was not occurring in the absence of growth, all PM
plates were carefully examined following each run. The plates were inverted upon a
light-box such that cells were visible in wells that supported growth. This approach
revealed that dipeptides containing lysine, histidine, and cysteine residues, and also the
amino acid histidine, sometimes supported reduction of the dye in the absence of growth
(dipeptides containing these residues were omitted from the analysis; see Results). Two
additional control measures were taken to ensure that the correlation between dye
reduction and cell density was robust. First, the PM assay was conducted once with each
wild-type strain in the absence of the tetrazolium dye. Second, several PM runs were
plated as dilution series to YPD media at the conclusion of the 48h run. These additional
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measures confirmed that, with the exceptions noted above, the PM assay signal is a
reliable indicator of growth in the presence of the nitrogen sources discussed in this study.
Bioscreen growth curve analysis: A selection of PM assay dipeptide-utilization
phenotypes were verified using a Bioscreen C (Growth Curves, USA) plate reader.
Strains were cultured as described for the PM assay, but were inoculated at an optical
density at 595 nm (OD595) of 0.02 into MM media supplemented with the indicated
nitrogen source. The mixture was inoculated into a 100-well plate and incubated in the
Bioscreen C at 30 °C with heavy shaking. Measurements of OD600 were made at 45-min
intervals. Each growth curve was conducted in duplicate wells and was repeated at least
once.
Screen for Ptr2p-independent dipeptide utilization: The screen was conducted
using a pRS202-based genomic library (2µ; URA3) containing Sau3AI-digested genomic
DNA with an average insert size of 6-8 kb (gift of Dr. Gerald Fink; originally constructed
by Connelly and Hieter from a strain congenic with S288c (CONNELLY and HIETER
1996)). A full description of the screen can be found in the supplemental information
(Protocol S2).
Halo assay of Ala-Eth toxicity: The sensitivity of deletion mutants to the toxic
dipeptide Ala-Eth was measured as previously described (ISLAND et al. 1987). Ethionine
(Eth) is an analog of methionine, and utilization of Eth causes cell death. The tested
strains were grown overnight in MMA medium. Yeast cells were harvested and washed
three times with sterile, distilled water, then counted and adjusted to 5x106 cells/ml. One
ml of the cell suspension was added to 0.8% noble agar (3 ml) and plated onto MMA
medium with or without leucine (30 µg/ml), an inducer of PTR2 expression. Four 6-mm
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sterile paper disks containing either 0.2, 0.1, 0.05, or 0.025 µmoles of Ala-Eth were
placed on the lawn of cells. The size of the halo was measured after two days of
incubation at 30 °C. Between two and four replicates were conducted for each assay.
Although strains Y55 and RM3 were unable to utilize allantoin in the PM assay (Figure
2E) and in additional Bioscreen C assays using liquid media (0.5 mM allantoin; data not
shown), both strains were capable of utilizing allantoin in the solid halo assay media.
Sequencing upstream of PTR2:

While the region comprising the PTR2

promoter has yet to be clearly defined, the sequenced span, an 889 bp region immediately
upstream of the PTR2 start codon, should contain the key regulatory elements. The
region bound by the Cup9p repressor has been narrowed to the region spanning -897 to 448 (BYRD et al. 1998), relative to the PTR2 start codon. In addition, a predicted amino
acid-dependent upstream activator sequence (UASAA) is located between -777 and -760
(DE BOER et al. 1998).

Genomic DNA was prepared using the “smash and grab”

technique (ROSE et al. 1990). A 927 bp fragment containing the desired sequence was
amplified with primers O-321 and O-324, using an equal amount of Taq and Vent
polymerases. Each reaction mix was split into eight aliquots and repooled following
amplification. This approach was taken to help control for the possibility that a single
replication error could propagate through the entire sample. PCR products were then
purified with a Qiagen PCR purification kit and sequenced in both directions by
Northwoods DNA Inc. using oligos O-321, O-322, O-323, and O-324. Sequencing data
were analyzed using Sequencher DNA sequencing software.
GFP microscopy: To test the localization of GFP-tagged Ptr2p, yeast strains
carrying PTR2 with a C-terminal FLAG-2xGFP-6xHis tag were grown at 30 °C in MMA,
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MMA+Leu, or YPD media. Yeast cells were collected during log-phase and imaged.
The GFP signal was observed by fluorescence microscopy with a 470-490 nm excitation
wavelength and 515 nm emission filter fitted to an Olympus microscope.

Both

fluorescent and differential interference contrast (DIC) images were taken with a
MicroFireTM camera (Model S99809, Olympus).

145

RESULTS

To advance our understanding of the processes contributing to nitrogen utilization
in S. cerevisiae, we studied a panel of strains isolated from several widely differing
growth environments (Table 1). We included two related laboratory strains, S288c and
W303, two California vineyard isolates, RM3 and RM8, a vineyard isolate thought to be
of French origin, Y55 (GREIG et al. 2003), and a clinical isolate, YAT7. Because
expression of the dipeptide transporter PTR2 is strongly induced by even micromolar
amounts of certain amino acids supplemented in the media (ISLAND et al. 1987), we first
restored all of these strains to full amino acid prototrophy (see Materials and Methods).
Assaying nitrogen source utilization in diverse strains using Phenotype
MicroArrays: We utilized the newly developed PM system to assay the ability of these
strains to utilize an extensive selection of dipeptides and other compounds as nitrogen
sources. Cells were grown in 96 well plates in which each well contained a different
nitrogen source. A proprietary tetrazolium dye solution, which is reduced to the purple
compound formazan, was included in each well. Plates were photographed every 15
minutes, generating a growth curve for each well that primarily reflected dye reduction
(BOCHNER 1989). The remaining growth signal was attributable to turbidity resulting
from cell growth.
As the technology was developed for bacterial cells, we first asked how well the
PM signal curves reflect yeast cell growth and respiration, and how reproducible these
phenotypes were in standard yeast laboratory media. Reduction of the tetrazolium dye
ostensibly results from cellular respiration (BOCHNER 1989), but when we tested petite
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strains of S. cerevisiae in the PM assay, they remained capable of robust dye conversion
(data not shown). Thus, mitochondrial respiration is not required to produce reductants
for this dye. Next, we employed dye-independent measures of growth, such as measuring
optical density of PM plates lacking the tetrazolium dye and plating serial dilutions of
cells from PM plates to solid media to measure the number of colony forming units in
each PM well. Dye-conversion correlated well with growth (see Materials and Methods),
except that dipeptides containing the amino acids histidine, lysine, and/or cysteine
sometimes caused dye reduction in the absence of growth (data not shown). Interestingly,
this growth-independent dye reduction occurred only in the presence of cells. Since it
reflects an unknown metabolic process, these dipeptides were omitted from our analyses.
It should be noted however, that this growth-independent dye reduction exhibited strong
inter-strain variation, suggesting yet another source of metabolic variation for further
study.
The PM assay utilizes a viscous medium which supports less vigorous growth
than typical laboratory media (data not shown). To determine if growth on diverse
substrates in PM plates correlates well with standard laboratory media, we assayed
growth on dipeptides as the sole nitrogen source in both solid and liquid standard media
(see below), using optical density at 600nm to measure growth in the liquid assays.
Given the sensitivity of the dipeptide transport machinery to environmental cues, it is
unsurprising that some differences were observed between these platforms. In large part,
however, these differing growth conditions provided similar results, and the
reproducibility on all tested media was robust.
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Shared properties and inter-strain variation in nitrogen source utilization:
Next, we asked if the natural diversity in our yeast strains produced phenotypic diversity
in nitrogen source utilization. The 48 hour PM growth curves for each strain on each
medium are provided in the supplemental materials. To simplify comparisons, each
growth curve was assigned a score reflecting the extent of growth, as shown for
representative curves in the legend of Figure 2 (see also Materials and Methods). In
agreement with an earlier study of the ability of individual amino acids to serve as
nitrogen sources in S. cerevisiae (LARUE and SPENCER 1967), we found that cysteine,
histidine, and lysine did not support growth in any of our strains (Figure 2A). These are
the same amino acids that, when present in dipeptides, caused some strains to reduce the
tetrazolium dye in the absence of growth. Apart from some inter-strain variation in
growth on glycine and tyrosine, the remaining amino acids supported robust growth in all
strains tested.
In contrast to the general uniformity in the utilization of individual amino acids,
the six strains we analyzed had very different patterns of dipeptide utilization. To assist
visualization of the data, dipeptides were separated into two classes, N-end rule
dipeptides, which upregulate PTR2 by enhancing Ubr1p-mediated degradation of the
Cup9p repressor (Figure 2B), and non-N-end rule dipeptides (Figure 2C). The clinical
isolate YAT7 utilized the broadest spectrum of dipeptides (see Figure 2C in particular)
and tripeptides (Figure 2D). Indeed, it grew robustly on many peptides that none of the
other strains could utilize well, if at all. (Preliminary analyses of two additional clinical
isolates, YAT17 and YAT21, suggest that robust di/tri-peptide transport may be a
common feature of strains adapted to the atypical mammalian host environment; data not
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Figure 2. Variation in nitrogen source utilization among six strains of S. cerevisiae.
(A) Amino acids. (B) N-end rule dipeptides. (C) Non-N-end rule dipeptides. (D)
Tripeptides; amino acids are represented as single letters. (E) Miscellaneous nitrogen
sources. Each square represents the growth of one strain in the PM assay supplied with
the indicated nitrogen source. The value reflecting the extent of growth was generated
from the 48 h signal curve of the Phenotype MicroArray (PM) assay and represented by
the intensity of coloration, as shown in the legend. All signal values exceeding 200
reflected very robust growth, and are therefore represented with the same color. Bluebordered squares denote nitrogen sources that produced varying results in that strain,
exhibiting substantial variation in signal among replicates (σ2/mean > 10 and at least one
replicate with signal > 50 or < 200). Red-bordered squares denote putative substrates of
the Asp3p asparaginase.
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shown). The laboratory strain W303 utilized the fewest dipeptides. It lacked the broad
capacity for N-end rule dipeptide utilization characteristic of the other strains (Figure 2B),
but it did grow robustly on some of these dipeptides. In contrast, the French vineyard
isolate Y55 was growth-limited on the non-N-end rule dipeptides in comparison to the
other strains tested (Figure 2C). Each strain also exhibited a unique pattern in the
utilization of other nitrogen sources (Figure 2, D and E).
Given the close relationship between W303 and S288c (W303 was derived in part
from crosses with S288c; R. Rothstein, personal communication), it was surprising that
the PM profiles of S288c more closely resembled those of the California vineyard
isolates RM3 and RM8. However, S288c and W303 did share two characteristics: both
grew robustly on all of the dipeptides in the array that contained C-terminal asparagine
residues (Figure 2, B and C, boxes with red borders), and both grew well on D-asparagine
(Figure 2E).
Overexpression of PTR2 masks inter-strain variation and enhances di/tripeptide utilization:

The diversity of dipeptide-utilization traits suggests profound

differences in the underlying mechanism of di-tri/peptide import among our conspecific
strains. One likely source of inter-strain variation in dipeptide utilization is differences in
PTR2 regulation. If dipeptide utilization is limited by low levels of Ptr2p, upregulation of
PTR2 should enhance growth. To determine how broadly a lack of PTR2 expression
limits dipeptide utilization, we eliminated the repressor of PTR2, Cup9p, in three strains
whose wild-type dipeptide-utilization profiles were robust, intermediate, and weak:
YAT7, RM8, and W303 respectively.
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In all three strain backgrounds, the CUP9 deletions caused robust growth on most
of the di- and tripeptides present in the arrays (Figure 3). Even dipeptides that had not
supported growth in any of the wild-type strains, such as dipeptides bearing the Nterminal acidic residues aspartate or glutamate, supported growth upon deletion of CUP9
(Figure 3B). Of the 197 dipeptides amenable to PM analysis, only a small fraction –
most notably Trp-Trp, Trp-Glu, Asp-Asp, and Pro-Pro – supported little growth in the
cup9Δ strains. These dipeptides may either be refractory to transport or less amenable to
use as a nitrogen source following transport. The robust dipeptide utilization phenotype
of the cup9Δ mutants indicates that Ptr2p is capable of transporting a very broad array of
di/tri-peptides, a property that has long been assumed but never addressed with such a
large spectrum of dipeptides.
Further, the robust dipeptide-utilization phenotypes of the cup9Δ mutant strains
indicate that differences in regulatory control of PTR2 are a key feature of the natural
diversity observed among the strain backgrounds.

Whereas the wild-type strains

exhibited different dipeptide utilization phenotypes (Figure 2, B and C), relief of PTR2
repression by deletion of CUP9 eliminated almost all inter-strain variation (Figure 3).
Thus, the limited capacity for dipeptide utilization in wild-type W303 relative to RM8
and YAT7 is likely to reflect a difference in PTR2 regulation rather than a difference in
Ptr2p function.
Ptr2p is not required for the utilization of some dipeptides: The only known
transporter of di/tri-peptides in S. cerevisiae is Ptr2p. Therefore, we expected that ptr2Δ
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Figure 3 Deletion of CUP9 and PTR2 strongly impacts di/tri-peptide utilization in S.
cerevisiae strains. Elimination of the PTR2-repressor Cup9p revealed that Ptr2p can
facilitate the utilization of nearly all di/tri-peptides tested in the PM assay, yet Ptr2p was
not required for the utilization of a subset of di/tri-peptides as a nitrogen source. (A) Nend rule dipeptides. (B) Non-N-end rule dipeptides. (C) Tripeptides; amino acids are
represented as single letters. See Figure 2 for a detailed explanation of the yellow boxes
and colored borders.
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Figure 3 Continued
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trains would be unable to utilize any di/tri-peptides in the PM assay. Surprisingly, this
was not the case, particularly for non-N-end rule di/tri-peptides (Figure 3, B and C). All
three strains tested did not require PTR2 to utilize a subset of these non-N-end rule
dipeptides. Indeed, the W303-ptr2Δ mutant grew just as well on the non-N-end rule
dipeptides as the wild-type strain.
When examined as a whole, these observations suggested that at least two
activities contribute to dipeptide utilization: Ptr2p-mediated transport and an as yet
unidentified activity. For N-end rule dipeptides, Ptr2p was the main activity contributing
to their utilization, as evidenced by the almost complete abrogation of growth on these
nitrogen sources by the ptr2Δ deletions (Figure 3A). For non-N-end rule di/tri-peptides,
both Ptr2p and the Ptr2p-independent activity played roles in their utilization (Figure 3B).
The contribution of Ptr2p to general dipeptide utilization varied from minimal, as
observed with W303, to substantial, as observed with the clinical isolate YAT7 (Figure 3,
compare wild-type and ptr2Δ strains). In contrast, the similar growth properties of the
ptr2Δ strains suggested that the contribution of the Ptr2p-independent activity was similar
in all three strain backgrounds.
Dal5p confers a Ptr2p-independent dipeptide utilization activity: To identify
the source of dipeptide utilization in the ptr2Δ strains, we took advantage of the robust
growth of the W303-ptr2Δ strain when Ala-Leu was the sole source of nitrogen in the
PM assay. We speculated that the concentration of Ala-Leu needed to support growth
would be reduced if the gene allowing its utilization was overexpressed. Accordingly,
we screened a high-copy (2µ) genomic library for plasmids that restored growth of
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W303-ptr2Δ on limiting quantities of Ala-Leu (0.75 mM). After eliminating candidates
that contained the PTR2 ORF, the three remaining plasmids were sequenced. Each
plasmid carried the allantoate/ureidosuccinate permease gene DAL5 (Swiss-Prot: P15365).
To analyze the contribution of Dal5p to basal dipeptide utilization, we constructed
ptr2Δ, dal5Δ, and ptr2Δdal5Δ mutants in a variety of strain backgrounds. We began by
testing the growth of serially diluted cells on conventional solid media containing
different nitrogen sources (Figure 4). These included the putative Dal5p substrate AlaLeu, as well as Tyr-Ala and Ala-Tyr, which had not supported growth of the ptr2Δ
mutant in any of the strains tested in the PM assay (Figure 3, A and B). In all strains
tested, the ptr2Δdal5Δ double-mutant abolished growth on all three assayed dipeptide
sources. Thus, utilization of these dipeptides required one of these two systems.
In the case of the dipeptides Ala-Tyr and Tyr-Ala, utilization was mediated by
Ptr2p. Growth on these dipeptides was abolished by deletion of PTR2 alone, whereas
deletion of DAL5 alone had no apparent effect. In contrast, the utilization of Ala-Leu
involved both Ptr2p and Dal5p, but the relative contributions of these two activities
varied between strains. Similar results were obtained using both solid (Figure 4) and
liquid media (2 mM Ala-Leu; Figure S1). Ala-Leu could be utilized in strains RM8 and
YAT7 via either Ptr2p or Dal5p, but Ptr2p was necessary and sufficient for wild-type
growth levels. Strains W303 and Y55 did not exhibit this functional overlap in Ala-Leu
utilization. W303-ptr2Δ grew as well as wild-type W303 on Ala-Leu, but W303-dal5Δ
was completely unable to grow. In Y55, the same deletions created the opposite effect:
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Figure 4 The relative contributions of Dal5p and Ptr2p to dipeptide utilization vary
among strains of S. cerevisiae. Strains were cultured on YPD plates, as with the PM
assays, and then suspended in water at a concentration of ~3.5x106 cells/ml and plated as
1x, 5x, and 25x dilutions (from left to right). Each plate contained MM media plus the
nitrogen source indicated at the top of the column (with the exception of the far right
column, in which YPD plates were used). Plates were incubated at 30º C for 4 d and then
photographed. A Y55-ptr2Δdal5Δ double mutant was not tested, since deletion of PTR2
alone was sufficient to eliminate dipeptide utilization.
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Y55-ptr2Δ could not grow, whereas Y55-dal5Δ grew as well as wild-type Y55. Thus,
Y55 relied upon Ptr2p for utilization of the assayed dipeptides, whereas W303 relied
predominantly on Dal5p.
The scope of the contribution of Dal5p to di/tri-peptide utilization: Next, we
used the PM assay to ask how many di/tri-peptides could be utilized as nitrogen sources
through the activity of the DAL5 gene. The gene was subcloned into a clean 2μ vector,
from the original plasmid that was isolated from the genomic screen, and tested in strain
W303-ptr2Δ. Unlike the effect of overexpressing PTR2 (in the cup9Δ strain), the multicopy DAL5 plasmid only enhanced growth on a small number of di/tri-peptides (Figure
5).

With the exception of Tyr-Gln, these di/tri-peptides were all non-N-end rule

dipeptides. N-terminal alanine, glycine, and serine residues were particularly favorable
to Dal5p-mediated growth.
To determine whether Dal5p activity was redundant or supplemental to that of
Ptr2p, the specific contribution of Dal5p to di/tri-peptide utilization was explored using
PM assays of the strains Y55-dal5Δ and RM8-dal5Δ (full data presented in Figure S2).
In the case of Y55, deletion of DAL5 had negligible impact upon dipeptide utilization
(Figure S2B and Figure 4). Because the strongest growth defect in wild-type Y55 was in
the utilization of those non-N-end rule dipeptides that we have found to depend on Dal5p,
we speculated that Y55 might lack Dal5p activity. This hypothesis was verified by a PM
assay of Y55-ptr2Δ. Unlike our earlier assays of ptr2Δ mutants in YAT7, RM8, and
W303, deletion of PTR2 in Y55 completely eliminated growth on all dipeptides and
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Figure 5 Utilization of a subset of dipeptides is enhanced in W303-ptr2Δ upon
overexpression of DAL5. Strain W303-ptr2Δ was transformed with either the vector
pRS426 or the plasmid pRS426-DAL5, a 2µ plasmid containing a genomic fragment
including DAL5, and phenotyped using the PM assay. The nitrogen sources shown
comprise all instances in which the signal values met our reliability criteria (see Figure 2)
and the presence of pRS426-DAL5 altered the signal value by more than 50 units relative
to the vector control. Dipeptides followed by “(2x)” are present in the PM assay plates at
twice the concentration of the other dipeptides.
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tripeptides (Figure S2). Thus, Y55 relies solely upon Ptr2p for the transport of dipeptides.
In contrast, Dal5p contributed substantially to the utilization of dipeptides in RM8. All of
the dipeptides that supported more robust growth in the presence of Dal5p belonged to
the non-N-end rule category, and the majority contained the small N-terminal residues
alanine or glycine (data not shown). Deletion of DAL5 in strains RM8 and W303 did not
significantly affect the utilization of any non-peptide nitrogen sources, except that growth
was eliminated on N-acetyl-L-glutamate, an intermediate in arginine biosynthesis (DE
DEKEN 1962) (Figure S2C).

(The fact that N-acetyl-L-glutamate utilization is an

indicator of Dal5p activity explains why wild-type Y55 cannot utilize this substrate;
Figure 2E). Clearly, DAL5 makes an important contribution to dipeptide utilization in
yeast, and variations in DAL5 activity contribute to the naturally occurring variation in
nitrogen utilization in diverse strains.
Elimination of Ptr2p and Dal5p uncovers additional dipeptide-utilization
activities: To determine whether Ptr2p and Dal5p account for all dipeptide utilization in
the PM assays, we analyzed ptr2Δdal5Δ double mutants in two strains: W303, which
showed the greatest dependence on Ptr2p-independent mechanisms, and RM8, which
relied heavily upon both Ptr2p and Dal5p (Figure S2). In both strains, deletion of these
two genes abolished all growth on most tested dipeptides and tripeptides in both strains.
The most notable exception was that W303-ptr2Δdal5Δ, but not RM8-ptr2Δdal5Δ,
retained the capacity to utilize all dipeptides with C-terminal asparagine residues (Figure
S2; boxes with red borders).

The obvious candidate for the underlying molecular

determinant of this activity is the periplasmic asparaginase II (see Discussion). Since this
protein is encoded by four copies of the ASP3 gene (Swiss-Prot: P11163), interspersed
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among rRNA and Ty loci in the genome, the origin of the phenotype was not amenable to
genetic analysis.
A second strong exception to the requirement for Ptr2p and Dal5 was the
utilization of Met-Arg by RM8, which was actually enhanced by the dal5Δ mutation
(Figure 6) and remained robust in the ptr2Δdal5Δ double mutant (Figure S2). Similar
analyses of YAT7, W303, and Y55 mutants (Figure S2B and data not shown) indicated
that the ability to robustly utilize Met-Arg in the absence of Ptr2p and Dal5p function
was unique to RM8. Closer examination of the PM assay plates revealed that this Ptr2pand Dal5p-independent activity might affect the utilization of other dipeptides as well.
When PM assay plates containing RM8-ptr2Δdal5Δ were incubated at 30 °C for an
additional one to three days following the PM assay, growth was seen in wells containing
other dipeptides - specifically, those with C-terminal arginine residues (data not shown).
This delayed growth phenotype did not require the function of Dal5p or Ptr2p and was
not observed in plates containing either W303-ptr2Δdal5Δ or Y55-ptr2Δ.

Thus, it

represented a distinct fourth dipeptide utilization activity.
Inter-strain variation in sensitivity to the toxic dipeptide Ala-Eth:

The

benefit of efficient utilization of di/tri-peptides as a nutrient source is likely to be
counterbalanced by the vulnerability associated with indiscriminate peptide transport. To
assay inter-strain variation in vulnerability to toxic peptides, the panel of diverse S.
cerevisiae strains was exposed to a dipeptide containing L-ethionine (Eth), a toxic
methionine analogue (Table 2). The purine derivative allantoin was provided as a
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Figure 6 Deletion of DAL5 in strain RM8 strongly affects the utilization of a subset
of assayed dipeptides. All instances in which RM8 and RM8-dal5Δ signal values differ
by more than 50 units and conform to our reliability criteria (see Figure 2) are presented.
Dipeptides followed by “(2x)” are present in the PM assay plates at twice the
concentration of the other dipeptides.
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Table 2 Halo assay for uptake of the toxic Ala-Eth dipeptide

Cells were plated onto MMA media with or without 30 µg/ml leucine, an inducer of PTR2 expression; halo
diameters in the presence of discs containing the indicated Ala-Eth concentrations are presented as the
mean ± S.D.; ptr2Δ strains were also tested, and exhibited no halos.
a
Halo boundary was indistinct, often slowly receding as cells closer to the disc began to grow.
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nitrogen source (COOPER 1996), to eliminate the nutritional requirement for dipeptide
uptake. Discs containing different concentrations of Ala-Eth were applied to lawns of
cells, creating gradients of dipeptide concentration. Thus, the diameter of the halo of
growth inhibition surrounding a disc is an indicator of dipeptide import. In the standard
halo assay, minimal medium with allantoin is supplemented with 30 μg/ml leucine to
induce PTR2 expression (MMA+Leu media). Under these conditions, wild-type strains
varied substantially in sensitivity to Ala-Eth toxicity (Table 2). S288c was the most
sensitive to the dipeptide, while W303 was completely resistant. In the absence of the
leucine inducer, only the clinical isolates YAT17 and YAT21 were sensitive to Ala-Eth
(Table 2).
Deletion of PTR2 alone was sufficient to confer complete resistance to the toxic
dipeptide under the conditions tested (RM8- ptr2Δ and YAT7- ptr2Δ were tested; data
not shown). While this might suggest that Ptr2p is the primary transporter of Ala-Eth, we
note that Dal5p may also transport allantoin (CHISHOLM et al. 1987; GRETH et al. 1977),
raising the possibility that allantoin competed with Ala-Eth for Dal5p-mediated uptake.
Indeed, Ala-Met, which is structurally similar to Ala-Eth, supports growth in ptr2Δ
strains (Figure 3B) and dal5Δ strains (Figure S2B), suggesting that Dal5p and Ptr2p both
contribute to the vulnerability of yeast cells to Ala-Eth.
Elimination of the PTR2 repressor Cup9p enhanced Ala-Eth sensitivity in all
strains tested, yet it also revealed additional diversity among the strains (Table 2, cup9Δ).
The resistance of strain W303 to Ala-Eth was overcome by the cup9Δ mutation to the
extent that the W303-cup9Δ mutant exhibited higher sensitivity to Ala-Eth than cup9Δ
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mutants of either RM8 or YAT7. All of the cup9Δ mutant strains exhibited some
sensitivity to Ala-Eth in the absence of the leucine inducer. Curiously, despite the robust
dipeptide import characteristic of the YAT7 strain, YAT7-cup9Δ produced much smaller
halos under these conditions than either W303-cup9Δ or RM8-cup9Δ (Table 2; see also
Figure 7). Some of the inter-strain variation observed in the halo assay might reflect
varying sensitivity to ethionine. However, since both changes in media composition and
the cup9Δ mutations affected strains differently, this diversity is clearly shaped by the
complex regulatory controls governing dipeptide import.
Expression and localization of Ptr2p varies substantially among strains:
Strain W303 was both highly resistant to the toxic Ala-Eth dipeptide and limited in
dipeptide utilization capacity. Therefore, we asked whether PTR2 expression in this
strain differed from that of the other strains tested. To directly visualize the expression of
PTR2, a C-terminal FLAG-2xGFP-6xHis tag was added to the endogenous PTR2 gene of
strains W303, RM8, and YAT7 by site-specific homologous recombination.

These

modified strains retained a similar capacity to utilize dipeptides (data not shown). To
facilitate comparison of PTR2 expression with the results of the halo assay, expression of
GFP-tagged PTR2 was assayed in a liquid version of the MMA and MMA+Leu media
and fluorescence was measured using a uniform exposure level (Figure 7; halo assay
images included for comparison).
The presence of Ptr2p at the plasma membrane correlated well with the extent of
Ala-Eth toxicity observed in the halo assay (except that fluorescence was weaker in RM8
than might have been expected from its strong Ala-Eth sensitivity in MMA+Leu). In all

165

Figure 7 Inter-strain variation in PTR2 expression and sensitivity to the toxic
dipeptide Ala-Eth. Media composition and the absence of Cup9p affect expression of
GFP-tagged PTR2 and Ala-Eth toxicity. Three types of media were tested: MMA,
MMA+Leu, and YPD. “MMA” refers to minimal nitrogen media containing 1 mg/ml
allantoin as the nitrogen source. “+Leu” refers to the addition of 30 µg/ml leucine, an
inducer of PTR2 expression. YPD is a standard rich S. cerevisiae media; the presence of
methionine precludes its use for the halo assay. The left and right discs in each halo
assay panel contained 0.1 µmoles and 0.2 µmoles of Ala-Eth, respectively. Microscopy
was conducted using cells grown to log phase in the indicated media. Three strains were
imaged: W303, RM8, and YAT7. In each strain, the endogenous PTR2 gene contained a
C-terminal tag consisting of a FLAG epitope, two copies of GFP, and a 6xHis tag. The
insets depict representative cells from the small sub-population of W303 cells that
exhibited fluorescence.
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other cases, conditions promoting strong Ala-Eth sensitivity also induced strong PTR2
expression.

Strikingly, wild-type W303, which was resistant to Ala-Eth, exhibited

virtually no Ptr2p fluorescence. The cup9Δ mutation restored strong PTR2 expression
and also restored Ala-Eth sensitivity. Thus, the resistance of W303 to Ala-Eth in the halo
assay resulted from an absence of Ptr2p at the plasma membrane.

Moreover, these

results confirm that W303 contains a functional PTR2 gene subject to atypical regulation.
Additional aspects of PTR2 regulation: Retrograde recycling of membranebound Ptr2p is thought to represent an additional layer of regulatory control of dipeptide
import (H. Cai and J. Becker, unpublished observations). Although GFP-tagged Ptr2p
was typically localized to the membrane, when strain RM8 was grown in YPD, additional
fluorescent signal was also observed in the vacuole and what appeared to be large
vesicles. The high levels of PTR2 expression in the rich YPD media was itself surprising,
since PTR2 is thought to be subject to nitrogen catabolite repression in the presence of
preferred nitrogen sources (ALAGRAMAM et al. 1995). Although YAT7 also exhibited
robust PTR2 expression under these conditions, Ptr2p was confined to the plasma
membrane. This inter-strain variation was likely influenced by cellular Ptr2p levels, as
cup9Δ mutants of RM8, YAT7, and W303 all exhibited robust PTR2 expression and
some intra-cellular Ptr2p localization in YPD media (Figure 7). However, while wildtype RM8 and YAT7 both exhibited strong Ptr2p fluorescence in YPD, only RM8
exhibited abundant intra-cellular compartmentalization of Ptr2p, indicating that
retrograde transport of Ptr2p is yet another regulatory process that varies between strains
in S. cerevisiae.
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The regulation of PTR2 in W303 differed significantly from the other strains
analyzed in this study. Considering the possibility that polymorphisms within the PTR2
promoter region may account for the limited PTR2 expression in W303, we sequenced an
889 bp region immediately upstream of the PTR2 start codon in the strains W303, S288c,
RM8, and YAT7 (Table S2). The promoter region in W303 differed from that of S288c
at only one base, a CÆT transition at position -799. However, this polymorphism was
shared by the strain RM8, which unlike W303 is sensitive to Ala-Eth and exhibits robust
PTR2-dependent utilization of N-end rule dipeptides. Thus, differences in promoter
sequence are not a likely source for the altered regulation of PTR2 in W303.
Telomeric regions are common sites of epigenetic regulation, and PTR2 is located
in proximity (~50 kB) to a telomere. In our analyses of GFP-tagged PTR2, a small
subpopulation (1 in 50 to 1 in 1000, depending on conditions) of strongly fluorescent
W303 cells was consistently observed during growth in either the MMA+Leu media or in
YPD (Figure 7; inset).

W303 cells exhibiting robust PTR2 expression also arose

spontaneously at a high frequency (>0.1%) on solid media.

These cells maintain

competency for PTR2 expression following serial propagation on media that relieve
selection for active dipeptide transport (J. Manjrekar and S. Lindquist, personal
communication).

These switching events were far too frequent to reflect mutation,

suggesting that an epigenetic switch exists that can stably confer competency for PTR2
expression in W303 cells.
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DISCUSSION

We establish that the rich inter-strain diversity and genetic tractability of S.
cerevisiae can be combined with high-throughput phenotyping to provide new insights
into basic cellular processes.

Using this approach, we have uncovered previously

unrecognized functions and regulatory systems governing the utilization of dipeptides as
a nitrogen source. In addition, we consider dipeptide utilization in the context of an
adaptive landscape shaped by opposing selective pressures.
Using high-throughput phenotyping to study di/tri-peptide utilization: The
exploration of natural diversity using high-throughput phenotyping techniques has the
potential for tremendous synergy with the existing high-throughput technologies that
have shaped our understanding of the cellular circuitry of S. cerevisiae. The pursuit of an
integrated understanding of yeast functional genomics and proteomics (reviewed in
(BADER et al. 2003)) has been enabled by numerous powerful high-throughput
approaches. For example, genetic networks have been elucidated by high-throughput
screens for synthetic lethality (TONG et al. 2004), protein interaction networks have been
mapped using mass spectrometry (GAVIN et al. 2002; HO et al. 2002), and transcriptional
networks have been elucidated by the now ubiquitous technique of transcriptional
profiling using microarrays and by the mapping of physical interactions between
transcription factors and promoters (LEE et al. 2002). The technology for global analysis
of growth phenotypes remains largely underdeveloped and unexploited - in spite of the
fact that it is phenotype that determines how cellular systems interface with selective
pressures. Thus, the broad synthesis of our understanding of genomic, transcriptional,
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and phenotypic diversity is contingent upon the development of robust technologies for
high-throughput phenotyping.
Here, we have tested one of the first such systems by assaying dipeptide and
tripeptide utilization on a previously unfeasible scale. The PM phenotypic assay allows
simultaneous testing of ~2000 growth conditions, providing a tremendous savings in time
and labor.

The technology was typically very robust and provided reliable and

reproducible data that were easily manipulated using the accompanying software.
However, the PM technology also has several drawbacks that need to be addressed before
this technology is broadly suitable for use by the yeast research community. Due to the
initial design focus on generalized bacterial phenotyping, many of the available PM assay
plates are not optimized for S. cerevisiae. Thus, the number of useful growth conditions
is considerably less than 2000. This issue is compounded by the high cost of the PM
assay plates. Further, different batches of media and PM assay plates provided by the
manufacturer often affected reproducibility. Such technical difficulties are not atypical
for a new technology, and the power of such tools in exploring the phenotypic diversity
of S. cerevisiae is clear. Hopefully, the importance of high-throughput phenotyping will
lead to reduced costs and enhanced suitability of these technologies.
Uncovering unexpected complexity in di/tri-peptide utilization:

Through

extensive phenotyping, we found that Ptr2p is but one component of a multifaceted
system in S. cerevisiae governing the utilization of dipeptides as nitrogen sources. The
discovery of these additional components was made possible by the dramatic inter-strain
variation observed in the contributions of these activities to dipeptide utilization
(summarized in Table 3). We have clearly identified one previously unknown
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Table 3. Activities contributing to the utilization of dipeptides as a nitrogen source
in each strain background
Activity
Ptr2p
Dal5p
X-Asnc
X-Argd

YAT7
yesa
yes
-

RM3
yes
yes
ND

RM8
yes
yes
yes

Y55
yes
-

S288c
yes
yes
yes
ND

W303
yesb
yes
yes
-

The contributions of the activities, as indicated by the number of plusses, represent a qualitative summary
of the data gathered in this study; -, activity is minimal or absent; ND, not determined due to insufficient
data
a
Ptr2p activity was exceptionally robust in this strain
b
Ptr2p activity was limited in this strain
c
Refers to the putative Asp3p activity
d
Refers to the capacity to utilize dipeptides containing C-terminal arginine residues (particularly Met-Arg)
in the absence of Ptr2p and Dal5p activity.
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component of this system: the allantoate/ureidosuccinate permease Dal5p, and have
defined parameters of two others that suggest mechanistic explanations.
Of these four components, Ptr2p exhibits the broadest dipeptide utilization
activity. Relief of PTR2 repression by deletion of CUP9 facilitated robust growth on
nearly all di/tri-peptides tested. This was even true of W303, which otherwise grew on
only a limited subset of the N-end rule dipeptides that supported growth of the other
wild-type strains. This restricted utilization of potential Ptr2p substrates provides a
window into the complex PTR2 regulatory system. For example, one can ask why W303
is capable of growing on Trp-Arg, but not Arg-Trp (Figure 3A), even though both are Nend rule ligands composed of identical residues. One possibility is that the N-end rule
pathway in W303 is more responsive to Type I ligands (basic N-terminal residues; e.g.
Arg) than Type II substrates (bulky hydrophobic N-terminal residues; e.g. Trp).
Alternatively, substrate preference may arise from dipeptidase specificity (HERRMANN et
al. 1978) resulting in more robust hydrolysis of Trp-Arg upon import. While beyond the
scope of this analysis, additional insights and hypotheses can be derived from the wealth
of data provided by our high-throughput analysis, and the approach developed here – the
application of a diverse panel of strains to the PM assay to analyze di/tri-peptide
utilization – can be employed in future studies to enrich our understanding of PTR2
regulation and Ptr2p function.
Dal5p, a second component of the dipeptide utilization system, was previously
identified as a permease for the pyrimidine biosynthetic precursor ureidosuccinate
(TUROSCY and COOPER 1987) and the nitrogen source allantoate (CHISHOLM et al. 1987) .
Expression of DAL5 is subject to complex regulatory control by the nitrogen catabolite
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repression system (CHISHOLM et al. 1987; RAI et al. 2004; RAI et al. 1987). It is
therefore fitting that Dal5p also be involved in the utilization of dipeptides as a nitrogen
source. With the exception of Tyr-Gln, all Dal5p di/tri-peptide substrates belonged to the
non-N-end rule class. Many of the dipeptides supporting growth in RM8-ptr2Δ (Figure 3)
did not support growth in RM8-dal5Δ (Figure 6).

Thus, Dal5p-mediated dipeptide

transport is not redundant to that of Ptr2p, but rather a complementary activity that
enhances the range of dipeptides that can be utilized.
A third component, evident in strains W303 and S288c, governs the utilization of
dipeptides containing C-terminal asparagine residues as nitrogen sources (Figure 2).
Several lines of evidence support the conclusion that the Asp3p periplasmic asparaginase
facilitates the utilization of these substrates. Asp3p activity is closely linked to nitrogen
utilization. Nitrogen starvation has been demonstrated to upregulate ASP3 expression
and promote the secretion of asparaginase II (BON et al. 1997).

Furthermore, the

enzymatic activity of asparaginase II hydrolyzes either L- or D-asparagine into ammonia
and aspartate, facilitating the use of D-asparagine as a nitrogen source (DUNLOP et al.
1978; DUNLOP et al. 1976). Of the strains tested, only W303 and the related laboratory
strain S288c were able to utilize D-asparaginase in the PM assay (Figure 2E). Genomic
analyses utilizing microarrays have noted a lack of detectable ASP3 in Y55 (LASHKARI et
al. 1997) and a clinical isolate, YJM789 (WINZELER et al. 1999). Neither Y55 nor our
clinical isolate, YAT7, were capable of utilizing the putative Asp3p substrates (Figure 2).
Most importantly, the asparaginase of the bacterial plant pathogen Erwinia carotovora
has been shown to deamidate C-terminal, but not N-terminal, asparagine residues of
small peptides (HOWARD and CARPENTER 1972). This specificity precisely matches the
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dipeptide utilization phenotypes observed for W303 and S288c. Both strains are unable
to utilize the two dipeptides with N-terminal asparagine residues present in the PM
nitrogen plates (Figure 2B), but are able to utilize all dipeptides containing C-terminal
asparagine residues (Figure 2; boxes with red borders). To our knowledge, our study
provides the first evidence for such an activity in S. cerevisiae, in which mechanisms of
extra-cellular peptide processing are rare.
A fourth component of the dipeptide utilization system, evident in strain RM8 but
not W303, governs the use of dipeptides containing C-terminal arginine residues, and
Met-Arg in particular. Utilization of Met-Arg is clearly enhanced by deletion of DAL5
(Figure 6) and persists in the ptr2Δdal5Δ double mutant (Figure S2), and thus represents
another previously unrecognized mechanism of dipeptide utilization.

Given the

specificity for a nitrogen-rich C-terminal residue, an arginase activity comparable to the
asparaginase activity of Asp3p would seem a likely candidate.
Balancing the benefits and potential risks of robust di- and tripeptide import:
The striking inter-strain diversity in dipeptide utilization revealed in this study represents
a broad phenotypic landscape.

Variation in the relative strengths of the activities

contributing to dipeptide import can strongly impact the range of dipeptide substrates
utilized by the cell. While di/tri-peptides can serve as a valuable source of nutrients,
evolutionary pressures opposing indiscriminate import may reinforce mechanisms
promoting transport specificity. One such pressure might be the need to avoid import of
antifungal agents that exploit the di/tri-peptide transport machinery to gain entry into the
cell (reviewed in (ST GEORGIEV 2000)).
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Of the di/tri-peptide-utilization activities characterized in this study, the Ptr2p
transporter provides the means to transport the broadest spectrum of dipeptide substrates
(Figure 3), yet it is also the source of vulnerability to the toxic Ala-Eth dipeptide (Table
2). Thus, strains that exhibit robust PTR2 expression, such as the clinical isolate YAT7,
efficiently utilize a broad spectrum of dipeptides as a nitrogen source (Figure 2), but are
also vulnerable to Ala-Eth toxicity (Table 2). In contrast, the limited PTR2 expression in
strain W303 provides protection from Ala-Eth at the cost of a more limited capacity to
utilize di/tri-peptides. However, in certain growth conditions a fraction of W303 cells
exhibit robust PTR2 expression, suggesting a possible epigenetic mechanism for
employing both high- and low-risk di/tri-peptide utilization strategies in an isogenic
population.
The optimal strategy for dipeptide utilization will vary between environments.
For instance, in the presence of toxic peptidomimetics that resemble Dal5p substrates,
strain Y55 would have a significant fitness advantage over the other strains tested in this
study, as it exhibits no detectable Dal5p activity (Figure S2). In environments with a
strong risk of exposure to a variety of toxic di/tri-peptides, the risks of Ptr2p- and Dal5pmediated import may outweigh the potential nutritional benefits. In such cases, the
utilization of a limited subset of di/tri-peptides may represent a low-risk mechanism by
which some nutritional benefit can be extracted from the available di/tri-peptides. For
example, extracellular release of ammonia from C-terminal asparagine residues by Asp3p
would serve as a more limited, but risk-free, means of obtaining nitrogen from dipeptides.
In contrast, in an environment in which nitrogen sources are scarce and the risk of
importing toxic species is minimal, robust expression of PTR2 would be a beneficial trait.
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We note that the clinical isolates YAT7 (Figure 2), YAT17, and YAT21 (data not shown)
exhibit the most robust dipeptide utilization of the strains studied, perhaps reflecting the
environmental pressures of the strains’ atypical growth environment in the human host.
Further investigation into the ecology, population structure and population genetics of S.
cerevisiae would benefit future attempts to link phenotypic diversity to likely
environmental pressures.
High-throughput phenotyping and genetic diversity can provide new insights into
the genetic determinants governing adaptation to the nutritional and chemical challenges
of diverse environments. Our study represents a first case example of how this approach
can be utilized to elucidate metabolic processes and provide a broader evolutionary
context within which the observed natural diversity can be considered.
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APPENDIX

Supplement Table S1 Oligos used in this study
Oligo
O-007
O-008
O-138
O-139
O-203
O-204

Sequence
CAATTCAACGCGTCTGTGAGG
GATTCTTGTTTTCAAGAACTTG
TATACGCATATGTGGTGTTG
CGACCGAGATTCCCGGGTAA
ATGGTTTGTGAACAGATTGA
TTGAATGGACGCCGAATTGC

O-206

GTATCGATAAGCTTGATATC
ATGTCGAAAGCTACATATAAGGAACGTGCTGCTACTCATCCTAGT
TTACCAATGCTTAATCAGTGAG
TTAGTTTTGCTGGCCGCATCTTCTCAAATATGCTTCCCAGCCTGC
GCAACAACGTTGCGCAAACTAT

O-223
O-224
O-248
O-252
O-253
O-278
O-279
O-286
O-287
O-288

TAATACGACTCACTATAGGG
GTGGCATGTGAACTGCCTACCGTAAGTGACATGAACACATGCATT
CAGCTGAAGCTTCGTACGCTGC
GGCGAAAAAAGAGATTAATCAACTTCTTCCATCTCGGTGTCAGCT
GCATAGGCCACTAGTGGATCTG
CGCAAGTCCTGTTTCTATGC
CTACGTTGCCTCCATCG
CAGGACGAAAAGCAAGGCGACTTCCCGGTCATCGAAGAGGGCCTC
GTCCCCGCCGGGTCA
ACTTTCCATTGGTTCTAATATTTCAATATCGTTAGCTTTACACTG
GATGGCGGCGTTAGT
GGGCTAACGGCGTCCGCAGA
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Purpose
Verify SFH deletions
Verify SFH deletions
Verify URA3 deletion
Verify URA3 deletion
Verify HSC82 deletion
Verify HSC82 deletion
Sequencing genomic library
plasmid insert
Amplify URA3 SFH deletion
cassette
Amplify URA3 SFH deletion
cassette
Sequencing genomic library
plasmid insert
Amplify lox-flanked HSC82 SFH
deletion cassette
Amplify lox-flanked HSC82 SFH
deletion cassette
Verify KanMX excision from HO
Verify KanMX excision from HO
Amplify PTR2 SFH deletion
cassette
Amplify PTR2 SFH deletion
cassette
Verify PTR2 deletion

Supplement Table S1 Continued
Oligo
O-289

O-291
O-292
O-293

Sequence
AAGAGAAAGTGTGGTCACAC
ATGAATTATAACTGCGAAATACAAAACAGGAACAGTAAGAGCCTC
GTCCCCGCCGGGTCA
ATTCATATCAGGGTTGGATAGCTTTTTCAATTCTTCCAGCCACTG
GATGGCGGCGTTAGT
GCGTGCTTCCTCACACTGGC
GAAAGAGAAGATGATAACTA

O-314

CGAATTTGATCTCAATCCAATTTCCGCACC

O-315

AATATGGACCTCTCTTCACAAATTGTTCTATAATACAATATATAT
TCTGGGCAGATGATGTCGAG

O-316

ATTGATCTTTGCTGGTAAGC

O-321

ATCTGAGCCTTGGCTGGGAT

O-322

CCGTCCTTTTCACTTCACGT

O-323

CCGTACAGATAAGAAACCCA

O-324
PTR2FLAG-GFPF
PTR2FLAG-GFPR

GATAAGCTTGGGGTAACGCA

Purpose
Verify PTR2 deletion
Amplify CUP9 SFH deletion
cassette
Amplify CUP9 SFH deletion
cassette
Verify CUP9 deletion
Verify CUP9 deletion
SFH integration of FLAG-2xGFP6xHIS/kanMX4 at C-terminus of
PTR2
SFH integration of FLAG-2xGFP6xHIS/kanMX4 at C-terminus of
PTR2
Verify FLAG-2xGFP-6xHIS/KanR
integration
PTR2 promoter sequencing (+30 to
+11)
PTR2 promoter sequencing (-466 to
-447)
PTR2 promoter sequencing (-368 to
-387)
PTR2 promoter sequencing (-897 to
-878)

GATCCACCACCAAATATGACTACAAGGACGACGATGACAAGCTTG
ATATCAACAAGACAGGG

Amplify GFP for insertion into
pMS2

GATGATGATGACTGCTGCCGCTGCCGCGCGGCACACCGGT
CCTCGAGCCGCTTTTCTTGTAC

Amplify GFP for insertion into
pMS2

O-290

185

C-582T

A-555G

A-496G

T-458G

G-385C

T-297C

T-152C

ins-46T

del-32CTT

Strain
S288c
W303
RM8
YAT7

C-799T

Supplement Table S2 Polymorphisms in the region upstream of PTR2, relative to
the standard S288c sequence

-+
+
--

--+
--

--+
--

--+
+

---+

--+
--

--+
--

--+
--

---+a

---+b

A region encompassing the bases spanning from positions -899 to +3 relative to the PTR2
stop codon was sequenced in the indicated strains.
a
“insT-46” refers to the expansion of a string of 11 “T”’s spanning from -46 to -36 by an
additional “T”.
b
“del-32CTT” refers to a deletion of the bases “CTT” spanning from -32 to -30 of the
published S288c sequence.
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Supplement Figure S1 Dal5p and Ptr2p exhibit strain-dependent contributions to
the utilization of Ala-Leu as a nitrogen source.

Wild-type, dal5Δ, ptr2Δ and

ptr2Δdal5Δ versions of the indicated strains were grown at 30°C in liquid MM media
containing 2 mM Ala-Leu as the sole nitrogen source. A few timepoints were omitted
because of technical difficulties with the Bioscreen C growth curve machine.
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Supplement Figure S2 Additional PM signal profiles reveal the varied contribution
of Dal5p to di/tri-peptide import in strains RM8, W303, and Y55. Refer to Figure 2
for details on data analysis and presentation. The column label “ptr2Δ (vector)” refers to
strain W303-ptr2Δ transformed with the high-copy (2µ) vector pRS426. The column
label “ptr2Δ (DAL5)” refers to strain W303-ptr2Δ transformed with plasmid pRS426DAL5.

Note that the PM assays presented in this figure utilized a more recent

manufacturing lot of the PM nitrogen plates than those presented in the other figures.
Different lots can produce subtle differences in signal magnitude. The wild-type RM8
and Y55 PM data presented here were derived from the same lot to facilitate direct
comparison.
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Figure S2A
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Figure S2B

Supplement Figure S2 Continued
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Figure S2C

Supplement Figure S2 Continued

191

PART IV

SUMMARY AND DISCUSSION
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SUMMARY AND DISCUSSION

Di/tri-peptides are important to organisms as amino acids, nitrogen, and carbon
sources, and Ptr2p as the major di/tri-peptide transporter is one of the proteins required
for the utilization of di/tri-peptides. In order to identify genes affecting di/tri-peptide
utilization, I have performed a systematic, functional examination of dipeptide utilization
in a haploid, non-essential, single-gene deletion mutant library in Saccharomyces
cerevisiae. I have identified 103 candidate genes: 57 genes whose deletion decreased
dipeptide utilization and 46 genes whose deletion enhanced dipeptide utilization. The 103
genes were distributed among most of the Gene Ontology functional categories indicating
a very wide regulatory network involved in the utilization of dipeptides in yeast. In
addition, to exploit the various strategies of importing and utilizing di/tri-peptides as
nitrogen sources, we used the Biolog system of “Phenotype MicroArrays™” (PM)
(BOCHNER 2003; BOCHNER et al. 2001) which represents 284 of the 400 possible
dipeptide and 11 tripeptide permutations to investigate the difference of growth
phenotype in these arrays for different strains of S. cerevisiae. Multiple gene products
contributing to di/tri-peptide utilization have been revealed ranging from the initial
processes of importing di/tri-peptides to the metabolic pathways of di/tri-peptide
degradation. Taken together, the identified genes are involved in different biological
pathways contributing to both direct and indirect regulation of di/tri-peptide utilization.
Ptr2p is the key contributor for di/tri-peptide utilization:
Ptr2p is the only known gene of the PTR family involved in di/tri-peptide uptake
at the plasma membrane in yeast. After analyzing the preference for any of 284
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dipeptides and 11 tripeptides as a sole nitrogen source, we demonstrated that Ptr2p is
essential for many, but all yeast strains, for the utilization of most di/tri-peptides and
exhibits the broad substrate recognition. For a limited number of peptides and for three
out of the seven strains tested, another transporter (Dal5p) was able to substitute for
Ptr2p’s role as peptide transporter. Relief of PTR2 repression by the deletion of CUP9
facilitated robust growth on nearly all di/tri-peptides tested. In contrast, the deletion of
PTR2 resulted in the almost complete abrogation of growth on N-end rule dipeptides,
which contain bulky or basic amino acid in the N-terminus, suggesting Ptr2p contributes
solely to the utilization of N-end rule dipeptides. For non-N-end rule di/tri-peptides, both
Ptr2p and Dal5p played roles in peptide utilization.

Several gene products contribute to di/tri-peptide utilization by regulating PTR2
expression:
I have identified genes affecting di/tri-peptide utilization by the regulation of
PTR2 expression or PTR2 mRNA stability, which considerably expands our
understanding of the regulation of PTR2 expression. First, I have identified gene products
negatively regulating PTR2 transcription via a modification of histones. For example,
deletion of Arp5p, Arp8p, Ies6p, or Taf14p, the components of the chromatin remodeling
INO80 protein complex, or deletion of Eaf3p, a component of the NuA4 histone
acetyltransferase complex, results in an increase in PTR2 transcription with a subsequent
increase of dipeptide utilization. The INO80 protein complex preferentially interacts with
histones H3 and H4 and is involved in the modification of the nucleosome, while Eaf3p is
involved in maintaining the acetylation of histone H3 and H4 (REID et al. 2004; SANDERS
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et al. 2002). Second, I have confirmed or identified four gene products with transcription
factor activity (Cup9p, Dal81p, Stp2p, and Rpn4p) that regulate PTR2 expression. Cup9p
is the known repressor of PTR2 transcription, and binds to the region between -488 and 897 upstream of the PTR2 start codon (BYRD et al. 1998). Deletion of this gene product
leads to an increase of di/tri-peptide utilization. Dal81p, Stp2p, and Rpn4p are positive
regulators of PTR2 transcription, and deletion of these gene products results in a decrease
of di/tri-peptide utilization. Dal81p is a transcriptional activator essential for PTR2
expression induced by the SPS signal pathway (BERNARD and ANDRE 2001). Stp2p is
proteolytically processed by truncation of the N-teminus and is translocated into the
nucleus in response to amino acid induction via the SPS system (ANDREASSON and
LJUNGDAHL 2002; ANDREASSON and LJUNGDAHL 2004). Dal81p and Stp2p might act
synergistically in PTR2 transcription since similar synergistic regulation between Dal81p
and Stp1p is also proposed in AGP1 regulation in response to amino acid induction
(ABDEL-SATER et al. 2004). Rpn4p may bind between -610 and -603 due to the existence
of the Rpn4p binding consensus sequence (5’-GGTGGAAA-3’) present at this site
(MANNHAUPT et al. 1999). The regulation of PTR2 by Rpn4p was identified in my
studies.

I have also identified or corroborated that several gene products proposed to
regulate transcriptional activators are involved in dipeptide utilization. For example,
Ubr2p, Ptr1p, and Ubc2p modulate the stability of Rpn4p and Cup9p, and deletion of
these regulators causes an alteration of di/tri-peptide utilization. Ubr2p has been shown to
be involved in the degradation of Rpn4p; Ptr1p and Ubc2p are involved in Cup9p
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degradation through the ubiquitination pathway (DU et al. 2002; WANG et al. 2004).
Since Ubr2p has a high amino acid sequence similarity to Ptr1p, this would presumably
allow competition with Ptr1p for the stabilization of Cup9p (BARTEL et al. 1990).
Therefore, Ubr2p likely regulates PTR2 transcription by influencing the stability of both
Rpn4p and Cup9p. The stability of Cup9p is also dependent on N-end rule dipeptides
with N-terminal residues containing basic (Type 1: Arg, His, or Lys) and bulky (Type 2:
Ile, Leu, Phe, Trp, or Tyr) amino acids. Dipeptides serve as ligands to bind to Ptr1p
substrate binding sites, and binding these peptides cause a release of the Ubr1p
autoinhibitory domain and allosteric activation of Ubr1p, which leads to the degradation
of Cup9p. Relief of Cup9p repression of PTR2 results in enhanced PTR2 expression and
ultimately di/tri-peptide uptake. This initiates a positive regulatory feedback loop for
di/tri-peptide utilization (BYRD et al. 1998; DU et al. 2002; TURNER et al. 2000).

Third, I have identified the components of an RNA polymerase mediator
(Ssn3p/Srb10p, Ssn8p/Srb11p, Ssn2p/Srb9p, and Srb8p) that are involved in PTR2
transcription, thus regulating dipeptide utilization. This protein complex belongs to a
cyclin-dependent serine/threonine protein kinase (KORNBERG 2005). The involvement of
this protein complex is not specific for PTR2 transcription since this protein complex also
affects the expression of PMA1 encoding a proton transporter. The deletion of SSN3
results in a change of both PMA1 and PTR2 expression.

Fourth, I have identified genes involved in the stability of PTR2 mRNA which
affects dipeptide utilization. Both Kem1p and Pat1p belong to an mRNA decay protein
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complex (BONNEROT et al. 2000; BOUVERET et al. 2000), and the amount of PTR2
mRNA is considerably higher in the kem1 strain than in wild type. It is likely that PTR2
mRNA is more stable in kem1 and pat1 strains, which results in more Ptr2p being
synthesized leading to increased dipeptide utilization. However a deletion of KEM1 could
affect expression of many different genes, resulting in a non-specific affect on dipeptide
utilization. Another gene product, Thp1p, is involved in mRNA export from the nucleus
to the cytoplasm (FISCHER et al. 2002), and deletion of this gene might interrupt PTR2
mRNA translocation.

Several gene products contribute to di/tri-peptide utilization by regulating Ptr2p
trafficking
I have identified genes affecting di/tri-peptide utilization by regulation of the
Ptr2p trafficking system. Interruption of Ptr2p targeting to the plasma membrane leads to
an alteration of di/tri-peptide uptake. I have shown that ESCRT-I (endosomal sorting
complex required for transport), ESCRT-II, and ESCRT-III protein complexes are
involved in Ptr2p trafficking since deletion of any component of these protein complexes
caused a defect in Ptr2p-GFP trafficking from the endosome to the vacuole. For example,
deletion strains srn2, vps36, snf7, eaf7 and vps8 demonstrated a defect in Ptr2p-GFP
localization and increased dipeptide utilization. Since ubiquitination of membrane
proteins is essential for sorting by the ESCRT protein system, I infer that Ptr2p
ubiquitination is required for its turnover. Ubiquitinated Ptr2p has been identified by a
mass spectrometer analysis supporting this hypothesis (HITCHCOCK et al. 2003). In
addition to the ESCRT protein complexes, several gene products, such as NPR1, LST4,
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BUD32, and REG1 showed an accumulation of Ptr2p-GFP in vesicles. They are also
likely involved in the Ptr2p trafficking system. Strains npr1 and lst4 showed an increase
of dipeptide utilization while bud32 and reg1 showed a decrease of dipeptide utilization.

Several gene products contribute to di/tri-peptide utilization via Ptr2p-independent
manner
I have identified an important gene product involved in di/tri-peptide utilization
independent of Ptr2p in yeast. Dal5p is a plasma membrane protein, which does not
belong to PTR system but imports di/tri-peptides from the extracellular environment.
Dal5p was previously identified as a permease for the pyrimidine biosynthetic precursor
ureidosuccinate (TUROSCY and COOPER 1987) and the nitrogen source allantoate
(CHISHOLM et al. 1987) . Expression of DAL5 is subject to complex regulatory control
by the nitrogen catabolite repression system (CHISHOLM et al. 1987; RAI et al. 2004; RAI
et al. 1987). With the exception of Tyr-Gln, all Dal5p di/tri-peptide substrates belong to
the non-N-end rule class. For example, many of the dipeptides supporting growth in the
RM8-ptr2Δ strain did not support growth in RM8-dal5Δ. Since Ptr2p can transport the
majority of di/tri-peptides, the spectrum of Ptr2p substrates overlaps with that of Dal5p
but the substrate specificity is strain dependent. In the RM8 strain, Dal5p-mediated
dipeptide transport is not redundant to that of Ptr2p, but rather a complementary activity
that enhances the range of dipeptides that can be utilized.

Ptr2p-independent di/tri-peptide utilization is also governed by the activity of
Asp3p, a periplasmic asparaginase, which facilitates the utilization of dipeptides
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containing C-terminal asparagine residues as nitrogen sources. For example, W303-ptr2Δ
dal5Δ strain could utilize X(Ala, Gly, Pro, Val, Ser, Ile, Leu)-Asn dipeptides as the
nitrogen source. Nitrogen starvation has been demonstrated to up-regulate ASP3
expression and promote the secretion of asparaginase II (BON et al. 1997). Furthermore,
the enzymatic activity of asparaginase II hydrolyzes either L- or D-asparagine into
ammonia and aspartate, facilitating the use of D-asparagine as a nitrogen source (DUNLOP
et al. 1978; DUNLOP et al. 1976).

Ptr2p-independent di/tri-peptide utilization also includes the extracellular peptide
degradation that is related to the utilization of dipeptides containing C-terminal arginine
residues, particularly Met-Arg. Since the utilization of Met-Arg is enhanced by the
deletion of DAL5 and persists in the ptr2Δdal5Δ double mutant, it is likely that an
arginase activity comparable to the asparaginase activity of Asp3p could contribute to
this dipeptide utilization.

Several cellular metabolic processes are involved in dipeptide utilization
independent of Ptr2p activity since no significant alteration of expression or localization
of Ptr2p-GFP was observed. These cellular processes are: 1) the conversion of pyruvate
into acetyl-CoA which requires pyruvate dehydrogenase complex (Pdx1p, Lpd1, Pdb1p,
and Lat1p); 2) the conversion of acetyl-CoA to malonyl-CoA, which involved in Hfa1p;
3) fatty acid synthesis which is involved in fatty acid synthase complex (Oar1p, Mct1p,
and Etr1p); 4) glycine degradation in (Gcv2p, Gcv3p, and Lpd1p); and 5) a peptidase
activity (Prd1p) (BUCHLER et al. 1994; NAGARAJAN and STORMS 1997; SCHNEIDER et al.
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1997; STOOPS et al. 1997). Since the accumulation of dipeptides is not impaired in these
mutants as indicated from the non-visible change in Ptr2p-GFP and accumulation of
[3H]Leu-Leu, the decrease in dipeptide utilization probably results from the inability to
release amino acids from accumulated dipeptides or from blocking metabolic pathways in
using the released amino acids for protein biosynthesis.

Other cellular processes might be involved in dipeptide utilization, such as found
in the ybt1 mutant. Ybt1p belongs to the ABC transporter family exhibiting ATPdependent bile acid transport (ORTIZ et al. 1997; PAULSEN et al. 1998). I speculate that
this protein might be involved in the transport of dipeptides into the vacuole. In the
deletion mutant the defect in the uptake of dipeptides into the vacuole would lead to an
increase of dipeptide availability in the cytoplasm. It is also possible that the deletion of a
gene might result in a de-repression or change in function of other transport systems that
may mediate dipeptide utilization in the mutant without alteration of PTR2 expression or
Ptr2p function.

I have identified 15 unknown strains with deletions in genes of unknown function
that had an alteration of dipeptide utilization, seven strains exhibiting increased and eight
strains showing decreased dipeptide utilization. Characterization of the phenotype of
these genes should lead to a further understand their cellular roles. In addition, other
genes such as UBP14, ubiquitin-specific protease activity, require additional study to
understand the mechanism of how these genes are involved in dipeptide utilization.
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To date, molecular components have been reported in the regulation of the human PTR2
homologs PEPT1 and PEPT2 (DANIEL 2004). In our research, I have identified 52 genes
encoding proteins with more than 30% identity to human genes, which might be involved
directly or indirectly in the utilization of dipeptides in yeast. Investigation of these genes
may promote understanding of the regulation of dipeptide utilization in mammalian
systems (the complete list of genes is in Table 1). These genes include those encoding
transcription factors and mRNA processing proteins (14 genes), proteins involved in
cellular metabolism (12 genes), protein kinases (4 genes), DNA damage repair proteins (4
genes), ribosomal proteins (4 genes), actin binding proteins and proteins involved in
sorting (4 genes), proteins related to ubiquitination (3 genes), peptidases (2 genes), a
transporter (1 gene), a protein involved in cell cycle regulation (1 gene), a DNA helicase
(1 gene), a protein related to growth regulation (1 gene) and a protein of unknown
function (1 gene).

Suggestions for future experiments
My research has considerably expanded the understanding of the regulation of
dipeptide utilization by PTR2 expression, Ptr2p trafficking, and other PTR2 independent
mechanisms. To further explore the role of these gene products, I propose the following
experiments.
1. I have identified that Dal5p is involved in dipeptide utilization by importing dipeptides
by showing that some of non-N-end rule dipeptide substrates can provide a nitrogen
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Table 1 Description of the function of yeast genes and their mammalian counterparts
Yeast gene
name

Description of yeast
gene product

mammalian
gene
counterpart
TRANSCRIPTION AND MRNA PROCESSING (14)
BYE1
Transcriptional elongation DIDO1
regulator activity
CUP9

Specific RNA polymerase
II transcription factor
activity

PKNOX1

DBR1

RNA lariat debranching
enzyme activity
Histone acetyltransferase
activity

DBR1

5'-3' exoribonuclease
activity
mRNA binding

XRN1

EAF3
KEM1
NPL3

Morf4l2

SYNCRIP

PHO2

Transcription factor
activity

SHOX2

RIM101

Specific transcriptional
repressor activity

Egr3

SFP1

Transcription factor
activity

DPF2

Description of human gene product

Death associated transcription factor 1, contains nuclear localization signals and
transactivation domains, may have a role in cell death during development,
overexpression inhibits limb outgrowth
PBX knotted 1 homeobox 1, a member of the homeodomain family of DNA binding
proteins that regulate gene expression and control cell differentiation, heterodimerizes
with PBX proteins to form Urokinase Enhancer Factor 3 (UEF3) DNA binding
complexes
RNA lariat debranching activity for processing of introns
Protein with high similarity to mortality factor 4 (human MORF4), which is a
predicted transcriptional repressor that binds transcriptional corepressors human
SIN3A and human TLE1 and negatively regulates cell proliferation
5'-3' Exoribonuclease, a putative exoribonuclease that localizes to the cytoplasm, and
is expressed ubiquitously
Synaptotagmin binding cytoplasmic RNA interacting protein, component of the ApoB
mRNA editosome involved in apolipoprotein B (APOB) mRNA editing, may bind
RNA, may play a role in the regulation of mRNA splicing or transport from the
nucleus
Short stature homeobox 2, a member of the paired-related family of homeodomaincontaining transcription factors, may have a role in craniofacial, brain, heart, and limb
development, involved in skeletal defects of Turner syndrome
Early growth response 3, member of the Egr family of immediate early transcription
factors; deletion of the corresponding gene results in gait ataxia, increased frequency
of perinatal mortality, scoliosis, resting tremors, and ptosis
D4 zinc and double PHD fingers family 2 (requiem), a member of the d4 domain
family of zinc finger proteins, may be required for the induction of apoptosis by
extracellular signals
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Table 1 Continued
Yeast gene
name

Description of yeast
gene product

mammalian
gene
counterpart
CDK8

SSN3

Cyclin-dependent protein
kinase activity

SSN8

Cyclin-dependent protein
kinase regulator activity

CCNK

STP2

Specific RNA polymerase
II transcription factor
activity
Transcriptional activator
activity
General RNA polymerase
II transcription factor
activity

HKR1

RPN4
TAF14

ZNF473
MLLT1

KINASE (4)
Protein serine/threonine
BUD32
kinase activity

TP53RK

MCK1

Protein kinases, positive
regulator of meiosis and
spore formation
Serine/threonine protein
kinase

GSK3B

Cyclin-dependent protein
kinase activity

CDK2

NPR1

PHO85

CHEK1

Description of human gene product
Cyclin dependent kinase 8, forms a complex with cyclin C that phosphorylates cyclin
H (CCNH) and the C terminus of POLR2A, plays a role in the regulation of
transcription through Notch signaling and as component of the RNA polymerase II
holoenzyme
Cyclin K, member of the transcription cyclin family, binds and activates CDK9
leading to phosphorylation of the RNA polymerase II large subunit, promotes RNA
polymerase II transcription elongation, overexpression suppresses glioblastoma cell
proliferation
GLI-Kruppel family member HKR1, putative transcription factor whose expression in
lung cancer cell lines is induced in response to cisplatin, may be involved in a signal
transduction pathway that regulates platinum resistance or lung cancer progression
Zinc finger protein 473, an snRNA binding protein in the snRNP U7 complex,
involved in mRNA processing
Myeloid-lymphoid or mixed-lineage leukemia translocated to 1, a transcription factor
with activator and putative repressor activities, binds CBX8; gene translocation causes
B-cell, myeloid, and acute lymphocytic forms of leukemia
a protein serine-threonine kinase that binds to and phosphorylates p53 (TP53) and
regulates p53-mediated transcriptional control, may be involved in the cell cycle and
apoptosis
Glycogen synthase kinase 3 beta, serine/threonine kinase that regulates beta-catenin
(CTNNB1) stability and binds presenilin 1 (PSEN1), associated with Alzheimer
disease, bipolar disorder, schizophrenia and various neoplasms
Checkpoint homolog 1 (S. pombe), protein kinase, required for mitotic G2 checkpoint
in response to radition-induced DNA damage, inhibits mitotic entry after DNA
damage via mechanism involving CDC25, alternative form is associated with lung
cancer
Cyclin-dependent protein kinase 2, interacts with cyclins to regulate kinase activity
and cell cycle progression, regulates DNA replication; decreased expression or
inhibition may be therapeutic for many types of cancer
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Table 1 Continued
Yeast gene
name

Description of yeast
gene product

METABOLISM (12)
ETR1
Enoyl-[acyl-carrier
protein] reductase activity

mammalian
gene
counterpart
MECR

GCV2

Glycine dehydrogenase
(decarboxylating) activity

GLDC

GCV3

Glycine dehydrogenase
(decarboxylating) activity

GCSH

HFA1

Acetyl-CoA carboxylase
activity
Molecular function
unknown
Dihydrolipoyllysineresidue acetyltransferase
activity

ACACA

LPD1

Dihydrolipoyl
dehydrogenase activity

DLD

PDB1

Pyruvate dehydrogenase
(acetyl-transferring)
activity
Pyruvate dehydrogenase
complex protein

PDHB

ELF1
LAT1

PDX1

ELOF1
DLAT

DLAT

Description of human gene product

Nuclear receptor binding factor 1, reduces trans-2-enoyl-CoA to acyl-CoA with chain
length from C6 to C16 in an NADPH-dependent manner with preference to medium
chain length substrate, plays a role in mitochondrial respiratory function
Glycine decarboxylase (glycine dehydrogenase, P-protein), part of the glycine
cleavage system that catalyzes the decarboxylation of glycine; mutation of the
corresponding gene causes nonketotic hyperglycinemia
Glycine cleavage system protein H, H-protein component of the glycine cleavage
system, catalyzes transfer of the methylamine group of glycine from P-protein
(GLDC) to T-protein (AMT); mutational inactivation results in atypical nonketotic
hyperglycinemia
Acetyl-Coenzyme A carboxylase alpha, catalyzes the rate-limiting step in long-chain
fatty acid biogenesis; deficiency leads to defects in fatty acid synthesis
Protein containing a DUF701 putative zinc binding domain, has very strong similarity
to uncharacterized mouse Elof1
Dihydrolipoamide S-acetyltransferase E2 component of pyruvate dehydrogenase
complex, binds coenzyme and pyruvate dehydrogenase kinase 2 (PDK2); mutation
may cause pyruvate dehydrogenase deficiency; may be associated with primary biliary
cirrhosis
Dihydrolipoamide dehydrogenase, E3 component of pyruvate dehydrogenase complex,
also a component of alpha-ketoglutarate dehydrogenase and alpha-ketoacid
dehydrogenase complexes; mutation in the corresponding gene causes lipoamide
dehydrogenase deficiency
E1 beta subunit of pyruvate dehydrogenase complex, oxidatively decarboxylates
pyruvate to acetyl-CoA
Dihydrolipoamide S-acetyltransferase E2 component of pyruvate dehydrogenase
complex, binds coenzyme and pyruvate dehydrogenase kinase 2 (PDK2); mutation
may cause pyruvate dehydrogenase deficiency; may be associated with primary biliary
cirrhosis
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Table 1 Continued
Yeast gene
name
SHM2
TSA1
YJL046W

Description of yeast
gene product
Glycine
hydroxymethyltransferase
activity
Thioredoxin peroxidase
activity
Unknown

PEPTIDASE (2)
Metalloendopeptidase
PRD1
activity

mammalian
gene
counterpart
SHMT1
PRDX2
LIPT1

THOP1

Unknown

CNDP2

DNA DAMAGE REPAIRMENT (4)
DNA binding; ATPase
MLH1
activity

hMLH1

MRE11

3'-5' exonuclease activity

MRE11A

RAD23

protein that binds to the
26S proteasome subunits
and is involved in
ubiquitin-dependent
protein degradation

RAD23B

YFR044C

Description of human gene product
Soluble serine hydroxymethyltransferase, catalyzes the tetrahydrofolate-dependent
interconversion of glycine and serine, source of folate-activated one-carbon units
required for purine, thymidine, and methionine synthesis
Peroxiredoxin 2, an antioxidant enzyme, acts in the response to lipid hydroperoxide
and may play a role in protection of cells from reactive oxygen species, expression is
altered in neurodegenerative diseases and breast cancer
Lipoyltransferase, putative enzyme that transfers the lipoyl group from lipoyl AMP to
the lysine residue of lipoate-dependent enzymes; tissue expression correlates well with
expression of lipoate-requiring proteins
Thimet oligopeptidase 1, a metalloendopeptidase that processes neuropeptides and
other polypeptides, degrades beta amyloid precursor protein (APP), acts in degrading
peptides released by proteasomes to limit the extent of MHC class I antigen
presentation
Cytosolic nonspecific dipeptidase 2, member of the M20 metalloprotease family, a
homodimeric enzyme that requires magnesium ions for full dipeptidase activity and is
inhibited by bestatin, expressed ubiquitously
MutL (E. coli) homolog 1, a DNA mismatch repair protein that may play a role in
DNA recombination; decreased expression is associated with various cancers;
increased expression may be therapeutic for colorectal cancer
Meiotic recombination (S. cerevisiae) 11 homolog A, an endo- and exonuclease that
functions in DNA double-strand break repair; mutation of corresponding gene is
associated with an ataxia-telangiectasia-like disorder, breast cancer, and malignant
lymphoma
RAD23 homolog B (S. cerevisiae), a damaged DNA binding protein that also binds
XPC to form a DNA damage recognition protein and functions in global genome
nucleotide excision repair, may be associated with Machado Joseph disease or
xeroderma pigmentosum
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Table 1 Continued
Yeast gene
name
TOM72

Description of yeast
gene product
Minor import receptor of
the mitochondrial outer
membrane

RIBOSOMAL PROTEINS (4)
Structural constituent of
MRP17
ribosome
MRPS9
Structural constituent of
ribosome
Structural constituent of
RPL21A
ribosome
Structural constituent of
RPS9B
ribosome

mammalian
gene
counterpart
PPP5C

Protein sorting in the prevacuolar endosome

UBIQUITINATION (3)
Ubiquitin binding;
SHP1
Enzyme regulator activity

Protein phosphatase 5 catalytic subunit, a protein serine-threonine phosphatase that
promotes cell proliferation, plays a role in DNA damage response and several
signaling pathways, may promote tumor growth, downregulated in Alzheimer disease
brain

Mrps6

Mitochondrial ribosomal protein S6

MRPS9

Member of the ribosomal protein S9 or S16 family, has low similarity to C. elegans
F09G8.3, which is involved in embryogenesis and positive growth regulation
Ribosomal protein L21, component of the large 60S ribosomal subunit; shows altered
expression in colorectal carcinogenesis
Ribosomal protein S9, a component of the small 40S ribosomal subunit, gene
expression is altered in human colorectal carcinoma cells and in pancreatic
adenocarcinoma

RPL21
RPS9

ACTIN BINDING AND PROTEIN SORTING (4)
Actin-related protein
Actr5
ARP5
Cytoskeletal protein
SH3RF1
HOF1
binding
Actin filament binding
PLS3
SAC6
SNF7

Description of human gene product

CHMP4B

NSFL1C

Member of the actin family, which are major cytoskeletal proteins
SH3 multiple domains 2, a ubiquitin ligase that functions in protein sorting at the trans
Golgi network, plays a role in targeting of HIV 1 to the plasma membrane
Plastin 3 (T isoform), an actin-binding protein involved in actin filament bundling, cell
invasion by bacteria, and possibly UV protection, expression is altered in cancer and
Sezary syndrome, autoantibodies are linked to systemic lupus erythematosous
Chromosome 20 open reading frame 178 (chromatin modifying protein 4b, charged
multivesicular body protein 4b), a member of the CHMP family of yeast class E
SNF7-Vps protein homologs, binds Alix (PDCD6IP), may act in protein sorting
Protein with very strong similarity to Nsfl1c protein (rat Nsfl1c), which is a
spermatocyte XY body component that acts in membrane fusion and regrowth of
Golgi cisternae following mitosis, member of the UBX (ubiquitin-regulatory) domain
containing family
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Table 1 Continued
Yeast gene
name

Description of yeast
gene product

UBA3

NEDD8 activating
enzyme activity

UBC2

Ubiquitin conjugating
enzyme activity

TRANSPORTER (1)
Bile acid transporter
YBT1
activity
CELL CYCLE REGULATION (1)
Involved in maturation of
NFU1
mitochondrial iron-sulfur
proteins
DNA HELICASE (1)
DNA helicase activity
HFM1

GROWTH REGULATION (1)
Mitochondrial protein
ISA1
required for normal iron
metabolism
UNKNOWN (1)
Unknown
YPL098C

mammalian
gene
counterpart
UBE1C
UBE2B

Description of human gene product
Ubiquitin-activating enzyme E1C, subunit of an E1 (ubiquitin-activating enzyme)-like
complex, interacts with the amyloid precursor protein binding protein (APPBP1) to
activate the ubiquitin-like protein NEDD8 and target CUL4A for NEDD8 modification
Ubiquitin-conjugating enzyme E2B, predicted to be involved in the conjugation of
ubiquitin to cellular proteins marking them for proteasomal degradation, involved in
DNA repair; activity is increased in multiple disease states

ABCC1

ATP-binding cassette subfamily C member 1 (multiple drug resistance protein 1), a
transporter and multidrug efflux pump that confers resistance to lipophilic drugs and
chemotherapeutic agents, upregulation correlates with severity of breast cancer

HIRIP5

HIRA interacting protein 5, interacts with histone cell cycle regulation defective
homolog A (HIRA) which is involved in the pathogenesis of DiGeorge syndrome and
the velocardiofacial syndrome

ASCC3

Member of the Sec63 domain containing, helicase conserved C-terminal domain
containing, and type III restriction enzyme res subunit families, contains two
DEAD/DEAH box helicase domains, has moderate similarity to human ASCC3L1,
which binds ATP

HBLD2

Protein with high similarity to C. elegans Y39B6A.3, which is involved in positive
growth regulation and larval development, member of the HesB-like domain
containing family

C20orf52

Protein of unknown function, has very strong similarity to uncharacterized mouse
2010100O12Rik
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source for the growth of a PTR2 deletion mutant, while a double deletion of PTR2 and
DAL5 lose the capability to utilize all dipeptides. At least three independent microarray
analyses carried out by other workers showed that the expression of DAL5 is regulated by
Ssy1p under different growth conditions. First, DAL5 expression decreased three-fold in
a wild-type strain when Leu was added to the medium. In addition, the expression of
DAL5 in a SSY1 deletion mutant resulted in an increase of four-fold compared with the
wild type in medium containing Leu (FORSBERG et al. 2001). Second, the expression of
DAL5 in a SSY1 deletion mutant increased six-fold compared with the wild-type in rich
(YPD) medium (KODAMA et al. 2002), and increased two-fold in minimal medium
(ECKERT-BOULET et al. 2004). Based on these data, I hypothesize that under inducing
conditions such as the addition of Leu, yeast cells utilize dipeptides in a PTR2-dependent
manner, while in non-inducing conditions yeast cells utilize certain dipeptides in a PTR2independent manner. Further, I postulate that in response to amino acid inducing
conditions, the SPS system (Ssy1p-Ptr3p-Ssy5p) increases PTR2 expression but represses
DAL5 expression. In our toxic dipeptide assay (Ala-Eth), preliminary results indicated
that the PTR2 deletion mutant (BY4742 genetic background) remained sensitive to a high
Ala-Eth concentration (0.4µmol), suggesting that the sensitivity to high concentration of
Ala-Eth might result from the activity of Dal5p function due to the fact that Dal5p has a
low affinity for importing some dipeptides. I suggest the following experiments (a, b, and
c) to test the above hypotheses:
a) Confirm Dal5p imports dipeptide in our lab strain. This could be done by creating a
PTR2/DAL5 double knockout in the BY4742 background; the double knockout
should not be sensitive to high concentrations of Ala-Eth, if Dal5p imports Ala-Eth.
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Furthermore, using non-N-end rule substrates, such as Ala-Leu or Ala-His in a
growth assay would demonstrate whether dipeptides could satisfy the auxotrophic
requirement of His in a ptr2 strain. Since Dal5p is a low-affinity dipeptide transporter,
high concentrations of dipeptides should be used for the growth assay.
b) Explore how Leu, an inducer for the SPS system, changes the expression level of
DAL5 and PTR2 by using Northern analysis or real time PCR. The wild type strain
BY4742 will be grown in minimal medium (using proline as the nitrogen source)
with Leu or without Leu, and total RNA will be extracted. I expect that the expression
level of DAL5 will be higher in medium without Leu than that with Leu, but the
expression level of PTR2 will be opposite.
c) Since the SSY1 deletion mutant is lethal in the BY4742 background, studying the
Ssy1p signaling effect should be performed in the FY2 genetic background. A series
of knockout strains, ssy1, ptr3, ssy5, dal5, ptr2, and double knockout mutant strains
ssy1 dal5, ssy1 ptr2, ptr3 ptr2, and ptr3 dal5 should be created. Growth assays, toxic
dipeptide assays, and expression of PTR2 and DAL5 under the induction of Leu could
be performed in these backgrounds. I expect that the expression level of DAL5 in ssy1,
ptr3, and ssy5 strains will be higher than that of the wild-type in the medium
containing Leu, but the expression level of PTR2 will have an opposite effect in the
above conditions. I should also be able to demonstrate the contribution of DAL5 to
dipeptide utilization by comparing the growth assay and toxic dipeptide assays in
ssy1/ ptr2 and ptr3/ ptr2 strains with that of ssy1/ dal5 and ptr3 /dal5 strains in
minimal medium with or without Leu.
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2. Dal81p, Rpn4p, Ubp14p, and Ubr2p played a role in the regulation of PTR2 expression.
How these genes fit into the SPS signal transduction pathway should be experimentally
determined. The following experiments could be performed:
a)

Epistasis experiments will address where these genes are in the SPS signal
transduction pathway. Several gene double knockouts need to be created. For
example, in order to understand the role of Rpn4p in the SPS signal transduction
pathway, a ptr3/ ubr2 double knockout strain will be created. If the phenotype
such as the sensitivity to toxic dipeptide in the ptr3/ ubr2 double knockout is the
same as that in ptr3, it suggests that Ptr3p is upstream of Ubr2p. If the phenotype
of the double knockout is the same as that in ubr2, it suggests that Ubr2p is
upstream of Ptr3p. However if the phenotype in the double knockout is additive, it
suggests that Ptr3p and Ubr2p are in independent regulation pathways.

b) Since Ubr2p showed homology to Ubr1p/Ptr1p and impacted the stability of
Rpn4p, how Ubr2p impacts the positive regulator Rpn4p and repressor Cup9p on
PTR2 transcription should be tested. The relative amount of Cup9p and Rpn4p
could be measured in these deletion mutants by Western analysis.
c) Dal81p has transcriptional activity, and Ubp14p has ubiquitin-specific protease
activity. Deletion of either of these two genes showed a decrease of the expression
level of PTR2. Since both genes are involved in the transcriptional regulation of
PTR2, it is necessary to exam whether these gene products are related to Cup9p
repression. The stability of Cup9p in these two deletion mutants could be tested
by western analysis. This experiment will answer whether Dal81p and Ubp14p
are involved in PTR2 transcriptional regulation via regulation of Cup9p.
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3. The gene products impacting Ptr2p trafficking showed a significant effect on di/tripeptide utilization. Since ESCRT I, II, III were shown to be involved in Ptr2p trafficking,
it is very likely that ubiquitination of Ptr2p is required. In addition, Ptr2p ubiquitination
was shown by mass spectrum analysis. Further experiments should be performed to
demonstrate the ubiquitination site(s).
a) Screening the lysine positions in Ptr2p to show which position(s) are the
ubiquitination site(s). Point mutations of Ptr2p could be generated to change
lysine to alanine in Ptr2p-GFP background plasmid (pMS4 or pMS2). The point
mutations in Lys sites should lead to reduction of Ptr2p turnover and increase the
amount of Ptr2p in the plasma membrane and lead to an increased uptake of
dipeptides.
b) The enzymes involved in the ubiquitination of Ptr2p should be identified and
tested. The Ptr2p ubiquination process likely follows a similar pattern to that of
other membrane proteins since involvement of ESCRT protein complex is a
ubiquitous process for a number of membrane proteins. Npi1p/Rsp5p,
Npi2/Doa4p, and Bul1p/2 Ptr2p are good candidates for the ubiquitination of
Ptr2p since these components are also involved in the Gap1p trafficking system.
c) Npr1p and Lst4p were shown be involved in the Ptr2p trafficking. Deletion of
NPR1 and LST4 led to accumulation of Ptr2p containing vesicles. Npr1p is a
Ser/Thr kinase and played a role in phosphorylation of Bap2p, a branched-chain
amino acid permease and is involved in the degradation process. Npr1p might
play a similar role in Ptr2p post-translational regulation. First, the plasmid with
Flag tagged Ptr2p (pMS2) will be transformed into the wild type and npr1 strain.
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The degradation of Ptr2p will be examined under NH4+-induced conditions. I
expect that the degradation of Ptr2p will be reduced in npr1 strain by western
analysis. Second, in order to find out the phosphorylation sites in Ptr2p, point
mutations at Ser/Thr sites of Ptr2p will be generated. The contribution of Npr1p to
the phosphorylation of Ptr2p will be determined by antibodies that react
specifically with phorphorylated residues.
d) To further finely define the subcellular localization of Ptr2p in those deletion
mutants showing changes in Ptr2p-GFP localizaion, the analysis of Ptr2p
localization by confocal microscopy will be performed. From my research, I
found deletion mutants of gene product encoding protein sorting such as srn2,
snf7 and vps36 showed higher accumulation of dipeptide Leu-Leu but no
significant Ptr2p-GFP expression at the cytoplasmic membrane. One outcome of
these experiments might lead to an explanation for those mutants that exhibit
higher Leu-Leu accumulation. In addition, these experiments will also show the
detail location of Ptr2p-GFP in the endosomal vesicles.

4. A number of metabolic genes, such as the components of pyruvate dehydrogenase
complex (Pdx1p, Lpd1p, Pdb1p, and Lat1p), are involved in dipeptide utilization. The
roles of these gene products should be further explored. Deletion of these gene products
does not influence di/tri-peptide accumulation. In order to examine how these deletion
mutants impact di/tri-peptide utilization, the degradation process from di/tri-peptide into
amino acids should be tested. Our preliminary data indicated that the tested dipeptide
Leu-Leu was degraded into Leu and an unknown metabolite after Leu-Leu is taken up
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into cells. This unknown compound is more hydrophilic than Leu, and might be an
intermediate product formed in the process of Leu-Leu degradation or a leu derivation
product. Identifying this compound will require application of techniques such as HPLC
and mass spectrometry.

5. Fifteen genes of unknown function were identified to be involved in di/tri-peptide
utilization. Characterization of these genes will help understand their roles in yeast
biology.

I propose to start with two gene deletion mutants that showed a strong

phenotype in the regulation of PTR2 expression and Ptr2p trafficking. High induction of
PTR2 expression was found in a yor323c mutant, and accumulation of Ptr2p vesicles in a
ypl073c mutant. In order to characterize the function of YOR323C, first, the expression
level of PTR2 will be examined by Northern analysis or Real Time PCR. Because a
deletion in yor323c leads to an increase in dipeptide utilization and a higher Ptr2-GFP
signal in the cell membrane, I expect to see a higher expression level of PTR2 in yor323c
strain in comparison to that of the wild-type. Second, bioinformatic analysis should be
performed for the protein sequence encoded by this gene to see whether there are any
known protein domains whose function is known. Third, the localization of this gene
product should also be tested by tagging this gene with GFP. Further an examination of
the interaction databases such as the synthetic lethal screens can determine whether there
are other known gene products interact with Yor323p. Another example for testing is
YPL073c since this gene is involved in Ptr2p trafficking. Whether this gene product
interacts with other trafficking related proteins should be tested. The two hybrid
experiment to detect protein-protein interaction between this gene product and ESCRT
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proteins or other vesicle sorting proteins will be tested. In addition, the localization of this
protein should also be tested by tagging with GFP, and Ptr2p turnover should be
examined by Western analysis in the ypl073 deletion strain.

In summary, the identified genes regulating dipeptide utilization represent a very
wide regulatory network involved in transport and utilization of dipeptides in yeast. This
is the first such study of a membrane transport system in any organism and initiates a
systems biology approach to understanding membrane transport in cells. Further
experiments of characterizing these identified genes could provide valuable information
of how these genes of different pathways are involved in di/tri-peptide utilization.
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